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Abstract 
CD23 is a Type II glycoprotein that exists in both membrane bound (mbCD23) and 
soluble (sCD23) forms and functions as the low affinity receptor for IgE. CD23 
interacts  with  a  range  of  proteins  to  fulfil  its  function  in  vivo.  Through 
interactions with its ligands IgE and CD21, CD23 regulates the levels of IgE in 
serum.  Soluble  CD23  also  interacts  with  members  of  the  integrin  family  of 
membrane receptors. Integrins are heterodimeric transmembrane receptors that 
participate in bidirectional signalling across membranes and have a critical role 
in cellular adhesion reactions. CD23 interacts with four integrins, αVβ3 and αVβ5 
from the αV integrin family, and αMβ2 and αXβ2, from the β2 family of integrins.  
Using  peptide  array  technology,  we  identified  set  of  overlapping  peptides 
derived from the soluble CD23 sequence that interact with integrins expressed 
on the surface of monocytic cells and with purified αVβ3 and αVβ5 integrins in in 
vitro Biacore assays. These peptides all contained a common basic tripeptide 
motif, termed the Arg Lys Cys (RKC) motif. Integrins traditionally recognise and 
bind  the  Arg Gly Asp  (RGD)  tripeptide  in  their  ligands  in  a  cation dependent 
manner. However, the in vitro interaction between RKC containing peptides and 
purified integrins was determined to be cation independent, salt sensitive and 
independent of RGD binding. The interaction was blocked by full length CD23. 
Substitution of the residues in the RKC motif reduced or abolished binding of the 
peptides to integrins expressed on cells and in vitro, as measured by Biacore 
analysis, and abolished the competition with CD23. Taken together, these data 
suggest that the RKC motif is the site in CD23 that is recognised and bound by 
αVβ3 and αVβ5 integrins. The RKC motif can be considered a novel recognition 
motif for integrins, as it is cation independent, and its binding is not blocked by 
the presence of RGD containing integrin ligands. Therefore it is likely that the 
RKC motif interacts with integrins at a site other than that used for RGD binding, 
similar to the interactions that have been described for the binding of the HIV 
Tat protein. 
The interaction between sCD23 and its integrin receptors is important in the 
regulation of cytokine production by monocytic cells. Most monocytic cells will 
express  a  combination  of  the  different  CD23 binding  integrins  simultaneously 
and, therefore, the cytokine output of that cell will be the net result of the  
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interaction  of  CD23  with  a  combination  of  integrins.  We  used  monoclonal 
antibodies to investigate the role of individual integrins in cytokine production. 
Antibodies  were  selected  to  allow  comparision  of  the  cytokine  response 
between, a) integrin families, b) integrin subunits, and c) integrin epitopes.  
The cytokine profile induced by integrin ligation did not differ between the αV 
and  β2  integrin  families,  although  the  concentration  of  cytokines  produced 
varied  depending  on  the  heterodimer  targeted.  However,  within  a  particular 
family, cytokine production induced by integrin ligation was specific and relied 
on the recognition of a precise epitope on the integrin. Cytokine production by 
CD23 binding integrins appears to require the ligation of the α subunit of the 
integrin  heterodimer.  We  identified  an  antibody  directed  against  the  αVβ3 
integrin that  induced  high  levels  of  cytokine  production.  Cytokine  production 
following ligation of the integrin with this antibody was dependent on activation 
of  the  ERK/MAPK  pathway  in  cells.  This  production  of  cytokines  and 
phosphorylation  of  ERK  was  enhanced  by  the  addition  of  macrophage  colony 
stimulating  factor  (M CSF)  and  partially  inhibited  by  an  anti TLR 2  antibody. 
Chronic stimulation (<3 days) of THP 1 cells with the anti αVβ3 antibody in the 
presence of M CSF led to morphological changes in the cell line associated with 
the  development  of  a  more  macrophage like  phenotype  and  the  continued 
production  of  cytokines.  Analysis  of  the  changes  in  cell  surface  marker 
expression and cytokine profiles suggested that the THP 1 cells had undergone 
an M2b programme of macrophage activation in response to αVβ3 ligation. Data 
presented herein reinforce the importance of the role of integrins in the control 
of adhesion independent signalling pathways in suspension cells.  
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1.1 The Immune System 
The immune system is the term used to describe the collection of mechanisms 
used by an organism to protect itself from injury and disease. It is composed of 
the innate and adaptive immune systems which work in conjunction to defend 
and  heal  the  body.  The  adaptive  immune  system  is  a  collection  of  highly 
specialised  cells  and  processes  that  combat  infections.  The  adaptive  immune 
response is specialised, and recognises and mounts a specific immune response 
against a particular pathogen and also stores a memory of that infection for 
later challenges. The major effector cells of the adaptive immune response are 
B  and  T  lymphocytes,  which  have  distinct  roles  in  cell mediated  adaptive 
immunity. The adaptive immune system is activated by the non specific innate 
immune response, which often forms the first line of defence against infection 
1.   
The innate immune system is an evolutionarily conserved mechanism of defence 
against pathogens and is capable of being activated in a non specific manner. 
This means that the response to infection is rapid and does not rely on prior 
encounter with a pathogen to mount an innate immune response against it. The 
innate  immune  system,  unlike  the  adaptive  immune  system,  does  not  confer 
long lasting  or  protective  immunity  to  the  host.  It  is  comprised  of  cellular 
components, such as monocytes and neutrophils, and non cellular components, 
such as the complement system, which work in conjunction to mount the innate 
defense against infection 
1. 
1.1.1   Cells of the Innate Immune System 
The innate immune system is comprised of a number of leukocytes, with defined 
functions.  These  include  basophils,  eosinophils,  neutrophils,  mast  cells  and 
monocytes, each of which has a specific role in innate immunity. Neutrophils 
defend  the  body  against  bacterial  or  fungal  infection  and  are  usually  first 
responders  to  microbial  infection.  Eosinophils  are  primarily  involved  in 
combating  parasitic  infections  and  are  also  the  predominant  cells  in  allergic 
reactions. Basophils are chiefly responsible for allergic and antigen responses by 
the release of the inflammatory mediator, histamine. Of particular interest in 
this thesis, is the role of monocytes and macrophages in innate immunity and 
inflammation 
2.  
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1.1.2   Monocytic cells 
Monocytes are leukocytes that play a major role in the innate immune system. 
Monocytes are the precursors for a number of terminally differentiated cells of 
the body, including cells such as macrophages 
3, dendritic cells 
4, and osteoclasts 
5. Monocytes develop in the bone marrow from a pluripotent stem cell via the 
common  myeloid  progenitor  cell,  which  is  the  precursor  for  all  cells  of  the 
granulocyte lineage. The earliest stage is the monoblast, which develops into a 
mature  monocyte  in  the  blood  via  a  promonocyte  stage.  Mature  monocytes 
circulate in the blood, where they constitute about 3 8% of the total leukocyte 
population. Monocytes also migrate into the tissues where they differentiate into 
macrophages, depending on the local environment 
2.  They are phagocytic cells, 
which  bind  and  engulf  pathogens  directly  or  via  opsonising  antibodies  or 
complement.  They  also  present  antigen  to  T  cells  and  produce  a  range  of 
cytokines  and  chemokines.  In  the  presence  of  specific  stimuli,  macrophages 
undergo  regulated  programmes  of  activation  that  give  rise  to  either  pro 
inflammatory or anti inflammatory macrophages (discussed further in Chapter 5) 
6 8. 
1.1.3   Cytokines  
Cytokines  are  small  (8 30kDa),  water soluble  proteins  that  are  secreted  by  a 
wide  variety  of  cells  and  play  an  important  role  in  cellular  communication. 
Cytokines mediate their effects by binding to their cognate receptors and are 
critical  mediators  of  both  the  innate  and  adaptive  immune  responses 
9.  In 
certain  cases,  cytokines  will  share  receptors  and  receptor  subunits  and  have 
overlapping functions. They are important in the recruitment, development and 
maturation or differentiation of cell types, as well as playing a role in a range of 
immunological  situations.  Cytokines  can  be  broadly  classified  as  either  pro 
inflammatory or anti inflammatory, although often this is misleading, as the net 
effect of the inflammatory response will be a result of the balance between pro  
and anti inflammatory mediators. The nature, duration and extent of cellular 
activities  induced  by  a  certain  cytokine  will  be  affected  by  the  individual 
cytokine concentration  and the  combinations  of  other cytokines  present.  The 
target cell type, the micro environment of that cell and the characteristics of 
neighbouring cells will also govern the effect of a particular cytokine 
10.   
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1.1.3.1   Pro-inflammatory Cytokines 
Pro inflammatory cytokines are those that generally favour the development of 
an inflammatory state. The group includes cytokines such as tumour necrosis 
factor alpha  (TNF α),  interferon gamma  (IFN γ),  interleukin 6  (IL 6)  and 
interleukin 1 alpha/beta (IL 1α/β), which are responsible for early inflammatory 
responses.  Other  inflammatory  cytokines  include  transforming  growth  factor 
beta (TGF β), interleukin 12 (IL 12) and interleukin 8 (IL 8).  Pro inflammatory 
cytokines induce the inflammatory state and also modulate the production of 
secondary mediators and the recruitment of immune cells 
11.  
1.1.3.2   Anti-inflammatory Cytokines 
Anti inflammatory cytokines are those immunomodulatory cytokines that control 
or counter act the magnitude of inflammatory responses in vivo. They act by 
inhibiting  the  production  or  biological  effects  of  pro inflammatory  cytokines. 
The  major  anti inflammatory  cytokines  are  interleukin 4  (IL 4),  interleukin 10 
(IL 10) and interleukin 13 (IL 13), but the group also includes interleukin 16 (IL 
6),  interferon alpha  (IFN α),  transforming  growth  factor beta  (TGF β),  and 
interleukin 1 receptor A (IL 1RA) 
11.  
1.1.3.3   Chemokines 
Chemokines are chemotactic cytokines that regulate the migration of different 
cell types 
12. Chemokines are generally small polypeptides (8 10 kDa) and often 
exhibit a  degree  of  sequence  similarity.  All  chemokines  contain  a  number  of 
conserved  cysteine  residues  involved  in  intramolecular  disulphide  bond 
formation.  Chemokines  can  be  further  classified  as  CXC chemokines  (α 
chemokines),  CC chemokines  (β chemokines),  C chemokines  (γ chemokines) or 
CX3C chemokines  (δ  chemokines)  depending  on  their  structural  features  and 
genomic location. Certain α chemokines also possess an additional Glu Leu Arg 
(ELR) sequence at the N terminal end. The biological activities of chemokines 
are  mediated  by  specific  receptors,  many  of  which  have  overlapping  ligand 
specificities and can bind several of different chemokines. These transmembrane 
receptors belong to the large group of seven transmembrane domain receptors  
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that contain seven hydrophobic alpha helical segments, which mediate signalling 
via coupling to heterotrimeric G proteins 
13.  
Chemokines have been shown to exert their effects on distinct subsets of cells. 
Some chemokines have been shown to induce selective migration of subsets of 
leukocytes. Chemokines containing the ELR motif are especially chemotactic for 
neutrophils, while chemokines lacking the ELR motif are chemotactic for other 
cell  types  (including  monocytes,  B cells,  basophils  and  eosinophils).  The 
combined effects of multiple chemokines will affect the cellular composition at 
inflammatory sites.  The existence of clearly defined subgroups of chemokines 
on the basis of structural and functional properties illustrates the importance of 
chemoattractant diversity in the regulation of the leukocytes migration in vivo 
14, 15.  
In  addition to  mediating  cell  recruitment, chemokines influence  a  number  of 
cellular  processes,  under  both  physiological  and  pathological  circumstances. 
Chemokines,  such  as  IL 8,  are  multi functional  cytokines  that  influence  and 
enhance  inflammation  through  chemotaxis  and  activation  of  cells  at 
inflammatory  sites 
13.  Certain  chemokines  activate  granulocytes  and/or 
monocytes, induce degranulation and lysosomal enzyme release. Others have a 
priming  effect  on  immune  cells,  allowing  them  to  respond  to  sub optimal 
amounts  of  inflammatory  mediators 
16.  Chemokines  are  important  during  the 
infection  of  cells  by  pathogens,  such  as  the  use  of  the  chemokine  receptors 
CXCR 4 and CCR5 as co receptors for the HIV virus 
17 19. The natural ligands (SDF 
1  and  RANTES/MIP 1β,  respectively)  and  antagonists  of  CXCR 4  and  CCR5  
compete with HIV for binding to these receptors 
20.  SDF 1 also has a role in the 
development and trafficking of cells during haematopoesis 
21. Many chemokines 
are correlated with a number of pathological conditions including autoimmune 
diseases 
22, chronic inflammatory diseases 
23, atherosclerosis and cancer 
24. 
1.1.4   Inflammation and Disease 
Inflammation is the complex vascular response of the body to a biological insult, 
such as an infection. The successful conclusion of inflammation is the removal of 
the  harmful  agent  and  healing  of  the  wounded  tissues.  Inflammation  can  be 
classified as either acute or chronic. Appropriate inflammation is necessary to  
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establish  the  environment  required  to  combat  an  infection,  including  factors 
such  as  the  activation  of  the  complement  system,  and  the  recruitment  of 
phagocytic cells and B and T lymphocytes to the inflamed area 
13, 25. However, in 
certain circumstances,  inflammation  can arise  either  due  to an  inappropriate 
stimulus or may be altered such that it leads to a disease state. Examples of 
such inflammatory diseases include disorders such as rheumatoid arthritis (RA), 
system  lupus  erythematosis  (SLE),  Sjogren’s  syndrome,  Crohn’s  disease  and 
certain  cancers 
9,  26 28.  A  common  characteristic  connecting  a  number  of  the 
inflammatory  disorders  described above  is  the  high  levels  of  the  low  affinity 
receptor for IgE, CD23 
29, 30.  
1.2 The Low Affinity Receptor for IgE (FCεRII / 
CD23) 
CD23 (Blast 2, FcεRII) is a 45 kDa, Type II membrane glycoprotein 
31, 32. CD23 is 
the  only  known  Ig  receptor  that  is  not  a  member  of  the  immunoglobulin 
superfamily 
32.  Membrane  bound  CD23  (mbCD23)  is  cleaved  by  membrane 
associated metalloproteases to yield soluble CD23 (sCD23) fragments of 37kDa, 
which are subsequently cleaved to yield CD23 species of 33kDa, 29kDa, 25kDa 
and 16kDa 
33,  34. All fragments contain the C type lectin domain of CD23 and 
varying portions of the stalk region. Cleavage of the mbCD23 to yield the 37 kDa 
species  occurs  at  a  site  close  to  the  membrane  and  the  single  site  of  N 
glycosylation 
35. CD23 can exist as a monomer and trimer in both membrane 
bound and soluble forms. These soluble fragments retain many of the activities 
of membrane associated CD23 and also possess cytokine like activity 
36 41.  
CD23  is  normally  expressed  on  mature  B  cells,  particularly  activated  cells, 
although  its  expression  is  significantly  altered  in  a  number  of  pathological 
conditions 
42 54. The normal levels of CD23 detected in human serum range from 
0.5 – 5 ng/mL, with children and neonates having higher levels than adults 
42. In 
some disorders, such as chronic lymphocytic leukaemia (CLL), elevated levels of 
CD23 may have prognostic value and may correlate with the progression of the 
disease 
43 47.  Elevated  CD23  levels  are  also  observed  in  disorders  such  as 
rheumatoid arthritis, where the levels of CD23
+ B cells are increased, as is the 
level of sCD23 in the serum and synovial fluid 
48 56.   
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In addition to being a marker for certain diseases, sCD23 possesses cytokine like 
activities. Soluble CD23 acts as a growth factor for Epstein Barr transformed cell 
lines 
57,  58,  prevents  apoptosis  of  germinal  centre  B  cells 
59  and  induces 
differentiation  of  prothymocytes 
60.  These  combined  activites  make  CD23  an 
interesting molecule in the regulation of cell growth and differentiation.  
1.2.1   CD23 Structure 
At the structural level, CD23 is comprised of a number of distinctive functional 
domains and motifs that define its activities (Figure 1 1) 
32, 61, 62. The C terminal 
extracellular domain of CD23 shares structural similarity with the C type lectin 
family.  The  3 dimensional  structure  of  the  lectin  head  of  CD23  has  been 
determined  by  NMR  spectroscopy 
62  and  X ray  crystallography 
63.  The  CD23 
domain contains two a helices orientated at right angles relative to each other 
and two antiparallel β sheets, each made up of four b strands. The structure has 
a  hydrophobic  core,  containing  7  tryptophans  and  other  highly  conserved 
residues, with 4 disulphide bridges maintaining the tertiary structure. The CD23 
lectin  domain  exhibits  a  polarity  with  respect  to  the  distribution  of  its 
electrostatic charges. The positive and negative residues of the highly charged 
surface are located on different faces of the molecule. The authors postulate 
that this is essential for the interaction of CD23 with itself and its ligands 
62.  
The stalk domain of CD23 contains 7 hydrophobic repeats that form an alpha 
helical coiled coil structure 
64. This region connects the lectin domain to the 
transmembrane domain and is the site of oligomerisation of CD23 into trimers. 
The leucine zipper region is near the transmembrane domain and has a 7 amino 
acid motif, beginning with a Leu or Ile residue, which is repeated 5 times in 
human CD23 
61. The stalk is the site of proteolytic cleavage that generates sCD23 
species 
33,  34. The N terminus of CD23 is cytoplasmic and associated with the 
cytoskeleton. There are two forms of CD23, CD23a and CD23b, which differ in 
the sequence of this region. CD23a contains the sequence ‘Met Glu Glu Gly Gln 
Tyr Ser Glu Ile Glu’ (MEEGQYSEIE) at the N terminus, while CD23b contains the 
sequence ‘Met Asn Pro Pro Ser Gln Glu Ile Glu’ (MNPPSQEIE) 
65. The residues in 
bold represent the consensus N terminal pentameric sequence for the two splice 
variants of CD23.   
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Figure   1-1 Schematic representation of CD23 structure 
Membrane-bound (A) and soluble (B) CD23 species are comprised of a number of domains which 
define their function. Cytoplasmic sequence of mbCD23 can be comprised of either the a or b N 
terminal sequence.   
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CD23a is constitutively expressed and confined to certain cell types. CD23b is 
upregulated by exposure to IL 4 and expressed on a wide range of cell types 
66. 
The a and b forms of human CD23 have different functions. The Asn Pro motif of 
CD23b is associated with phagocytosis, while the Tyr based motif of CD23a is 
involved in endocytosis 
65.  
Human CD23 contains an inverse RGD (DGR) sequence near the C terminus. The 
RGD sequence is a common recognition motif for integrin mediated binding and 
is found in a wide range of diverse proteins that are involved in cell adhesion 
(discussed fully later) 
67. The conformation of this DGR containing region is not 
known. The DGR sequence is only found in human CD23 and not in CD23 from 
other species, although the role of this motif remains undefined. One suggestion 
is that this DGR sequence (inverse RGD) in CD23 may interact with an inverse 
‘RGD binding  inhibitory  sequence’.  This  suggestion  is  based  on  a  similar 
interaction with respect to the integrin gpIIb/IIIa. In this case, an RGD binding 
inhibitory sequence in the platelet integrin gpIIb/IIIa blocks the binding of RGD 
containing  ligand  fibrinogen.  Indeed,  CD23  contains  a  possible  ‘DGR binding 
inhibitory motif’ in the stalk region near the membrane. Complete definition of 
the role of the DRG motif will rely on further information on the mechanism of 
RGD recognition and binding by integrins 
61, 68.                    
1.2.2   CD23 Function 
CD23 participates in both protein protein interactions and protein carbohydrate 
interactions. To date, CD23 has been shown to form partnerships with IgE 
62, 69, 
CD21 
62,  70 73,  αXß2  and  αMß2 
74  (leukocyte  integrins)    and  the  vitronectin 
receptors αVß3 
40 and αVß5 
75 (Figure 1 2). The interaction of mbCD23 and sCD23 
with  these  ligands  results  in  specific  events  in  the  cell,  particularly  in  the 
context of allergy, inflammation and cytokine production.   
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Figure   1-2 Interactions of CD23 and its ligands 
Membrane-bound and soluble CD23 interact with a number of ligands, including (A) IgE, (B) CD21, 
(C) αMβ2 and αXβ2 integrins, and (D) αVβ3 and αVβ5 integrins. The interaction with CD21 and IgE 
is important in the regulation of serum levels of IgE, while the interaction of CD23 with its integrin 
receptors induces cytokine production (αMβ2, αXβ2, αVβ3) and cell proliferation (αVβ5).  
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1.2.2.1   CD23 interaction with IgE 
IgE  is  one  of  the  classes  of  human  antibodies  and  is  produced  exclusively  in 
mammals. IgE is particularly effective in defending the body against parasitic 
infections and as such, B cells secreting IgE are found in high concentrations in 
areas of the body most susceptible to parasitic invasion (skin, lungs and gut). 
Allergy  is  caused  by  the  over expression  of  IgE  in  response  to  common 
environmental allergens found in a variety of substances. Although IgE comprises 
a  very  small  fraction  of  the  total  antibody  in  human  serum,  its  action  is 
amplified significantly by the interaction between IgE and its receptors.  
CD23 is the low affinity receptor for IgE, binding IgE with an affinity of Ka ~10
7 
M
 1. CD23 recognises the Cε3 domain of IgE, with Lys352 on IgE shown to be 
essential for CD23 binding 
76. The site of interaction between CD23 and IgE has 
been determined from the recent NMR solution structure of the CD23 C type 
lectin domain, which suggests a continuous interaction surface for IgE comprising 
selected CD23 amino acids in the region between residues Trp184 and Ala279 
62. 
All  of  the  fragments  of  sCD23  retain  the  ability  to  bind  IgE,  although  only 
fragments greater than 28kDa promote IgE synthesis and the 16kDa species can 
in fact inhibit this activity 
42. 
The  CD23/IgE  interaction  is  important  in  the  regulation  of  IgE  levels.  The 
membrane bound  and  soluble  forms  of  CD23  have  different  roles  in  the 
regulation of IgE expression and associated activities 
42 (Figure 1 3). Ligation of 
trimeric mbCD23 by IgE results in negative regulation of IgE synthesis, reducing 
serum levels of IgE 
32, 77, 78. IgE binding to mbCD23 inhibits the release of sCD23 
from  the  membrane  by  stabilising  the  stalk  region  of  CD23  and  preventing 
proteolytic  cleavage,  thereby  further  repressing  IgE  synthesis.  In  contrast, 
ligation of IgE by soluble CD23 species leads to an upregulation in IgE synthesis. 
The ability of sCD23 trimers to enhance IgE production is thought to be through 
its ability to cross link IgE and CD21, another CD23 ligand, on cells 
32, 62, 79.  
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Figure   1-3 Regulation of IgE Synthesis by CD23 
The interaction of mbCD23 and sCD23 with its ligands CD21 and IgE differentially regulates IgE 
synthesis. (A)The interaction between mbCD23 and IgE leads to downregulation in the production 
of IgE. (B) The complex of CD21 and IgE with sCD23 upregulates the production of serum levels of 
IgE.  
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1.2.2.2   CD23 interaction with CD21 
CD21  is  a  145  kDa,  Type  I  transmembrane  glycoprotein,  also  known  as  the 
complement  receptor  type  2  (CR2)  that  plays  a  major  role  in  human  B  cell 
activation and proliferation 
72. CD21 and CD23 interact in both their membrane 
bound and soluble forms and these interactions are mediated via protein protein 
interactions and via N linked sugar chains on CD21. The interaction site on CD23 
for CD21 is found in the C type lectin head and involves residues Glu294, Gly295, 
Ser296 and Glu298 
62.  
Binding sites for CD21 and IgE on CD23 are distinct from each other 
37, 62. sCD21 
and sCD23 form a complex composed of a sCD23 trimer, sCD21 and IgE 
42, 62. This 
soluble  complex  is  similar  to  the  trimeric  CD23/IgE  structure  formed  at  the 
membrane, although the ability of sCD23 to form trimers remains contentious 
80. 
In this case, two of the CD23 lectin heads bind IgE, leaving the third domain 
available for interaction with CD21. This interaction between sCD21 with sCD23 
was shown to be biologically relevant in inhibiting the production of IgE in IL 4 
stimulated B cell cultures 
79. In addition the CD23/CD21 interaction is relevant in 
the regulation of IgE production, the survival of germinal centre B cells and B 
cell  presentation  of  antigens  to  T  cells.  These  results  suggest  a  role  for  the 
sCD21/sCD23 interaction in the context of inflammation and allergy.  
1.3 Integrins 
CD23 is important in the regulation of IgE serum levels through its interaction 
with  CD21  and  IgE 
73,  79,  81,  82.  These  interactions  have  been  the  focus  of  a 
significant  quantity  of  research.  In  addition  to  these  effects,  CD23,  and  in 
particular sCD23, is able to induce the production of proinflammatory cytokines. 
It is the interactions between CD23 and members of the integrin family of cell 
adhesion molecules that may play a role in mediating these cytokine functions 
40, 
41,  83,  84.  The  interaction  between  CD23  and  integrins  may  therefore  be  a 
potential point of intervention for the treatment of inflammatory disorders in 
which overproduction of cytokines is a hallmark 
85, 86.   
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Integrins mediate cell adhesion in a number of biological processes, including 
cell  migration,  morphogenesis  and  differentiation 
87,  88.  Cell  adhesion  is  a 
fundamental  event  that  is  essential  for  a  number  of  processes,  such  as 
embryonic  development 
89,  tumour  cell  metastasis 
90,  wound  healing 
91  and 
monocyte extravasation 
92. Integins physically link the extracellular environment 
with  the  cellular  cytoskeleton.  They  participate  in  both  the  transmission  of 
signals from the extracellular matrix (ECM) to the inside of the cell (‘outside in’ 
signalling) and from the cell to the ECM (‘inside out’ signalling) 
88. They are a 
diverse family of receptors that mediate cell matrix, cell cell and cell pathogen 
interactions 
87.  
1.3.1   Integrin Structure 
Integrins are membrane associated heterodimeric molecules formed by a non 
covalent interaction between two Type I transmembrane glycoproteins, named 
the alpha (α) and beta (ß) subunit. To date, 18 α and 8 ß subunits have been 
identified. These subunits associate to form 24 different αß integins, each of 
which has defined functions and cellular expression patterns and levels (Figure 
1 4).  These  features  of  integrins  result  in  a  large  network  of  molecules  that 
control cell adhesion and related events 
93.  
The integrins are predominantly extracellular, with short cytoplasmic tails (with 
the  exception  of  the  ß4  integrin).  The  overall  assembly  of  the  structure 
represents  an  extracellular  globular  headpiece  supported  by  two  ‘legs’,  one 
from  each  subunit,  anchored  in  the  membrane.  The  N terminal  extracellular 
region of the heterodimeric integrins contains 12 structural domains (Figure 1 
5). The headpiece is the site of the majority of interactions between the two 
subunits and is comprised of 4 domains from the α subunit and 8 from the ß 
subunit. The headpiece is made up of the ß propeller domain from the α subunit 
and the ß subunit hybrid and ßA domains. The α subunit leg is made up of the 
Thigh  and  Calf 1  and  Calf 2  domains.  The  ß  subunit  leg  comprises  the 
plexin/semaphorin/integrin (PSI) domain, 4 epidermal growth factor (EGF) like 
domains and a ß tail domain. A flexible region between the globular headpiece 
and legs, known as the ‘genu’, is the site of bending during integrin activation. 
The main interactions between the two subunits are found in the globular head 
region, between the α subunit ß propeller and the ß subunit ßA domain 
93, 94.   
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Figure   1-4 Association of α and β subunits to form integrin heterodimers 
18 α and 8 β subunits associate to form 24 different integrin heterodimers with different cellular 
functions and distributions. The vitronectin family of integrins contain the common αV subunit and 
can all bind the ECM protein vitronectin. The leukocyte integrins all contain the common β2 subunit 
and are expressed on leukocytes. The integrins known to bind CD23 are shaded grey.  
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1.3.1.1   Alpha Subunit 
The α subunit is comprised of four or five domains. There are two types of α 
subunit, differentiated by the presence or absence of a domain known as the 
inserted (I) domain. The I domain contains 200 amino acids, inserted between ß 
sheets 2 and 3 of the ß propeller domain. It is also known as the von Willebrand 
A  domain  due  to  similarities  to this  structure.  The  I domain is  only  found in 
certain α subunits, although its presence has been predicted in other α subunits. 
This  domain  is  the  major  ligand  recognition  and  binding  site  in  I domain 
containing α subunits, via a metal ion dependent adhesion site (MIDAS). Residues 
from  this  site  (DXSXS)  are  integral  for  the  coordination  of  metal  ions,  in 
conjunction with complementary sites on the ß subunit, during cation dependant 
ligand binding by integrins 
95.  
The N terminal ß propeller domain forms a seven bladed ß propeller structure, 
comprised of seven segments of approximately 60 amino acids that share weak 
homology.  The  ß  propeller  contains  the  ‘active  site’  amino  acids  that,  in 
conjunction with amino acids from the ß subunit, participate in ligand binding in 
integrins  that  lack  an  I domain.  In  I domain containing  α  subunits,  the  ß 
propeller  domain  may  cooperate  with  the  I domain  residues  during  ligand 
binding. Ligand binding residues cluster at the top and side of the ß propeller. At 
the base of the ß propeller, opposite the αß interface, are four solvent exposed 
calcium  binding  sites.  The  coordination  of  calcium  at  these  sites  and  other 
numerous contacts between the ß propeller and the Thigh domain suggests that 
the ß propeller is structurally rigid 
94.  
The remaining C terminus of the extracellular domain of the α subunit contains 
stalk like structures of the Thigh and Calf 1 and Calf 2 domains.  These are 3 β-
sandwich domains. The Thigh region adopts an Ig like structure, although it is 
significantly  larger.  The  interface  between  the  Thigh  and  ß propeller  is 
relatively  large  and  elongated  (about  700Å
2)  and  is  suggestive  of  possible 
interdomain movement. This movement may be rotation and may be mediated 
by the binding of calcium at the base of the ß propeller 
94.  
The two Calf domains share structural similarity. Both contain two antiparallel ß 
sheets, Calf 1 domains contain four ß strands and Calf 2 contains 5. Calf 2 also  
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contains  the  Arg860  residue  that  is  the  site  of  proteolytic  cleavage  that 
generates the heavy and light chains of αV. The interface between the Thigh and 
Calf 1 domain occupies approximately 200Å
2. The base of the Thigh and the top 
of  the  Calf 1  domain  that  form  the  genu  are  rich  in  acidic  residues  that 
coordinate a calcium ion. This ion may stabilise these acidic residues when the 
integrin is in the open conformation 
94.  
1.3.1.2   Beta Subunit 
The N terminal 50 amino acids of the ß subunit are predicted to form a plexin 
semaphorin integrin (PSI) like domain. Despite being encoded at the N terminus, 
structurally, this domain forms part of the ß subunit leg. The region is cysteine 
rich, 6 of which are common to other PSI domains. The first of the cysteines 
forms a long range disulphide bridge with the C terminal cysteine rich region of 
the ß subunit, which restrains the integrin in an inactive state 
96.  
The highly conserved ßA domain, also known as the I like domain, comprises a 
domain  of  approximately  240  residues  (residues  100  –  340).  The  ßA  domain 
adopts a Rossman fold and, aside from the presence of two extra loop regions, is 
identical to that observed in the integrin I domain. It comprises a central ß sheet 
of 6 strands, surrounded by 8 α helices. This domain donates the majority of 
residues  involved  in  ligand  binding and  contains  two  metal  coordination  sites 
that participate in ligand binding – the MIDAS (Metal Ion Dependent Adhesion 
Site) and LIMBS (Ligand Induced Metal Binding Site).  The MIDAS is formed by the 
side  chains  of  residues  Asp112,  Ser121,  Ser123  (DXSXS  motif),  Glu220  and 
Asp251. The MIDAS is located in a crevice at the top of the central ß strand. The 
LIMBS is defined by residues Asp158, Asn215, Asp217, Pro219 and Glu220. The 
Mn
2+ ion coordinated by LIMBS does not directly contact the ligand, but ligand 
binding is reliant on the presence of the Mn
2+ ion 
94, 97.  
The Hybrid domain is formed from two stretches of linear sequence on either 
side of the ßA domain that fold into an Ig like structure. The Hybrid and ßA 
domains  form  a  relatively  large,  circular  interface  (approximately  650Å
2)  of 
mixed hydrophobic and hydrophilic nature. The numerous interactions between 
the Thigh and ßA domains suggest that interdomain movement is minimal 
94.  
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Figure   1-5 Structural feature and conformational activation of αVβ3 integrin 
(A) Schematic representation of the domains comprising the α and β integrin subunits. (B) Bent 
(inactive) and extended (active) conformations of integrins as proposed by the switchblade model 
of integrin activation 
98.  
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The Epidermal Growth Factor like (EGF) domains (EGF1/2, EGF3 and EGF4) are 
contained  in  residues  340  to  700  of  the  ß  subunit.  Each  domain  contains  3 
disulphide bridges that are necessary for the integrin EGF structure. A fourth 
disulphide bridge links the domains. EGF1/2 is largely unstructured in the crystal 
structure, although the predicted sequence predicts a high degree of structural 
similarity with EGF3 and 4. These domains are one of 3 structural subtypes of 
EGF like domain that occur in proteins. The EGF domains lie in the genu region 
and the lack of resolution may be a result of the movement in this area. EGF3 
and 4 are similar in structure and together form an extended rod shaped unit. 
The interface between EGF3 and 4 is small (200Å
2) and probably rigid due to 
extensive  interdomain  contacts,  including  a  disulphide  bridge,  main  chain 
hydrogen  bonds  and  hydrophobic  interactions.  Antibodies  that  selectively 
recognise  activated  integrins  have  been  shown  to  bind  epitopes  that  map  to 
these EGF domains 
95. These ß subunit regions correspond to the α subunit stalk 
region and are considered important for signal transduction 
99, 100.  
The  very  C terminal  region  contains  the  ß  tail  domain  (ßTD).  The  ßTD  is 
comprised of a ß sheet of 4 antiparallel and parallel ß strands. Facing it is an α 
helix, that interacts hydrophobically with the ß sheet. The ßTD does not share 
any significant homology with other known domains and may be considered a 
new fold. This domain forms two weak hydrophobic interactions with the EGF 
domains, suggesting that this interface may be flexible 
94.  
1.3.2   Ligand recognition by Integrins 
Binding of ligands by integrin is dependent on the presence of a particular motif 
within  that  ligand.  The  Arg Gly Asp  (RGD)  peptide  was  first  discovered  in 
fibronectin and is now widely recognised as the classical recognition sequence 
for most integrins 
101. This sequence is found in a diverse range of receptors and 
integrin ligands. The presence of a small motif in a range of functionally diverse 
ligands creates an extensive system for recognition by cell adhesion molecules. 
Introduction of the RGD sequence to lysozyme and hirudin gave the proteins the 
ability to function in cell adhesion 
102.  
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1.3.2.1   The Classical Recognition Sequence, ‘RGD’ 
The RGD tripeptide is the smallest unit that can be recognised and bound by 
integrins and in some cases is sufficient to mimic (when attached to a surface) 
or block (when in solution) the adhesive action of the natural ligand 
103. The 
effect elicited by the RGD peptide is generally less than that mediated by its 
natural ligand. The sequence is specific and even conservative changes (such as 
Gly to Ala) significantly reduce the activity of the peptide. The conformation of 
the amino acid residues in the peptide is important for activity, with an RGD 
peptide  containing  D arginine  being  inactive 
101.  Although  the  minimal  unit 
necessary for activity is the RGD motif, there is a requirement for a further 
residue  at  the  C terminal  end,  to  block  the  carboxyl  group  of  Asp.  The  C 
terminal  sequence  affects  the  affinity  and  selectivity  of  the  RGD  peptide 
binding.  Peptides  with  Gly,  Trp  or  Phe  residues  C  terminal  to  the  RGD  have 
higher binding affinities for the α5ß1 integrin, while the αVß3 and αVß5 integrins 
prefer Ser or Ala, and αIIBß3 requires a Tyr or Arg 
104. The rigidity or flexibility 
of RGD containing loops has been linked in NMR studies to a narrow or wide 
range  of  recognition  profile,  respectively.  Cyclisation  of  the  RGD  containing 
peptides  increases  interaction  with  vitronectin  receptors,  but  not  fibronectin 
receptors 
105.  
Proteins  containing  RGD  motifs  and  participating  in  cell  adhesion  include 
fibronectin,  vitronectin,  fibrinogen,  von  Willebrand  factor,  thrombospondin, 
laminin,  entactin,  tenascin,  osteopontin,  bone  sialoprotein  and  under  certain 
conditions  collagens 
106.  Some  proteins  that  do  not  naturally  mediate  cell 
attachment,  such  as  Gamma  II  crystallin  and  Escherichia  coli  (E.coli)  lambda 
receptor, are capable of binding integrins in vitro. This is most likely due to the 
recognition of the specific conformations of the RGD motif in these proteins by 
integrins  (especially  αVß3).  The  recognition  of  the  RGD  tripeptide  is  also 
exploited by pathogens to gain entry into the cell. Adenovirus penton protein, 
foot and mouth virus coat protein and Bordetella pertussis surface protein all 
contain RGD motifs capable of being bound by cell surface integrins.  The RGD 
site is evolutionarily conserved in other organisms and may mediate attachments 
in Drosophila and certain plants 
101.  
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Recent interrogation of sequence databases revealed 7182 proteins containing 
RGD sequences. Of these 7182, 404 are membrane proteins, 120 of which have 
the RGD peptide located in their extracellular domain. These proteins contain a 
number of known cell adhesion proteins, in addition to 48 well characterised 
receptors. In most cases the authors determined that the RGD motifs form or are 
predicted  to  lie in  a  loop  structure  similar  to that observed in  cell  adhesion 
complexes. In addition, RGD motifs from receptors with known crystal structures 
were shown to assume a similar conformation, with the Arg and Asp residues 
pointing away from each other, to that observed in cell adhesion complexes. 
Receptors have not been considered as having cell adhesion properties before 
this  study  and  the  significance  of  these  RGD  sequences  will  need  to  be 
determined experimentally 
102.  
While the RGD peptide is the smallest recognisable unit, the conformation in 
which the peptide is presented is essential for its function. The conformation of 
the peptide will influence binding by different integrins. α5ß1 preferred binding 
larger, RGD containing fibronectin polypeptides, while αVß3 was more efficient 
at binding smaller RGD containing fibronectin fragments 
107. This could suggest 
that the presence of surrounding sequence will influence the peptide recognition 
and binding ability 
104. Alternatively, while the RGD motif is the basic unit of 
recognition,  binding  specificity  may  also  rely  on  the  presence  of  synergistic 
sites.    The  presence  of  synergistic  sites  has  been  suggested  for  ligands  of 
integrins αIIbß3, α5ß1, αVß3 and αVß5 
75, 108, 109.  
Insights into the binding of RGD containing ligands have been provided by the 
crystal  structure  of  the  extracellular  domain  of  αVß3  integrin  alone  and  in 
complex  with  a  cyclic  RGD containing  pentapeptide.  The  availability  of  both 
ligand bound and ligand free structures allows analysis of both the fundamental 
residues involved in the interaction and conformational changes that arise due to 
ligand binding 
94, 98. 
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Figure   1-6 Binding of cyclic RGD containing peptide by αVβ3 
(A) Binding of the cyclic RGD containing peptide by αVβ3 involves residues from both subunits. 
(B)The conformation of the cyclic RGD containing peptide in complex with αVβ3.  
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Ligand binding is cation dependent and mediated by residues from both the α 
and ß subunit. The Asp of the RGD sequence is coordinated by a divalent cation 
bound by the MIDAS on the α subunit. In I containing α subunits the MIDAS is 
located  in  the  I domain  and  in  non  I domain  containing  integrins  there  is  a 
corresponding MIDAS on the ß subunit. In certain cases, the ß propeller domain 
from  the  α subunit  also  donates  residues  to  bind  the  ligand.  The  ß  subunit 
contains  two  sites  capable  of  coordinating  metal  ions,  the  MIDAS  and  LIMBS, 
which participate in ligand binding. ADMIDAS (adjacent to MIDAS) coordinates 
either  Ca
2+  or  Mn
2+  in  the  presence  and  absence  of  ligand,  while  the  LIMBS 
contains a Mn
2+ when ligand is present, but not in the absence of ligand 
98.  
The RGD peptide binds a shallow groove at the interface of the ß propeller of 
the α subunit and the ßA domain of the ß subunit. The Arg
RGD residue is bound by 
the  ß propeller  groove.  The  Arg
RGD  guandinium  group  forms  a  bidentate  salt 
bridge  with  Asp218  and  another  salt  bridge  with  Asp150.  These  ß  propeller 
residues are located at the base and rear of the groove, respectively. In this 
conformation,  the  majority  of  the  upper  Arg
RGD  sidechain  is  solvent exposed, 
making it likely that the interaction is further stabilised by interactions with 
water  molecules.  The  interaction  with  the  ß  subunit  ßA  domain  is  mediated 
primarily by the Asp carboxylate group. This group forms the centre of a network 
of polar interactions with the ßA residues and the MIDAS. One of the carboxylate 
oxygen atoms is coordinated by a Mn
2+ ion at MIDAS, while the second hydrogen 
bonds with backbone amides of Tyr122 and Asn 215 and the Arg214 sidechain. 
The  Asp
RGD  residue  is  completely  buried  within  its  binding  pocket,  with  the 
remainder of the chain forming hydrophobic contacts with the beta carbon of 
Asn215.  The central Gly
RGD projects into the interface between the α and ß 
subunits. It interacts with the αV subunit, primarily via the carbonyl oxygen of 
Arg216.  The  main chain conformation  of  the  RGD  peptide  in the  structure  is 
identical to that observed in the natural integrin ligand Echistatin 
98 (Figure 1 6). 
The binding to the ßA domain is similar to that observed with the αA integrin 
ligand  interaction.  In  both  cases,  an  acidic  residue  contacts  a  metal  ion  at 
MIDAS. ßA differs from αA in that a ligand is required for divalent cation binding, 
however  the  αA  domain  can  bind a  metal  ion in the  presence  or absence  of 
ligand. This is explained by the conformation of the side chain of Glu220 in the 
unliganded ßA domain. Glu220 intrudes into the MIDAS, restricting cation binding  
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possibly through steric hindrance. The structure of the ligand bound ßA domain 
shows a change in the conformation of the Glu220 sidechain, allowing access to 
the MIDAS for cations. The ßA domain also contains a second cation binding site 
termed LIMBS. At this site, the metal ion is coordinated by the other carboxylate 
oxygen of Glu220, the side chains of Asp158, Asn215 and Asp217, the carbonyl 
oxygens of Asp217 and Pro219. Although this site does not directly contact the 
ligand, it is required for metal ion coordination, as the coordination sphere is 
absent  in  the  unliganded  structure.  Its  most  likely  role  is  to  stabilise  the 
orientation of Glu220 and provide structural stability to the ligand binding region 
98 (Figure 1 6).  
Changes  in  the  overall  structure  between  the  ligand free  and  ligand bound 
integrin are observed, despite the binding of only the small simple recognition 
sequence. At the tertiary level, there is a change in the conformation of some of 
the loops in the ßA domain. Quaternary changes are observed in the head region, 
with  the  ßA  and  ß propeller  domains  coming  closer  together  at  the  peptide 
binding site. The ß propeller is slightly rotated at the propeller thigh interface, 
with a corresponding rotation observed from the ßA domain. These changes are 
analogous  to  the  change  observed  with  G  proteins,  where  the  ßA  alters  its 
orientation relative to the ß propeller. It is likely that this change is going to be 
more  pronounced  when  the  integrin  is  bound  by  one  of  the  larger  and 
structurally diverse natural ligands 
98. 
1.3.2.2   Other Recognition Sequences 
Integrins also recognise sequences other than the RGD motif in their ligands. In 
certain  cases,  these  recognition  sequences  are  slight  variations  on  the  RGD 
motif. The Gly position of the RGD may be occupied by a number of residues or 
in certain cases by two residues and still be bound by integrins 
101. A peptide 
containing the sequence NGR binds with low affinity to integrins, although the 
inverse  RGD  sequence,  DGR,  does  not  have  any  measurable  integrin  binding 
activity. This is interesting in the context of CD23, as it contains a DGR sequence 
and is known to interact with RGD binding integrins. Whether the interaction is 
via this DGR sequence remains to be fully determined 
67.   
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αIIbß3 also binds the sequence KQAGDV, an interaction that is blocked by RGD 
containing peptides and so presumably occurs at the same binding site. α4ß1 and 
α4ß7 recognise the LDV peptide 
110. This motif is found in a splice variant of 
fibronectin. α4ß1 also recognises the IDA(PS) and REDV sequences in fibronectin. 
IDA could be regarded as a version of LDV and REDV as a version of RGD. α2ß1 
has  been  shown  to  recognise  the  DGEA  motif,  YGYYGDALR  from  laminin  and 
FYFDLR from type IV collagen. The α1ß1 integrin recognises a motif composed of 
Arg  and  Asp  residues  on  type  I  collagen.  The  αMß2  integrin  recognises  the 
sequence KRLDGS from fibrinogen and sequences containing L/IET in I CAMs are 
recognised by ß2 integrins 
101, 104.  
Despite the range of sequences recognised by integrins, in most cases, those 
alternative motifs described thus far all include an Asp, or the closely related, 
Glu residue. This requirement for the Asp may be due to its ability to coordinate 
metal ions essential for integrin based ligand recognition. The group of snake 
proteins, the disintegrins, contain RGD motifs and can interact with integrins 
111. 
In some cases the RGD sequence is replaced by KGD. The ADAM (a distintegrin 
and  metalloproteinase)  family  of  mammalian  proteins  is  homologous  to  the 
disintegrins, although they do not contain the RGD motif. The recognition site 
determined  for  one  ADAM,  fertilin,  was  found  to  be  TDE,  which  may  be 
analogous to the disintegrin RGD 
112, 113.   
The recognition of the RGD binding motif was fully determined by the solution of 
the structure of αVß3 bound to an RGD containing pentapeptide. As such, full 
elucidation of the mechanism of recognition of these alternative motifs will rely 
on the future crystallisation of integrin ligand complexes. 
1.3.2.3   Alternate Binding Sites 
In addition to the recognition of different sequences at the ‘RGD recognition 
site’ of integrins, the existence of an additional, distinct ligand binding site on 
the aVb3 and aVb5 integrins has been suggested. These alternate binding sites 
have been suggested by the binding of ligands, such as tumstatin 
114, HIV Tat 
protein 
109 and entactin 
115, to these integrins at RGD independent sites. These 
studies have proposed either the existence of an additional distinct binding site 
or  a  synergistic  ligand  recognition  site  that  cooperates  with  the  RGD  binding  
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site.  Analysis  of  the  binding  of  Type  IV  collagen  indicates  that  this  protein 
contains additional aVb5 and aVb3 binding sites 
108. These sites, however, are 
recognised  more  efficiently  when  in  the  context  of  the  intact  protein  (and 
potentially  the  RGD  site),  than  as  individual  peptides.  This  may  suggest  a 
synergistic relationship or a requirement for a specific conformation during the 
binding of the non RGD collagen derived peptides. Similarly, studies with the 
HIV Tat protein have suggested the presence of a synergistic binding site in aVb5 
109. A 9 residue basic peptide derived from Tat was shown to bind the  aVb5 
integrin in an RGD and divalent cation independent fashion. This basic peptide 
was  highly  specific  with  respect  to  sequence  and  capable  of  mediating  cell 
attachment. The authors postulate that, although Tat contains an RGD motif, it 
is not presented in a context that allows it to bind aVb5. They suggest that the 
basic peptide binds a synergistic site on aVb5 to mediate specific interactions. 
Studies on the binding of tumstatin derived peptides to aVb3 indicated that the 
protein contains an RGD independent aVb3 binding site, as the binding of the 
peptides was not inhibited by the presence of cyclic RGD peptides 
114. Entactin 
was  also  shown  to  contain  two  distinct  RGD independent  cell  attachment 
peptides.  Mutants  of  entactin  lacking  the  RGD  motif  were  still  capable  of 
mediating cell attachment, although identification  of the integrin involved in 
binding still requires elucidation 
115.  
1.3.3   Integrin Activation and Signalling 
Integrins  are  capable  of  transmitting  signals  bidirectionally  across  the 
membrane.  They  form  a  mechanical  link  between  the  cytoskeleton  and  the 
extracellular matrix and activate intracellular signalling pathways 
116,  117. They 
are  capable  of  transmitting  signals  from  the  ECM  to  the  interior  of  the  cell 
(‘outside in’  signalling)  and  from  the  interior  of  the  cell  to  the  external 
environment  (‘inside out’  signalling) 
88.  Formation  of  mechanically  stable 
integrin  complexes  is  essential  for  the  transduction  of  mechanical  signals 
between  the  cell  and  ECM.  Integrins  are  physically  associated  with  the 
contractile cytoskeleton in the cytoplasm of cells and form transient interactions 
with  ligands  through  their  extracellular  domains.  Except  for  the  b4  subunit, 
which  is  connected  to  intermediate  filaments  of  the  cytoskeleton,  all  of  the 
cytoplasmic tails of integrins are linked to the actin based microfilament system 
of the cell 
118 120.   
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The transmission of a signal from a ligand binding site, across the membrane and 
to the cytoskeleton (or vice versa), requires long range conformational changes 
and cooperation between integrin domains. Many integrins are not constitutively 
active, but require activation prior to ligand binding and signalling. The signal 
for  activation  or  inhibition  may  come  from  interactions  between  different 
integrins 
95. The current model for integrin activation is based on the recently 
solved structure of the extracellular domains of the aVb3 integrin 
94, 97, 98. This 
model  is  referred  to  as  the  ‘Switchblade  model’  and  suggests  the  integrin 
changes  between  active  and  inactive  forms  by  conformational  rearrangement 
(Figure 1 5). The inactive form of the aVb3 integrin has a bent shape, with the 
protein anchored in the membrane and the extracellular domains bent over to 
create a V shape. The site of bending is the genu between the headpiece and 
stalk regions of the heterodimer. This structure was determined in the presence 
of Ca
2+ ions, known to promote the inactive form of integrins. In addition, the 
lack of ligand or Mg
2+ ions supports the interpretation that this is the inactive 
conformation of the integrin.  Structural analysis of integrins in the presence of 
ligand indicates an open extended conformation is the active structure. Thus the 
‘Switchblade’ model proposes that that activation of the integrin results in an 
extension of the headpiece away from the membrane, in a manner analogous to 
the  opening  of  a  switchblade  knife.  This  conformational  change  makes  the 
activation and functional binding residues accessible 
94, 121.   
1.3.3.1   Inside-out signalling 
Inside out signalling relates to the transmisson of signals from the interior of the 
cell to the ECM. For example, integrins on leukocytes and platelets will need to 
be activated by internal signals or agonists to bind their ligands. The current 
hypothesis  is  that  the  α  subunit  blocks  the  ß  subunit  contacts  with  the 
cytoskeleton when the integrin is in an inactive state. The activation of integrins 
by inside out signalling is regulated by the movement apart of the areas of the a 
and b subunit domains in response to a stimulus 
100,  122,  123. This is thought to 
supply the trigger for the upward switchblade movement of the extracellular 
headpiece, leading to activation of the integrin from within the cell. In addition 
to  these  changes  in  affinity,  it  has  been  suggested  that  changes  in  integrin 
avidity (clustering) affect signalling. Many studies report an increase in integrin 
activity and signalling due to receptor clustering. This would obviously lead to  
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improved  efficiency  of  ligand  binding,  particularly  in  the  case  of  multivalent 
ligands 
95. It is difficult, however, to distinguish whether integrin clustering is 
the stimulus for, or the consequence of, an increase in ligand binding affinity. 
Despite this, changes in avidity are generally regarded as important for inside 
out  signalling,  not  least  because  of  the  difficulties  in  direct  quantitation  of 
binding of soluble ligands that affect integrin affinity. The most likely situation 
of  integrin  activation  will  include  a  combination  of  changes  in  affinity  and 
avidity, depending on the integrin and cell type of its expression 
124.  
1.3.3.2   Outside-in signalling 
Integrin mediated  ‘outside in’  signalling  refers  to  the  transduction  of  signals 
generated by ligand binding to the extracellular domains of integrins, across the 
membrane to activate intracellular signal pathways. The activation of integrins 
for  ‘outside  in’  signalling  is  also  dependent  on  changes  in  integrin  avidity, 
although avidity alone is not enough to stimulate complete outside in signalling 
95.  Concurrent changes in affinity will also affect the ability of an integrin to 
participate  in  outside in  signalling.  Using  electron  microscopy,  Takagi  and 
collegues  showed  that  gross  conformational  changes  occur  when  an  inactive 
integrin (αVß3) is exposed to a high affinity ligand mimetic and Mn
2+ ions. The 
inactive integrin opened in a switchblade like manner, with an accompanying 
swinging out of the hybrid domain. The authors propose that integrin activation 
occurs  in  two  stages.  In  the  first  stage,  ligand  or  Mn
2+  binding  induces  the 
opening of the inactive integrin and subsequent conformational changes in the 
integrin result in high affinity binding of the ligand 
125. This suggests there are 
three  activation  states  for  the  integrin   the  closed  conformation  when  the 
integrin is inactive, the extended conformation with a ‘closed’ headpiece due to 
ligand or Mn
2+ binding and the high affinity state, where the integrin headpiece 
is  open  due  to  conformational  changes  and  the  ligand  is  bound.  The 
susceptibility of individual integrins to activation will differ according to their 
ligand  binding  capabilities,  requirements  for  divalent  cations  and  biological 
function 
126, 127.     
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1.3.3.3   Integrin cytoplasmic signalling cascades 
Outside in  signalling  by  integrins  in  response  to  binding  of  external  ligands 
results in the activation of a number of signalling pathways within the cell, the 
ultimate consequence of which is a change in gene expression and behaviour of 
that cell depending on the nature of the particular stimulus. Integrin signalling 
controls a range of cellular functions including adhesion, cytokine production, 
cell growth and differentiation 
128.  
The  cytoplasmic  tails  of  integrins  are  short  and  lack  any  inherent  enzyme 
activity. Signal transduction from integrins is via a series of adaptor proteins, 
which  link  the  integrin  to  the  cytoskeleton,  cytoplasmic  kinases  and 
transmembrane growth factor receptors. Integrins directly activate cytoplasmic 
kinase  signalling  pathways  themselves  and  are  also  able  to  modulate  the 
signalling pathways that arise from growth factor receptors. The major signalling 
pathways activated by integrins are summarised in Figure 1 7 
90.  
1.3.3.3.1  Src family kinases (SFKs) and Focal Adhesion Kinase (FAK) 
signalling by integrins 
Integrin mediated signalling occurs predominantly through the activation of Src 
family kinases (SFK) and focal adhesion kinase (FAK) 
128. FAK activation is most 
important in adhesion based signalling mechanisms for integrins and controls the 
activation  of  a  number  of  downstream  pathways.  FAK  interacts  with  the  β 
subunit cytoplasmic domains of integrins, either directly or via an interaction 
with  the  cytoskeletal  proteins  paxillin  and  talin.  Activation  results  in  the 
autophosphorylation of FAK on Tyr
397 and acts as a scaffold for SFKs (Src and Fyn) 
in  focal  adhesions,  leading  to  the  phosphorylation  of  p130
CAS  and  paxillin, 
recruitment  of  Crk DOCK180n  complex  and  activation  of  Rac.  Active  Rac  can 
subsequently activate the NFκB transcription factors directly or lead to the PAK 
dependent activation of JNK (c jun N terminal kinase). Active Crk is also capable 
of  activating  C3G,  leading  to  the  Rap1/B Raf/ERK  (extracellular regulated 
kinase) activation cascade. FAK can also directly or indirectly (via SFKs) activate 
the signalling molecule PI3K (phosphatidyl inositol 3 kinase), which in turn leads 
to  the  activation  of  the  serine/threonine  kinase  Akt/PKB  and  GEF  (guanine 
exchange  factor)  via  the  synthesis  of  phosphatidylinositol 3,4,5 triphosphate  
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(PtdIns(3,4,5,)P3).  Cross  talk  between  FAK  and  TLR  signalling  pathways  (via 
MyD88)  has  also  been  shown  to  enhance  of  the  activation  of  NFκB  and 
transcription of NFκB controlled genes, such as IL 6 
129. 
1.3.3.3.2  Mitogen Activated Protein Kinase (MAPK) signalling by 
integrins 
Integrins can activate ERK via the GTPase dependent Ras/Raf/MEK/ERK mitogen 
activated  protein  kinase  (MAPK)  pathway  through  a  FAK  dependent  or 
independent mechanism 
117. Integrin ligation can lead to the activation of SFKs 
or FAK, both of which lead to the activation of Shc, Grb2, and Sos and results in 
the phosphorylation of the Ras GTPase. Active Ras phosphorylates Raf, which 
activates MEK, which in turn activates ERK 
130. The MAPK cascade which results 
in the activation of the ERK is a key regulator of a number of cellular processes. 
The  effects  of  this  pathway,  activated  by  both  adhesive  and  growth  factor 
signals, are mediated by the dynamics of the magnitude and duration of ERK 
activation.  Both  FAK dependent  and  Shc dependent  mechanisms  of  activating 
ERK are likely to be important during integrin mediated signalling. Shc, which 
activates  rapidly,  is  most  likey  responsible  for  the  initial  high  levels  of  ERK 
phosphorylation, while FAK, which is activated more slowly, may contribute to 
sustaining this ERK activation 
128.   
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Figure   1-7 Cytoplasmic signalling cascades from integrins 
Integrin-mediated  signalling  can  lead  to  the  activation  of  a  number  of  cytoplasmic  signalling 
cascades that result in a change in gene expression. Integrin-mediated signalling can arise directly 
from the integrin itself or from the association between an integrin and growth factor receptor. 
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1.3.3.3.3  Nuclear Factor Kappa B (NFκB) signalling by integrins 
NFκB is the collective name given to the family of dimeric transcription factors 
(made up of combinations of the monomeric p50, p52 and p60 subunits) which 
control the transcription of a range of pro inflammatory genes 
131. The proteins 
are held in an inactive form in the cytoplasm by their association with the IκB 
(inhibitory κB) protein inhibitor. The targeted phosphorylation of IκB protein by 
the IκK (inhibitory κ kinase) and subsequent IκB degradation releases the active 
NFκB complex, which translocates to the nucleus and induces the transcription 
of  target  genes.  NFκB  activation  has  been  implicated  in  many  biological 
processes,  including  inflammation,  apoptosis  and  cell  proliferation.  Integrin 
ligation  leading  to  the  production  of  cytokines,  including  TNF α  and  IL 1, 
involves the activation of NFκB (p50:p65 dimer) via the activation of the Rac 
GTPase. FAK can either activate Rac via the Cas/Crk/Dock180 cascade or via 
PI3K and GEF 
90.  
There  is  also  evidence  for  cross talk  between  FAK  and  MyD88  (myeloid 
differentiation factor 88) pathways. MyD88 is an adaptor protein that controls 
signalling from a number of Toll like receptors (TLRs), which are a major group 
of  surface  receptors  that  activate  NFκB  and  play  an  essential  role  in  innate 
immune  signalling  and  detection  of  pathogens  (Figure  1 8).  Signalling  arising 
from different TLRs is either MyD88 dependent or MyD88 independent. MyD88 is 
associated with TLR cytoplasmic tails and activation leads to a signalling cascade 
involving  TIRAP/Mal,  IRAK  and  TRAF 6  signalling  molecules,  leading  to  NFκB 
activation 
132.   
MyD88 and FAK are key adaptors involved in signalling downstream of TLR 2, 
TLR 4,  and  integrin  α5β1,  linking  pathogen  detection  to  the  initiation  of  an 
inflammatory response. FAK activation leads to activation of the downstream 
components of the MyD88 signalling pathway and subsequent activation of MAPK 
and  NFκB  and  synthesis  of  cytokines.  The  MyD88  and  integrin  pathways  are 
interlinked, but the mechanism of this cross talk is poorly understood at present 
129.  The  αMβ2  integrin  was  shown  to  signal  using  TLR  pathway  intermediates 
during the activation of NFκB in THP 1 cells. The αMβ2 integrin was shown to 
bind  to  IRAK  and  to  activate  the  TRAF 6  and  TAK  signalling  molecules. 
Interestingly,  this  αMβ2 mediated  activation  of  NFκB  was  determined  to  be  
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MyD88 independent.  The  most  recent  study  has  identified  a  role  for  FAK  in 
integrin mediated  activation  of  NFκB.  FAK  induced  the  activation  of  Etk  (a 
member of the Tec family of kinases) and TIRAP/Mal (a TLR adaptor protein). 
FAK was shown to be associated with the Etk, MyD88, and TIRAP/Mal molecules 
in the cell 
133.  
1.3.3.4   Integrin modulation of other receptors 
In  addition  to  direct  adhesion based  signalling,  integrins  modulate  signalling 
from other receptors 
116, 134, 135. Growth factors (GF) induce their activity through 
binding  their  cognate  receptors  on  the  surface  of  cells.  In  most  cases,  the 
interaction between integrin and growth factor receptor (GFR) is a synergistic 
one and leads to an enhancement of GFR signalling and an amplification of the 
response of the cell to the presence of the GF 
116. The ability of integrins to 
activate ERK may be especially important when the concentrations of GF in the 
cell are low. Under these circumstances, the synergy between integrins and GFR 
leading  to  ERK  activation  will  be  essential  for  cell  proliferation  and 
differentiation.  Activation  of  ERK  in  this  case  is  usually  via  the 
Grb2/Sos/Ras/Raf/MEK/ERK pathway 
136. Integrins can also modulate the GFR 
activity by influencing its localisation and/or internalisation and degradation 
134.  
Integrin  modulation of  GFR  activity  has  been  described  for  a  number  of GFR 
including,  basic  fibroblast  growth  factor  receptor  (bFGFR) 
137,  vascular 
endothelial growth factor receptor (VEGFR) 
138, platelet derived growth factor 
receptor (PDGFR) 
139, insulin growth factor receptor (IGFR) 
140, 141, and c FMS (M 
CSF receptor) 
142.  The β2 integrins also play an important role as part of the 
endotoxin signalling complex, which contains CD14, TLR 4 and β2 integrins 
143.    
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Figure   1-8 Toll-like Receptor (TLR) signalling pathways 
TLR receptors are an evolutionarily conserved group of receptors with important roles in the innate immune sensing of pathogens. Signalling from TLR dimeric receptors 
may be depedent or independent of the MyD88 molecule. 55 
 
1.3.4  CD23/Integrin Interactions  
1.3.4.1   CD23 interaction with beta-2 (CD18) Integrins. 
The ß2 integrins are exclusively expressed on leukocytes (and are often referred 
to as ‘the leukocyte intergrins’). They are heterodimeric αß integrins, formed by 
the association of one of 4 α chains (αD, αL, αM or αX) with the ß2 integrin. 
αMß2 and αXß2 bind a number of ligands, including CD54, fibrinogen, factor X, 
lipopolysaccharide (LPS), concanavalin A and zymosan 
144. Integrins are proteins 
that play a critical role in cell adhesion and signalling across membranes. They 
control  cell cell  and  cell extracellular  matrix  contacts  and  participate  in 
signalling both from the cytoplasm to the exterior of the cell and vice versa. Cell 
adhesion is essential for cell migration, proliferation and differentiation.  Thus, 
integrins  are  crucial  for  correct  cell  development  and  function  and  are 
implicated in a number of pathologies 
124. An absence of the ß2 integrin results 
in impairment of a variety of immune functions, including macrophage oxidative 
burst and phagocytosis and lymphocyte proliferation. The ß2 integrins control a 
number of leukocyte functions. The αMß2 and αXß2 integrins are responsible for 
regulation of functions in myeloid cells (aggregation, adhesion and spreading, 
phagocytosis  and  oxidative  burst),  while  αLß2  predominates  in  lymphocytes 
(lymphocyte proliferation, T and B cell aggregation and cell killing) 
145.   
CD23  interacts  with  the  alpha  chains  of  the  leukocyte  integrins  αMß2 
(CD11b/CD18) and αXß2 (CD11c/CD18). Membrane bound CD23 incorporated into 
liposomes was shown to interact with αXß2 and αMß2 expressed on the surface 
of monocytes. The interaction between CD23 and αMß2/αXß2 was determined to 
be cation dependent and was inhibited by factor X, but not by the presence of 
fibrinogen.  The  interaction  was  reduced  after  tunicamycin  treatment  and 
increased in with the presence of calcium ions, supporting this hypothesis that 
this interaction between CD23 and these ß2 integrins is, at least in part, via 
carbohydrate moeties on αMß2 and αXß2. This suggests that the C type lectin 
domain  of  CD23  is  involved  in  this  interaction.  The  lack  of  inhibition  by 
fibrinogen also supports the fact that CD23 is unlikely to bind αMß2 or αXß2 at 
the RGD recognition site 
74.   
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sCD23 was shown to bind αMß2 and αXß2 and induce production of the  pro 
inflammatory cytokines IL 1ß, IL 6 and TNFα.  This cytokine production was NOS 
dependent  although,  unlike  the  sCD21/sCD23  interaction  that  stimulates  the 
inducible  form  of  NOS,  this  interaction  resulted  in  the  activation  of  Type  III 
constitutive NOS (cNOS). The induction of cNOS was due to increased catalytic 
activity  due  to  an  increase  in  intracellular  calcium,  as  opposed  to  an 
upregulation of expression of cNOS. The nitric oxide produced by this interaction 
increased the levels of cGMP by the stimulation of guanylate cyclase, similar to 
the  increase  observed  during  sCD21/sCD23  interaction.  cNOS  stimulation  is 
tightly regulated and declines rapidly after activation. This stimulation of cNOS, 
with a subsequent induction in pro inflammatory cytokines supports the role for 
sCD23 in the early events of inflammatory responses 
146.  
The  exact  signalling  pathways  of  sCD23/ß2  integrin stimulated  cytokine 
production  in  monocytes  are  not  well  characterised.  The  pathway  for  the 
production  of  IL 1ß,  a  key  pro inflammatory  cytokine,  has  been  described. 
Expression of IL 1ß was controlled at the transcriptional level and the pathway 
shown to involve the activation of members of the mitogen activated protein 
kinase (MAPK) family 
84.  
1.3.4.2   CD23 interaction with alpha-V (αV) Integrins. 
The αV family of integrins includes the αV subunit in complex with one of β1, β3, 
β5, β6 or β8 subunits. All members of the aV group of integrins recognise and 
bind  the  RGD  motif  in  substrates.  Substrates  for  these  integrins  include 
vitronectin 
147, fibronectin 
148, osteopontin 
149, fibrinogen 
150, collagen 
108, von 
Willebrand factor 
151, tenascin 
152 and thrombospondin 
153. Apart from αVβ6, all 
the integrins bind vitronectin. Their ligand specificity is quite varied, although 
only αVβ1 and αVβ3 bind more than two different extracellular matrix proteins. 
However, the substrate preference for members of the αV integrin family is also 
influenced by the cell type of expression.  αV integrins are expressed on a range 
of  cells,  including  smooth  muscle  cells,  fibroblasts,  keratinocytes  and 
endothelial  cells.  Expression  of  different  isoforms  will  also  change  during 
developmental stages. There is evidence for redundancy between the different 
αV isoforms. Many cells will express more than one receptor for a specific ECM 
protein  (the  best  example  is  vitronectin).  The  expression  of  a  number  of  
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receptors for the same substrate may indicate a link to different pathways in the 
cell,  culminating  in  different  effector  functions.  αVβ3  and  αVβ5  both  bind 
vitronectin.  FG  carcinoma  cells  expressing  αVβ5  bind  but  do  not  migrate  on 
vitronectin, while cell variants expressing αVβ3 migrate on vitronectin. Addition 
of epidermal growth factor (EGF) to αVβ3 deficient FG carcinoma cells enabled 
these cells to spread on vitronectin in a PKC mediated αVβ5 dependent manner 
154. This indicates that αV integrins are capable of acting independently or in 
cooperation with each other to fulfil specific functions 
155.  
The  lack  of  reagents  has  prevented  the  investigation  of  the  cellular  roles  of 
some of the members of the αV family. The best described members in terms of 
function of the αV family are the αVβ3 and αVβ5 integrin isoforms. αVβ5 can 
only  mediate  spreading  on  vitronectin 
156,  157.  In  contrast  to  this,  αVβ3  can 
mediate spreading on several substrates such as vitronectin 
158, fibronectin 
148, 
fibrinogen 
159,  laminin 
160,  osteopontin 
161  and  collagen 
108.  The  modified 
expression and function of αV integrins on many tumour cells has indicated a 
possible  role  for  these  proteins  in  tumour  metastasis  and  progression.  αV 
integrins are expressed on a variety of tumourogenic cell lines. αVβ3 expressed 
on  melanoma  cells  mediates  cell  invasion 
162.  αV  integrins  have  a  role  in 
formation  of  tumours  in  nude  mice,  demonstrating  that  they  contribute  to 
malignancy. Preliminary data indicate that αVβ1, αVβ6 and αVβ8 expression is 
altered  during  tumour  progression.  These  isoforms  show  differing  expression 
levels  at  specific  stages  of  differentiation,  restricted  tissue  expression  and 
improve growth of transfected cells 
118, 163. Elevated levels of αVβ3 are noted in 
infiltrating cells of breast carcinoma and renal cell carcinoma, while reduced 
levels  are  associated  with  angiosarcomas.  In  addition,  αVβ3  expression  is 
involved in tumour progression, with more advanced tumours containing higher 
levels of the protein 
155, 164.  
CD23  interacts  with  the  vitronectin  receptor  αVß3.  αVβ3  is  associated  with 
CD47,  a  50kDa  multispan  transmembrane  protein,  to  form  the  αVβ3  integrin 
signalling complex.  This complex regulates leukocyte activation and mediates 
the phagocytosis of aging apoptotic leukocytes. This latter function is mediated 
by  proinflammatory  cytokines  such  as  GM CSF,  TNF α,  IL 1  and  IFN γ 
40.  The 
highest level of expression of αVβ3 in vivo is the osteoclast, cells responsible for 
the resorption of bone. It is also expressed at lower levels in other cells, such as  
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megakaryocytes, kidney, smooth muscle and endothelium. Expression of αVβ3 is 
upregulated in certain malignancies and cultured cell lines. αVβ3 binds a wide 
range of RGD containing ligands, particular bone proteins, and has a critical role 
in  promoting  cell  migration  and  controlling  the  balance  between  cell 
proliferation and differentiation. αVβ3 also plays an important role in mediating 
heterotypic  cell  adhesion,  analogous  to  the  VCAM/α4β1  and  ICAM 1/αMβ2 
interactions.  αVβ3  plays  a  role  in  cytokine  production  through  its  interaction 
with CD23 
155.  
Our laboratory has recently determined an interaction between CD23 and αVß5 
75.  The  interaction  between  sCD23  and  αVß5  is  implicated  in  prevention  of 
apoptosis  of  pre B  cells  and  shown  to  be  independent  of  the  classical  RGD 
recognition site on the integrin, as it was not inhibited by the presence of an 
RGDS  peptide.  The  region  of  CD23  binding  to  αVß5  contains  the  motif  RKC. 
Peptides  containing  this  RKC  motif  were  able  to  bind  αVß5  and  αVß3.  This 
interaction  motif  may  be  relevant  to  the  interaction  of  CD23  with  its  other 
receptors 
75. This suggests an alternate interaction and recognition site for CD23 
and signifies an additional, undefined role for this multifunctional molecule.  
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1.4 Research Aims 
The  interaction  between  CD23  and  specific  integrins  is  important  in  the 
production  of  cytokines  by  monocytic  cells.  We  hypothesise  that  integrin 
mediated cytokine production occurs via an interaction distinct from that used 
in adhesion based integrin interactions. We hypothesise that the interaction is 
highly specific and will be influenced by the individual characteristics of the 
integrin(s) involved. 
The specific aims of this project were as follows: 
1.  To  analyse  the  nature  of  interaction  between  commercially available 
purified αVβ3 and αVβ5 integrins and CD23 in vitro.  
2.  To analyse if the newly identified CD23 integrin receptor, αVβ5, plays a 
role in cytokine production by monocytic cells. 
3.  To analyse the importance of integrin ligation to cytokine production by 
CD23 binding  integrins.  The  effect  of  targeting  different  integrin 
heterodimers, different integrin subunits and different integrin epitopes 
will be investigated. 
4.  To investigate the roles of the different CD23 binding integrins, namely 
αVβ3,  αVβ5,  αMβ2  and  αXβ2,  with  respect  to  cytokine  production  and 
monocyte  biology,  and  attempt  to  identify  any  potential  hierarchy  of 
importance that exists.  
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2  METHODS AND MATERIALS  
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2.1  Chemicals and Reagents 
All routine chemicals used were purchased from Sigma Chemical Co, Poole, UK 
unless  otherwise  stated.  The  details  of  purchase  of  speciality  chemicals  are 
indicated in the sections pertaining to their use.   
2.2 Antibodies, Oligonucleotides and Peptides 
Eighty three (83) overlapping nonameric peptides derived from the 25kDa form 
of  the  human  CD23a  sequence  were  synthesised  by  Mimitopes,  Victoria, 
Australia. The peptides were numbered according to their position in the original 
CD23 sequence 
75 and were synthesised as biotinylated peptides (with a common 
SGSG linker and N terminal biotin) and/or as unlabelled peptides (lacking the 
linker  and  N terminal  biotin  moiety).  The  details  and  sequences  of  the 
unlabelled peptides used in this study are described in Table 2 1. The primary 
and  secondary  antibodies  used  for  flow  cytometry,  immunofluorescence, 
Western analysis, neutralisation and stimulation assays are detailed in Table 2 2. 
Olignucleotides used in RT PCR, PCR or EMSAs in this study are detailed in Table 
2.4. The details of commonly used buffers are in Table 2 3.  
In addition to the CD23 derived peptides, a peptide inhibitor of MyD88 signalling 
was  purchased  from  Imgenex  (CA,  USA)  and  used  in  the  analysis  of  TLR 2 
signalling. The details of this peptide and its control peptide are also detailed in 
Table 2 1.  
2.3 Cell lines and culture 
Dulbecco’s Modified Eagle’s Medium (DMEM), Trypan Blue, 200mM L Glutamine 
and  Penicillin Streptomycin  solution  were  purchased  from  Sigma  Chemicals, 
Poole,  UK.  OptiMEM and  RPMI 1640  media  were  from  Invitrogen,  Paisley,  UK. 
Foetal  Calf  Serum  (FCS)  was  supplied  by  TCS  Cellworks,  Buckingham,  UK. 
Recombinant human cytokines M CSF and GM CSF were from Peprotech, UK.   
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Table   2-1 Table of Peptides used in this study 
 
 
PEPTIDE 
 
ABBREVIATION 
 
SEQUENCE 
 
SUPPLIER 
 
Peptide 8 
 
P8 
 
PEKWINFQR 
 
 
Peptide 9* 
 
P9 
 
KWINFQRKC 
 
 
Peptide 10* 
 
P10 
 
INFQRKCYY 
 
 
Peptide 11* 
 
P11 
 
FQRKCYYFG 
 
 
Peptide 12* 
 
P12 
 
RKCYYFGKG 
 
 
Peptide 13 
 
P13 
 
CYYFGKGTK 
 
 
Long Peptide* 
 
LP 
 
KWINFQRKCYYFGKG 
 
 
Peptide 58 
 
P58 
 
GSGRWNDAF 
 
 
 
 
 
 
 
 
 
 
 
 
Mimitopes, 
Victoria, 
Australia 
 
Anti MyD88** 
   
DRQIKIWFQNRRMKWKKRDVLPGT 
 
 
Control anti 
MyD88 
   
DRQIKIWFQNRRMKWKK 
 
 
Imgenex, CA, 
USA 
 
* Common active RKC tripeptide motif is shown in bold 
** TIR homodimerisation sequence is in bold 
 
 
THP 1 
165, U937
166, Jurkat
167 and IB4
168 cell lines used in these analyses were 
from  laboratory  stocks.  Purified  primary  human  CD14+  monocytes  from 
peripheral blood and bone marrow were purchased from Lonza, UK and cultured 
with or without 10ng/mL M CSF (Peprotech) in RPMI 1640 medium supplemented 
with 10% (v/v) FCS, 2mM glutamine and 1% (v/v) penicillin/streptomycin. Unless 
otherwise  stated,  all  stimulation  experiments  were  conducted  in  OptiMEM 
lacking  FCS  but  supplemented  with  2mM  glutamine  and  1%  (v/v) 
penicillin/streptomycin.   
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Table   2-2 Antibodies used in this study 
 
ANTIGEN* 
 
 
SOURCE 
 
 
CLONE 
 
ISOTYPE 
 
SUPPLIER 
 
CONJUGATE 
 
DILUTION OR 
WORKING 
CONCENTRATION 
 
USED IN 
Actin  Rabbit polyconal     IgG1  Sigma Chemicals Co, Poole, UK    1/1000  WB 
Αv  Mouse Monoclonal  AMF7  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
Αv  Mouse Monoclonal  LM142  IgG1  Millipore, MA, USA    1  g/mL  STIM 
Αv  Rabbit Polyclonal     IgG1  Millipore, MA, USA    1/500  WB 
αVβ3  Mouse Monoclonal  23C6  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
αVβ3  Mouse Monoclonal  LM609  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
αVβ5  Mouse Monoclonal  P1F6  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
αVβ5  Mouse Monoclonal  15F11  IgG2a  Millipore, MA, USA    1  g/mL  FACS, STIM 
αVβ6  Mouse Monoclonal  10D5  IgG2a  Millipore, MA, USA    1  g/mL  FACS 
β1  Mouse Monoclonal  47BR  IgG1  Autogen Bioclear, Buckinghamshire, 
UK 
  1/500  WB 
β2  Mouse Monoclonal  PAH9  IgG3  Millipore, MA, USA    1  g/mL  FACS, STIM 
β2  Mouse Monoclonal  MEM48  IgG1  Millipore, MA, USA    1  g/mL  FACS,STIM 
αMβ2  Mouse Monoclonal  44  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
αMβ2  Mouse Monoclonal  ICO GMI  IgG2a  Millipore, MA, USA    1  g/mL  FACS, STIM 
αXβ2  Mouse Monoclonal  3.9  IgG1  Millipore, MA, USA    1  g/mL  FACS,STIM 
αXβ2  Mouse Monoclonal  HC1/1  IgG1  Millipore, MA, USA    1  g/mL  FACS, STIM 
Phospho p44/42 MAP 
kinase(Thr202/Tyr204) 
Rabbit polyclonal       Cell Signalling Technologies, MA, USA    1/1000  WB 
p44/42 MAP kinase  Rabbit polyclonal       Cell Signalling Technologies, MA, USA    1/1000  WB 
Phospho Beta3 
(Tyr785) 
Rabbit polyclonal       Millipore, MA, USA    1/1000  WB 
Phospho Beta3 
(Tyr773) 
Rabbit polyclonal       Millipore, MA, USA    1/1000  WB 
CD1a  Mouse Monoclonal  NA1/34  IgG2a  Abcam, Cambridge, UK  PE  1  g/mL  FACS, IFA 
CD14  Mouse Monoclonal    IgG2a  Millipore, MA, USA  FITC  1  g/mL  FACS,IFA 
CD23  Mouse Monoclonal    IgG3  Autogen Bioclear    1  g/mL  FACS 
CD25  Mouse Monoclonal  ACT 1  IgG1  DAKO, Glostrup, Denmark    1  g/mL  FACS 
CD86  Mouse monoclonal  B T7  IgG1  Diaclone, Besancon,France    1  g/mL  FACS 
HLA DR  Mouse Monoclonal  B F1  IgG1  Abcam, Cambridge, UK  Biotin  1  g/mL  FACS,IFA  
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Table 2.2  contiuned. 
 
ANTIGEN* 
 
 
SOURCE 
 
 
CLONE 
 
ISOTYPE 
 
SUPPLIER 
 
CONJUGATE 
 
DILUTION OR 
WORKING 
CONCENTRATION 
 
USED IN 
CCR5  Mouse Monoclonal    IgG1  R&D Systems, Abingdon, UK    1  g/mL  FACS 
cFMS  Rabbit polyclonal       Santa Cruz Biotechnology, CA, USA    1/1000  WB, NEUT 
TLR2  Mouse monoclonal  TL2.1  IgG2a  Santa Cruz Biotechnology, CA, USA    1/500  WB, NEUT 
IRAK 1  Rabbit polyclonal  H 273     Santa Cruz Biotechnology, CA, USA    1/500  WB,IFA 
TRAF 6  Mouse monoclonal  D 10  IgG1  Santa Cruz Biotechnology, CA, USA    1/500  WB,IFA 
p65  Rabbit polyclonal       Cell Signalling Technologies, MA, USA    1/500  WB,IFA,EMSA 
IFN γ receptor subunit 
1 
Mouse monoclonal  92101  IgG1  R&D Systems, Abingdon, UK    1/500  WB,IFA,NEUT 
IgG1  Mouse isotype 
control 
     Sigma Chemicals Co, Poole, UK    1/1000  FACS,STIM 
IgG2a  Mouse isotype 
control 
     Sigma Chemicals Co, Poole, UK    1/1000  FACS,STIM 
IgG3  Mouse isotype 
control 
     Sigma Chemicals Co, Poole, UK    1/1000  FACS,STIM 
Streptavidin HRP         BD Bioscience, Oxford, UK.  HRP  1/1000  WB 
Anti mouse IgG HRP         Sigma Chemicals Co, Poole, UK  HRP  1/1000  WB 
Anti rabbit IgG HRP         Sigma Chemicals Co, Poole, UK  HRP  1/1000  WB 
Secondary PE         BD Bioscience, Oxford, UK.  PE  1/1000  FACS,IFA 
Secondary FITC         BD Bioscience, Oxford, UK.  FITC  1/1000  FACS,IFA 
 
*All antibodies are against human antigens unless otherwise stated. Abbreviations used: FITC fluorescein isothyanate; PE phycoerythrin; WB Western Blotting; FACS – 
flow cytometry; IFA immunofluorescence assay; STIM stimulation assays, NEUT neutralisation assays, EMSA electromobility shift assays  
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2.4 Flow cytometry 
Expression of surface markers on cells and cell lines was measured by indirect 
immunofluorescent  staining  (flow  cytometry).  Cells  were  harvested  by 
centrifugation and washed twice with ice cold phosphate buffered saline (PBS). 
100  L of cell suspension in ice cold PBS (5x10
6 cells/mL) was incubated with 
primary antibody and isotype matched controls (Table 2 2) or biotinylated CD23 
derived peptides and controls (Table 2 1) for 30 – 60 mins at 4
0C. The cells were 
washed  twice  with  ice cold  PBS  and  incubated  with  secondary  antibody  (for 
unlabelled  primary  antibodies)  or  streptavidin  (for  biotinylated  primary 
antibodies  and  CD23 derived  peptides)  conjugated  to  either  a  FITC  or  PE 
fluorescent label. After 30 – 60 mins incubation at 4
0C, cells were washed twice 
with  ice cold  PBS  and  resuspended  in  PBS/formaldehyde  for  flow  cytometry 
using  the  Becton  Dickinson  FACScan  machine  and  CellQuest  software  (BD 
Bioscience, NJ, USA).  
2.5 Biotinylation of Antibodies and Proteins 
Antibodies and CD23 were biotinylated using N hydroxysuccinimidobiotin (NHS 
Biotin) treatment. NHS biotin was purchased from Sigma Chemicals Co, Poole, 
UK.  CD23  (0.1mg/mL)  or  antibodies  (1mg/mL)  were  incubated  with  1mg/mL 
NHS Biotin/DMSO  on  a  rotator  overnight  at  4
0C.  Uncongujated  biotin  was 
removed by dialysis against PBS. 
2.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), Western Blotting 
and chemiluminescent based detection of 
proteins 
Western analysis  and  chemiluminescence based immunodetection  was  used  to 
detect  the  presence  of  specific  proteins.  Discontinuous  SDS PAGE  using  the 
Invitrogen  NuPage  system  was  conducted  according  to  the  manufacturer’s 
instructions (Invitrogen, Paisley, UK). Buffers used are described in Table 2 3.  
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Cells  (1  x  10
6)  in  OptiMEM  were  stimulated  with  integrin specific  antibodies, 
CD23, CD23 derived peptides, LPS or Zymosan at 37 ºC at concentrations and 
time periods indicated in figure legends. Cells were harvested by centrifugation, 
lysed in radio immunoprecipitation assay (RIPA) buffer (50mM Tris HCl pH7.4, 
150mM NaCl, 1mM EGTA, 1mM Na3VO4, 1% (w/v) NP40, 1mM Na deoxycholate, 
1mM PMSF and 2mg/mL Leupeptin) and the lysate cleared by centrifugation at 
13,000 x g for 15 min. Protein concentrations were measured by Bradford Assay 
(BioRad  Laboratories  Ltd,  Hampstead,  UK),  using  BSA  as  a  standard.  Equal 
quantities of total protein (20 40 g) were loaded per lane and resolved on a 4 
12% NuPAGE Novex Bis Tris gradient gels (Invitrogen, Paisley, UK) according to 
manufacturer’s instructions (based on the standard SDS PAGE method 
169).  
Proteins  on  the  gel  were  transferred  to  nitrocellulose  (Amersham, 
Buckinghamshire, UK) and non specific sites on the membrane blocked for 1 h in 
5%  (w/v)  bovine  serum  albumin  (BSA)  in  Tris buffered  Saline  with  Tween 20 
(TBST).  Proteins on the membrane were detected by incubation overnight at 4ºC 
with specific primary antibodies (1/200 – 1/1000 dilution in TBST with 5% (w/v) 
BSA).  Membranes  were  washed  extensively  in  TBST  and  incubated  with 
secondary  antibodies  for  1  h  (1/10000  dilution  in  TBST  with  5%  (w/v)  BSA) 
conjugated to HRP. The chemiluminescent signal was detected by exposure of 
the  membrane  to  Kodak  MXB  film,  after  a  5min  incubation  period  with  the 
SuperSignal Pico Western Chemiluminescence Substrate (Pierce, Rockford, USA). 
The  membrane  was  subsequently  stripped  and  total  protein  in  each  lane 
quantified (to standardise any signals for loading inaccuracies) using matched 
primary and secondary antibodies to actin according to the above mentioned 
procedure.  Bands  were  recorded  and  quantified  by  densitometry  using  the 
ImageJ program. 
2.7 Cell Migration Assays  
The  migration  of  cell  lines  in  response  to  conditioned  media  from  integrin 
stimulated THP 1 cells was assessed using disposable transwell plates (Corning 
NY, USA). The plates consisted of a polycarbonate membrane insert, with a pore 
size of 5 m, separating the upper and lower chambers. Cells were washed twice 
and resuspended in OptiMEM (Invitrogen, Paisley, UK). 5x10
5 cells were placed in 
the upper chamber and 500uL of cleared supernatant (undiluted or diluted as  
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stated in figure legends) from stimulated THP 1 cells was placed in the lower 
chamber.  The plates were incubated at 37
0C in 5% CO2 for 3 hours, after which, 
cells that had migrated to the lower chamber were harvested by centrifugation, 
washed  in  PBS  and  resuspended  in  equal  volumes  of  PBS/formaldehyde. 
Unstained  total  cell  counts  were collected  by  flow  cytometry over  a  defined 
time  period  (30 60  sec).  The  effect  of  proteins  on  migration  across  the 
membrane  was  tested  by  coating  the  polycarbonate  membrane  with  FCS, 
vitronectin (VN), fibronectin (FN), fibrinogen (FBGN) or BSA (control) for 1 hour 
at 37
0C or overnight at 4
0C prior to setting up the migration experiments. All 
these coating proteins were purchased from Sigma, Poole, UK. 
Table   2-3 Composition of buffers in routine use 
 
BUFFERS 
 
ABBREVIATION 
 
COMPOSTION 
 
Phosphate buffered 
saline 
 
 
PBS 
 
13mM NaCl, 27mM KCl, 4.3mM 
Na2HPO4, 1.4mM KH2PO4, pH 7.2 
 
Tris buffered saline 
 
TBS 
 
50mM Tris HCl pH 7.4, 150mM 
NaCl  
 
 
Tris buffer saline with 
Tween 20 
 
TBST 
 
50mM Tris HCl pH 7.4, 150mM 
NaCl, 0.1% w/v Tween20, 
 
 
Tris Acetate EDTA 
buffer 
 
TAE 
 
40mM Tris Acetate pH 8.5, 2mM 
Na2EDTA  
 
 
Tris Borate EDTA buffer 
 
TBE 
 
45mM Tris Borate pH 8.3, 1mM 
EDTA 
 
 
Western transfer buffer 
   
25mM Tris, 192mM Glycine , 20% 
v/v methanol 
 
 
Nitrocellulose stripping 
buffer 
   
62.5 mM Tris HCl pH 6.7, 2% w/v 
SDS, 100mM β mercaptoethanol 
 
 
NuPAGE MOPS buffer 
 
MOPS 
 
Invitrogen proprietry information 
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2.8 Cell stimulation and Analysis of Cytokine 
Production  
The antibodies used for cell stimulation are indicated in the figure legends and 
described fully in Table 2 2. DerCD23 
62 was a kind gift of Dr. Jim McDonnell 
(Oxford, UK). Bacterial LPS, dibutryl cyclic AMP (db cAMP) and yeast zymosan A 
were purchased from Sigma, Poole, Greiss reagent was purchased from Promega, 
WI, USA and the nitroblue tetrazolium assay (NBT) was from Sigma Chemicals Co, 
Poole.  
Cells  were  stimulated  with  antibodies  against  specific  integrins  (0.5 g/mL  – 
10 g/mL),  bacterial  lipopolysaccharide  (LPS)  (1ng/mL  –  1 g/mL),  zymosan 
(10ng/mL  –  20ug/mL),  derCD23  (0.1 g/mL  –  1 g/mL),  CD23 derived  peptides 
(0.5 g/mL  –  20 g/mL),  either  alone  or  in  conjunction  with  cytokines/growth 
factors (M CSF at 5ng/mL and GM CSF at 1ng/mL). After incubation 37
0C for 24 
to 72 hours, supernatants were collected, cleared by centrifugation and stored 
at  20
0C until analysis.   
Cytokines in cell supernatants were detected using sandwich ELISA assays and 
Cytokine protein array techniques (Biosource, UK). The cytokine arrays Human 
Cartesian  Array  Set  II,  and  ELISAs  for  detection  of  IL 8,  IL 12,  IL 4,  VEGF, 
RANTES, and MIP 1β were from Biosource, Invitrogen, Paisley, UK. ELISA kits for 
TNF α detection were from R&D Systems and those for detection of IL 10 and 
IFN γ  were  from  Peprotech.  All  cytokine  protein  arrays  and  ELISAs  were 
performed as per manufacturer’s instructions.   
2.9 Analysis of mechanisms of cell signalling and 
cytokine production 
The activation of MAPK signalling pathways was analysed by Western blotting 
over time and in response to different stimuli, as indicated in figure legends. 
The importance of ERK phosphorylation to cytokine production was analysed by 
ELISA (enzyme linked immunosorbent assay) after incubation with the specific 
MEK  inhibitor,  U0126.    The  MEK  inhibitor  U0126  was  purchased  from  Sigma, 
Poole, UK.  
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2.10   Differentiation of monocytes 
THP 1  cells  or  CD14
+  primary  human  monocytes  were  grown  in  OptiMEM 
supplemented with M CSF (5ng/mL), GM CSF (2ng/mL) or db cAMP (100 M) for 4 
days. The effect of these differentiating agents on the cytokine production and 
integrin  expression  profile  was  determined  by  ELISA  and  flow  cytometry, 
respectively.  Morphological  changes  observed  in  THP 1  cells  treated  with 
antibodies  and  M CSF  (5ng/mL)  were  recorded  by  phase  contrast  microscopy 
using  the  Zeiss  Axiovert  135  microscope.  M CSF  and  GM CSF  were  from 
Peprotech  and  dibutryl  cyclic  AMP  (db cAMP)  was  purchased  from  Sigma 
Chemicals (Poole, UK). 
2.11  RNA extraction and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR)  
Total  RNA  was  extracted  using  the  Trizol  reagent  (Invitrogen,  Paisley,  UK) 
according  to  the  manufacturer’s  instructions.  Briefly,  10
6 10
7  cells  were 
harvested  and  resuspended  in  1mL  Trizol/10
7  cells.  Chloroform  (0.2mL/1mL 
Trizol) was added and the sample shaken vigorously  for 15 seconds by hand. 
Phase separation was achieved by centrifugation at 12 000 x g at 4
0C for 15 min 
and the colourless aqueous phase collected and RNA precipitated by addition of 
isopropanol (0.5mL/1mL Trizol) for 10 min at room temperature, followed by 
centrifugation at 12 000 x g at 4
0C for 10 min. The RNA pellet was washed with 
75%  (v/v)  ethanol  (1mL/1mL  Trizol),  air dried  and  resuspended  in  50 l  of 
nuclease  free  water  (Sigma,  Poole,  UK).  RNA  concentration  and  purity  were 
determined spectrophotometrically by absorbance at 260nm and 280nm.  
Table   2-4 Table of Primers for RT-PCR and PCR 
 
TARGET 
 
SUPPLIER 
 
AMPLICON SIZE (BP) 
CXCL8 
  R&D Systems  158 
GAPDH 
  R&D Systems  576 
M CSF 
  R&D Systems  464 
IFN γ 
  R&D Systems  453 
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Total RNA extracted was used for RT PCR reactions. First strand cDNA synthesis 
was performed at 37 ºC for 1 hour using the M MLV reverse transcriptase enzyme 
and  random  primers  (Promega,  Southampton,  UK)  according  to  the 
manufacturer’s  instructions.  Subsequent  PCR  reactions  were  performed  using 
Taq polymerase (Promega, Southampton, UK) and the transcript specific primers 
(Table 2.4) and cycling parameters described below.  
Initial denaturation  94 ºC / 2min  1 cycle 
Denaturation  94 ºC / 45 sec 
Annealing  55 ºC / 45 sec 
Extension  72 ºC / 45 sec 
 
30 cycles 
 
Final extension  72ºC / 5 min  1 cycle 
Hold  4 ºC / hold   
 
 
2.12   Indirect Immunofluorescence Assay (IFA) and 
Confocal Microscopy 
Primary and secondary antibodies used in IFA are described in Table 2.2. The 
DAPI nuclear stain (4',6 diamidino 2 phenylindole) was from Sigma, Poole, UK. 
Stimulated  cells  were  prepared  for  confocal  microscopy  using  the 
acetone/methanol  method.  Subsequent  to  stimulation  as  indicated  in  figure 
legends, cells (1 x 10
6/mL) were washed in PBS and 50 L spread on multiwell 
microscope slide. Cells were fixed with ice cold acetone/methanol (1:1) solution 
for  5min  and  air  dried.  Cells  were  permeablised  with  0.02%  (w/v)  Triton 
X100/PBS solution for 30min at room temperature and blocked with 3% (w/v) 
BSA in PBS for 15min, before incubation with primary antibody (1/50 dilution in 
3% (w/v) BSA in PBS) for 30   60 min at 37
0C. Cells were washed with 0.1% (w/v) 
BSA/PBS and incubated for 30 – 60 min at 37
0C with the appropriate secondary 
antibody conjugated to a fluorescent label (FITC, Cy5 or PE). Cells were washed 
with 0.1% (w/v) BSA/PBS, nuclei stained with DAPI solution (1ug/mL), and the 
slides air dried and mounted in Citifluor before analysis using the Zeiss LSM 510 
confocal microscope.    
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2.13   Electrophoretic Mobility Shift Assays (EMSA) 
The  activation  of  NFκβ  transcription  factors  was  performed  using  the 
radioactively  labelled  NFκβ  consensus  oligonucleotide  (Santa  Cruz 
Biotechnology, CA, USA) in EMSA reactions. The [γ 
32P] ATP was purchased from 
Perkin Elmer (MA, USA) and polynucleotide kinase oligonucleotide end labelling 
kit was from Promega. The antibodies used are described in Table 2 2. 
Nuclear  extracts  were  prepared  from  1x10
7  cells  stimulated  with  agents  as 
indicated  in  figure  legends.  Cells  were  collected  by  centrifugation  and 
resuspended on ice in Sucrose Buffer with NP 40 (0.32M sucrose, 10mM Tris HCl, 
pH 8.0, 3mM CaCl2, 2mM MgOAc, 0.1 mM EDTA, 0.5% (w/v) NP 40, 1mM DTT, 
0.5mM PMSF). Nuclei were harvested by centrifugation at 500 x g at 4
0C for 5 
min.  The  nuclear  pellet  washed  with  Sucrose  Buffer  without  NP 40  (0.32M 
sucrose, 10mM Tris HCl, pH 8.0, 3mM CaCl2, 2mM MgOAc, 0.1 mM EDTA, 1mM 
DTT, 0.5mM PMSF), collected by centrifugation at 500 x g at 4
0C for 5 min and 
resuspended in Low Salt Buffer (20mM HEPES KOH pH 7.9, 1.5 mM MgCl2, 20 mM 
KCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM DTT, 0.5 mM PMSF). An equal 
volume of High Salt Buffer (20mM HEPES KOH pH 7.9, 1.5 mM MgCl2, 800 mM KCl, 
0.2 mM EDTA, 25% (v/v) glycerol, 1% (w/v) NP 40, 0.5 mM DTT, 0.5 mM PMSF) 
was added in small aliquots and the samples incubated on a rotary shaker at 4
0C 
for 45 min. Samples were cleared by centrifugation at 14 000 x g at 4
0C for 15 
min and the protein content of the resultant supernatant containing the nuclear 
fraction quantitated by Bradford’s assay prior to use in EMSA assays.    
Olginucleotides were labelled with [γ 
32P] ATP using the polynucleotide kinase 
oligonucleotide end labelling kit according to manufacturer’s instructions. The 
labelled  oligonucleotides  were  purified  by  ethanol  precipitation.  1ng  of 
radioactively  labelled  (“hot”)  oligonucleotide  was  incubated  with  10   g  of 
nuclear extracts for 30 mins at room temperature, prior to resolution on a 5% 
polyacrylamide gel in 0.5 x TBE. The gel was dried and exposed to X ray film at   
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0C for various lengths of time (overnight 2 weeks) until an acceptable signal 
was  obtained.  Specificity  of  reactions  was  confirmed  by  addition  of  2ng  of 
competing unlabelled NFkappaB consensus oligonucleotide (“cold” oligo) and the 
inclusion of 1 g of antibodies to specific NFκβ signalling proteins (supershift).  
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2.14   Surface Plasmon Resonance (SPR) analysis 
using the BIACORE System 
Interactions between CD23 derived peptides and aVb3 and aVb5 integrins were 
performed at 25
0C using the automated Biacore 2000 machine (Biacore AB). The 
integrins were immobilised at approximately 4000 response units on a C1 chip 
using amine coupling chemistry. An underivatised reference cell was employed 
as a control surface. CD23 derived peptides in HBS EP buffer (0.01 M HEPES KOH 
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) Surfactant P20) were injected 
over the test and control chip surfaces at a flow rate of 40mL.min 1 and allowed 
a 3min association phase followed by a 6 min dissociation phase. The sensor 
surfaces were regenerated to baseline by injection of 0.2M glycine HCL, pH2.5, 
where necessary. In all experiments, peptides bound exclusively to the test cell, 
there was no non specific binding to the control reference cell and regeneration 
of a stable baseline was readily achieved. Data collected was standarised using 
control  and  blank  injections  prior  to  kinetic  analysis,  according  to  standard 
double  referencing  data  subtraction  methods 
170.  All  kinetic  analysis  was 
performed using BIAevaluation 3.0.2 software (Biacore AB). 
2.15   Ellman’s Assay for free Sulphydryl groups in 
CD23-derived peptides 
CD23 derived peptides contain a single cysteine, so the moles of total sulphydryl 
(SH) can be determined from the peptide concentration (i.e. equivalent to the 
moles  of  peptide  contained  in  the  sample).  The  proportion  of  this  total 
sulphydryl (SH) existing as free SH was determined by reaction with Ellman’s 
Reagent (5,5' Dithio bis 2 nitrobenzoic acid/DTNB) 
171. DNTB was purchased from 
Sigma Chemicals Co, Poole, UK. 50 L of CD23 derived peptides were incubated 
with  200 L  of  DNTB  for  30mins  and  the  absorbance  at  415nm  recorded.  The 
moles of free SH were calculated and the data represented as a percentage of 
total SH.   
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3  ANALYSIS OF THE CD23-αV INTEGRIN 
INTERACTION  
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3.1 INTRODUCTION 
3.1.1   The Classical Recognition Sequence ‘RGD’ 
Binding of ligands by integrins is dependent on the presence of a particular motif 
within  that  ligand.  The  Arg Gly Asp  (RGD)  peptide  was  first  discovered  in 
fibronectin and is now widely recognised as the classical recognition sequence 
for most integrins 
101. This sequence is found in a diverse range of receptors and 
integrin ligands. The presence of a small motif in a range of functionally diverse 
ligands creates an extensive system for recognition by cell adhesion molecules 
102.  
3.1.2   Integrin ligand recognition 
Insights into the binding of RGD containing ligands have been provided by the 
crystal  structure  of  the  extracellular  domain  αVß3  integrin  alone 
94  and  in 
complex with a cyclic RGD containing peptide 
98. The availability of both ligand 
bound  and  ligand free  structures  allows  analysis  of  both  the  fundamental 
residues involved in the interaction and conformational changes that arise due to 
ligand  binding.  Ligand  binding  is  cation dependent  and  mediated  by  residues 
from both the α and ß subunit of the integrin heterodimer (Figure 1.6). The RGD 
peptide  binds  a  shallow  groove  at  the  interface  of  the  ß propeller  of  the  α 
subunit and the ßA domain of the ß subunit. The central Gly
RGD projects into the 
interface between the α and ß subunits. It forms hydrophobic interactions with 
the αV subunit, primarily via the carbonyl oxygen of Arg216. The main chain 
conformation of the RGD peptide in the structure is identical to that observed in 
the natural integrin ligand Echistatin 
98. 
In addition to the recognition of different sequences at this ‘RGD recognition 
site’ of integrins, the existence of an additional, distinct ligand binding site, for 
ligands such as tumstatin, HIV Tat protein and entactin, on the aVb3 and aVb5 
integrins has been suggested. These studies have proposed either the existence 
of an additional distinct binding site or a synergistic ligand recognition site that 
cooperates with the RGD binding site.   
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3.1.3   CD23-integrin interactions 
CD23 exists in both membrane bound and soluble forms. Soluble CD23 binds four 
members of the integrin superfamily of proteins, in addition to its ligands CD21 
and  IgE.  CD23  has  been  shown  to  bind  the  αMß2  (CD11b/CD18),  αXß2 
(CD11c/CD18) 
83  and  αVβ3
40  integrins  on  monocytic  cells.  Our  laboratory  has 
recently identified αVβ5 as a new integrin ligand for CD23 
75. The interaction 
between CD23 and these integrins on monocytes is functionally important in the 
production of pro inflammatory cytokines, including IL 1ß, IL 6 and TNFα
40, 41, 83, 
but the site of interaction between CD23 and these integrins remains to be fully 
elucidated.   
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3.2  RESULTS 
3.2.1   Macrophage cell lines express integrin receptors for 
CD23 
CD23  interacts  with  four  members  of  the  integrin  family  of  receptors  –  two 
members of the β2 family (αMβ2 and αXβ2) and two members of the αV family 
(αVβ3 and αVβ5) 
40,  75,  172. The expression of these integrins on the surface of 
model cell lines, THP 1 and U937, was determined by flow cytometry (Figure 3 
1). The antibody staining for individual integrins is shown as black lines with the 
isotype matched controls shown in grey shading.  
Both THP 1 and U937 cell lines showed high levels of surface expression of αVβ3, 
αVβ5  and  αXβ2  integrins,  shown  by  an  increase  in  staining  compared  to  the 
isotype control staining. Of these integrins, the αVβ3 and αVβ5 heterodimers 
were  expressed  at  higher  levels  on  the  surface  of  cells  than  the  αXβ2 
heterodimer.  Both  THP 1  and  U937  expressed  only  low  levels  of  the  αMβ2 
integrin heterodimer. Overall, there was no major difference in the levels or 
relative ratios of expression of different integrin isoforms between the two cell 
lines, THP 1 and U937.  
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Figure   3-1 Expression of CD23 binding integrins on monocytic cell lines 
Surface  expression  of  CD23-binding  integrins  on  U937  (A)  and  THP-1  (B)  cell  lines  was 
determined by flow cytometry. Cells were incubated with antibodies against specific integrins, as 
indicated  in  the  right  hand  corner  of  the  plots.  Primary  antibody  binding  was  detected  using 
secondary antibody conjugated to PE. The binding of isotype matched controls is shown as grey 
shading and the integrin staining shown as a bold black line.   
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3.2.2   Identification of the recognition sequence in CD23 
for αV integrins 
The classical sequence recognised and bound by integrins is the RGD motif. This 
RGD (or a closely related sequence) is found in most integrin ligands. CD23 has 
been shown to bind integrins, but it does not contain a classical RGD motif. CD23 
does, however, contain a DGR motif (inverted RGD motif) near the C terminus 
(Figure  1 1).  There  has  been  much  debate  as  to  whether  this  DGR  motif  is 
functionally equivalent to an RGD motif and is the site of integrin recognition of 
CD23 
61, 67, 173.  
In order to define the integrin binding motif on CD23, we generated a library of 
83 overlapping nonameric peptides derived from residues 131 321 of the 25kDa 
soluble CD23 sequence. The peptides are numbered sequentially as they occur in 
the CD23 sequence (starting with P1 from residue 131) and included an SGSG 
linker and an N terminal biotin label 
75. The biotinylated CD23 derived peptides 
were assessed, for their ability to bind to the surface of SMS SB cells by flow 
cytometry (Figure 3 2). SMS SB cells express the αVβ5 integrin as the only CD23 
receptor 
174.  The  binding  of  CD23 derived  peptides  was  detected  using 
streptavidin conjugated PE, which was used to detect the biotin label on the 
peptides. Figure 3 2 shows the mean fluorescence values for the binding of the 
83 biotinylated peptides to the surface of SMS SB cells.  
A  peak  in  binding  was  observed  for  four  peptides,  named  P9     P12,  which 
corresponded  to  residues  Lys
166  to  Gly
180  in  the  soluble  CD23  sequence. 
Interrogation of the sequence of the CD23 derived peptides identified a common 
RKC motif in these peptides (Figure 3 3). A low level of binding was observed 
with  peptides  P60     P63.  These  peptides  (P60 P63)  all  contain  a  common 
sequence, which includes a RK dipeptide. This is similar to the RK dipeptide in 
the RKC containing CD23 peptides and may account for the low levels of binding. 
Peptides P78   P80, which contain the DGR motif, did not bind to SMS SB cells.  
The preliminary screening for binding was conducted using SMS SB cells, a pre B 
cell  line  which  expressed  only  a  single  CD23  binding  integrin  (αVβ5).  It  was 
therefore  necessary  to  establish  whether  the  RKC  containing  peptides  were 
capable of binding other cell types expressing CD23 binding integrins. Binding of  
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P9     P12  to  the  established  model  monocytic  cell  lines  THP 1  and  U937  was 
tested by flow cytometry. THP 1 and U937 cells did not express CD23 (data not 
shown). Figure 3.3 shows the binding of CD23 and RKC containing CD23 derived 
peptides to THP 1 cells. CD23/CD23 derived peptide binding is shown as a solid 
black  line  and  background  staining  shown  as  grey  shading.  CD23  and  CD23 
derived  P9     P12  bound  to  THP 1  cells,  as  indicated  by  an  increase  in 
fluorescence  (Figure  3 3A).  All  these  species  contain  a  common  RKC  motif 
(Figure 3 3B). CD23 derived P8, which does not contain the RKC motif but does 
have some sequence similarity with P9, did not bind to THP 1 cells. An identical 
binding pattern was observed for the second monocytic cell line, U937 (data not 
shown). Subsequent to identification of the RKC motif, an additional peptide, 
named LP (long peptide), was also synthesised. The LP contained 15 residues 
spanning the entire sequence from the beginning of P9 to the end of P12 and 
contained the entire putative CD23 binding sequence.  
Cell binding analysis represents the overall binding of the CD23 derived peptides 
to multiple integrins on the cell surface. Most cells will express more than one 
CD23 ligand (Figure 3 1) and, therefore, to establish these peptides as bone fide 
integrin  ligands,  it  was  essential  to  analyse  their  binding characteristics  with 
respect to individual purified integrins. Binding of peptides to purified αVβ3 and 
αVβ5  integrins,  which  are  commercially  available,  was  measured  by  surface 
plasmon resonance (SPR), using the BIACORE system. Interactions between CD23 
derived peptides and immobilised aVb3 and aVb5 integrins were performed at 
25
0C using the automated Biacore 2000 machine. In all experiments, peptides 
bound  exclusively  to  the  test  cell,  there  was  no  non specific  binding  to  the 
control  reference  cell  and  regeneration  of  a  stable  baseline  was  readily 
achieved. Data collected were standarised using control and blank injections, 
according to standard double referencing data subtraction methods 
170. Figure 3 
4 shows the sensorgram for the binding of CD23 derived peptides (Figure 3 4A) 
and CD23 (Figure 3 4B) to the purified αVβ5 integrin. Both CD23 and the RKC 
containing  CD23 derived  peptides  showed  characteristic  binding  curves  over 
time,  with  association  and  dissociation  phases  indicative  of  a  specific 
interaction. The control P58, which is derived from the CD23 sequence but does 
not contain the RKC motif, did not bind to the purified integrin, as shown by the 
lack of any association or dissociation curves on the sensorgram. This binding 
trace appears as a flat line on the sensorgram (Figure 3 4A, black line).   
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A qualitative hierarchy of the strength of binding can be obtained by observation 
of  the  amplitude  of  the  binding  response  for  equivalent  concentrations  of 
different peptides. This suggested that under these conditions the LP interacted 
most  strongly  with  the  immobilised  αVβ5  integrin,  as  this  peptide  gave  the 
largest binding response, even at a ten fold lower concentration than the other 
peptides (1 M for LP compared to 10 M for the other CD23 derived peptides).  In 
this manner, the peptides were ranked in order of highest to lowest binding as 
follows; LP > P11 > P12 > P9 > P10. Equivalent traces and qualitative binding 
hierarchy data was obtained for the immobilised αVβ3 integrin (data not shown).  
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Figure   3-2 Binding of biotinylated CD23-derived peptides to SMS-SB cells 
The binding of biotinylated CD23-derived nonameric peptides was determined by flow cytometry analysis. Biotinylated peptides were incubated on ice with SMS-SB cells 
and peptide binding detected using streptavidin conjugated to the fluorescent label PE. The mean fluorescence intensity for each peptide binding is plotted against peptide 
number in the bar chart. Data are representative of at least 3 separate experiments. The error bars indicate standard deviations (SD).   
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Figure   3-3 Binding of CD23 and CD23-derived peptides to THP-1 cells 
The binding of CD23 and CD23-derived peptides P9-P12 to THP-1 cells was determined by flow 
cytometry. The grey shading indicates autofluorescence and peptide binding is show as a black 
line. (A). Cells were incubated on ice with biotinylated peptides or CD23. Binding of biotinylated 
peptides was detected using streptavidin conjugated to PE. CD23 binding was detected by anti-
CD23 antibody conjugated to PE. Analysis of the sequence of CD23-derived peptides which bind to 
cells reveals a common RKC motif (B). *Long peptide (LP) was synthesized subsequent to the 
identification of P9-P12 and contains the entire CD23-derived sequence spanning P9-P12. 
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Figure   3-4 BIACORE analysis of binding of CD23-derived peptides and CD23 
to purified αVβ5 integrin 
Interactions between (A) CD23-derived peptides, (B) derCD23 and integrins were performed at 
25
0C  using  the  automated  Bicore  2000  machine  (Biacore  AB).  Purified  αVβ5  integrin  was 
immobilized on the chip surface and CD23-derived peptides (10µM) or derCD23 in solution were 
injected over the chip surface. An underivatised reference cell was employed as a control surface. 
In Panel A, the different peptides are shown as distinct line colours as indicated in the legend, and 
in Panel B the different colours indicate different concentrations of soluble derCD23 injected over 
the integrin surface. Data collected were standarised using control and blank injections prior to 
kinetic  analysis,  according  to  standard  double  referencing  data  subtraction  methods 
170,  using 
BIAevaluation 3.1 software (Biacore AB).  
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3.2.3   CD23-derived peptides compete with CD23 for 
binding 
Integrins are known to recognise the tripeptide RGD motif in their ligands at the 
interface of the α and β subunit of the heterodimer. As the RKC motif is also a 
tripeptide motif, we examined whether this RKC motif was a variant of the RGD 
motif and would therefore compete with RGD containing ligands and/or CD23 for 
integrin binding.  
The  RKC containing  peptides  compete  with  CD23  for  binding  to  the  cells,  as 
shown by the inhibition of binding of one species by the other in flow cytometric 
binding  assays  (Figure  3 5A).  These  assays  showed  that  CD23  was  capable  of 
blocking the binding of P11 to THP 1 cells, when incubated with cells prior to 
CD23 binding and, vice versa, P11 was capable of blocking the binding of CD23 to 
THP 1 cells. (Figure 3 5A). However, preincubation with RGD containing integrin 
extracellular matrix proteins vitronectin and fibronectin, failed to prevent the 
binding of biotinylated P11 to THP 1 cells (Figure 3 5B). 
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Figure   3-5 CD23 but not RGD containing ligands compete with CD23-derived 
peptides for binding 
CD23, CD23-derived peptides, vitronectin (Vn) and fibronectin (Fn) were assessed for the ability to 
compete for binding to THP-1 cells by flow cytometry. Binding of biotinylated peptides and CD23 
was detected using streptavidin conjugated to PE. The identity of the staining is indicated on the 
histograms.(A) THP-1 cells were incubated with P11 or CD23 prior to binding of biotinylated CD23 
or P11, respectively. (B) THP-1 cells were incubated with vitronectin (Vn) or fibronectin (Fn) prior to 
binding of biotinylated P11. In Panel A, the binding of CD23 or P11 alone is shown as grey shading 
and the competiion binding is shown as black line. In Panel B, the autofluorescence (auto) of cells 
is shown as grey shading and the binding of P11 with or without RGD-containing ligands is shown 
as a black line.   
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3.2.4   Substitution of RKC motif abolishes both integrin 
binding and competition with CD23 
The  importance  of  the  RKC  motif  to  integrin  binding  was  determined  using 
peptides  carrying  substitutions  in  the  residues  comprising  the  RKC  motif. 
Peptides with mutations in the RKC motif were synthesised to exactly the same 
specifications  as  the  previous  peptides  and  assessed  for  their  ability  to  bind 
monocytic cell lines by flow cytometry and purified integrins by Biacore analysis. 
Figure 3 6A shows the binding of P9 to THP 1 cells (grey shading), as measured 
by flow cytometry. Background binding and the binding of mutant peptides is 
shown as a solid black line. Mutation of any of the residues in the RKC (R￿A, 
R￿Q, K￿A, RK￿AA and C￿S) abrogated peptide binding to cells and resembled 
the background staining. The analysis of the binding of these mutant peptides to 
purified αVβ3 and αVβ5 integrins was extended using Biacore analysis. 
 
Figure  3 7  shows  the  binding  of  P9  and  mutants  in  solution  to  immobilised 
integrin  αVβ5.  Mutation  of  any  of  the  residues  affects  the  binding  of  the 
peptides to the immobilised αVβ5 integrin. Peptides carrying the RK￿AA and 
C￿S substitutions showed no binding to the immobilised αVβ5 integrin. Mutant 
peptides  P9RK,  P9KA  and  P9RQ  showed  some  residual  binding,  although  the 
binding was reduced compared to wild type P9. The binding of mutants P9RK and 
P9RA  was  reduced  by  approximately  50%  and  75%,  respectively.  The  P9RQ 
mutant showed only a very low level of residual binding, approximately one 
tenth of the wild type P9 binding. Equivalent binding traces were obtained for 
the binding of mutants of P11 to αVβ5; and for the binding of mutants of P9 and 
P11 to the αVβ3 integrin (data not shown).   
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Figure   3-6 Mutation of the RKC motif abrogates cell binding and competition 
(A) Mutation of residues of the RKC motif abolishes binding of P9 to cells. The cells were incubated 
with  biotinylated  peptides  and  peptide  binding  detected  by  streptavidin  conjugated  to  PE.  The 
autofluoresence of cells (auto) is shown as grey shading and binding of biotinylated P9 mutants is 
shown as a bold line. The particular mutation is indicated in the top right corner of the plot. (B) 
Mutation of the RKC motif abolishes the ability of CD23-derived P11 to compete with CD23 for 
binding. Cells were incubated with CD23 with or without non-biotinylated P11, prior to detection of 
CD23 binding by anti-CD23 antibody conjugated to PE. The binding of CD23 alone is shown in 
grey shading and the binding of CD23 in the presence of P11 or P11RKAA is shown as a bold 
black  line.  (C)  Sequences  of  CD23-derived  peptides  and  mutants  thereof  (with  substitutions 
indicated in bold). 
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Figure   3-7 Mutation of the RKC motif abrogates binding to purified integrins 
Binding  of  CD23-derived  peptides  in  solution  to  immobilized  αVβ5  integrin  was  measured  by 
BIACORE analysis. Purified αVβ5 integrin was immobilized on the chip surface and CD23-derived 
P9 and mutants (10µM) in solution injected over the chip surfaces. An underivatised reference cell 
was  employed  as  a  control  surface.  Data  collected  were  standarised  using  control  and  blank 
injections  prior  to  kinetic  analysis,  according  to  standard  double  referencing  data  subtraction 
methods 
170, using BIAevaluation 3.1 software. The colour coding used for identification of each 
injected peptide is shown in the the panel itself.  
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3.2.5   In vitro kinetic analysis of interaction between CD23 
or CD23-derived peptides and αV integrins 
Figures 3 4 and 3 7 demonstrate the type of qualitative information that can be 
obtained  from  the  Biacore  sensorgram.  Extending  this  analysis  using  kinetic 
modelling  and  a  range  of  analyte  concentrations  allows  the  calculation  of 
quantitative parameters to define the interaction. 
Figures 3 8 and 3 9 show the Biacore sensorgrams for the binding of a range of 
concentrations  of  CD23 derived  peptides  to  immobilised  αVβ3  and  αVβ5 
integrins, respectively. For both integrins, the RKC containing peptides (P9 P12 
and  LP)  show  characteristic  association  and  dissociation  curves.  As  the 
concentration  of  the  peptides  increases,  so  does  the  amplitude  of  the 
interaction. The control P58, which is derived from CD23 but does not contain 
the RKC motif, does not bind at any concentration. These data were used to 
quantify the interaction between the αVβ3 and αVβ5 integrins and derCD23 and 
CD23 derived peptides.  
As  the  exact  site  and  mechanism  of  interaction  between  the  integrins  and 
CD23/CD23 derived peptides remains to be identified fully, we applied a simple 
1:1 binding model to the kinetic analysis. The Langmuir binding model is based 
on the fact that the interaction involves the Analyte A (in this case the peptide 
in solution) binding to a Ligand B (in this case the immobilised integrin). 
The  kinetic  constants  derived  from  the  analyses  are  shown  in  Table  1 1.  All 
constants were generated using BIAevaluation 3.1 Software. For both the αVβ3 
and the αVβ5 integrin, the qualitative hierarchy of binding (LP > P11 > P12 > P9 
> P10) noted by visual observation of the sensorgram is confirmed by the values 
obtained for the dissociation constants (KD) for peptides binding to integrins. 
DerCD23  binds  with  an  affinity  similar  to  P11,  so  the  hierarchy  for  binding 
affinities  under  these  conditions  for  both  αVβ3  and  αVβ5  integrins  including 
derCD23 is LP > P11 and derCD23 > P12 > P9 > P10.  
The affinities of the individual peptides for the different integrins are similar, 
for example, derCD23 binds to αVβ3 with a KD of 6.00 x 10
 6M
 and to αVβ5 with a 
KD of 6.04 x 10
 6M and LP binds to αVβ3 with a KD of 2.33 x 10
 7M and to αVβ5  
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with a KD of 3.68 x 10
 7M. Only P9 and P10 have KD values that differ significantly 
for αVβ3 and αVβ5 (two orders of magnitude). The KD values determined in this 
study are in a similar range to those determined for the interaction between 
derCD23 and its other ligands CD21 and IgE 
62.  
3.2.5.1    Potential role for disulphide bond in CD23 derived 
peptides during integrin binding 
The  integrin binding  CD23 derived  peptides  contain  a  cysteine  residue  which 
may be capable of forming an inter peptide disulphide bond. To test the ability 
of  the  RKC  containing  peptides  to  form  disulphides,  peptide  solutions  were 
prepared and stored at 4
0C for up to 30 days. Samples were removed at intervals 
and reacted with Ellman’s reagent to detect the molar concentration of free 
sulphydryl groups.  
Reaction of Ellman’s reagent with free sulphydryl groups can be followed by an 
increase in absorbance at 405nm and the concentration determined using Beer’s 
Law 
171. As P9 P12 and LP contain only a single cysteine, the molar concentration 
of  total  sulphydryl  can  be  calculated  from  the  peptide  concentration.  The 
percentage disulphide for each peptide over time was calculated by determining 
the molar concentration of free sulphydryl by reaction with Ellman’s reagent.  
All of the peptides exhibited some degree of disulphide formation (reduction in 
free  sulphydryl  concentration) over  time (Figure  3 10).  Peptide  P9 P12  had a 
significant proportion (between 80 90%) disulphide after 1 day of storage at 4
0C. 
The LP exhibited a lower percentage of disulphide (approximately 30%) after 1 
day of storage at 4
0C. After 10 days storage, all peptides displayed increased 
levels of disulphide formation. P58, which does not contain any cysteines, was 
used as a control and did not produce any change in absorbance at 405nm with 
Ellman’s reagent.  
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3.2.5.2   Effect of cations and salt concentrations on CD23-αV 
integrin binding 
As RGD binding is cation dependent, we tested if CD23 derived peptide binding 
to αV integrins required divalent cations. Magnesium, supplied as chloride salts, 
was spiked into the Biacore running HSB buffer and the effect on peptide binding 
determined.  
After  testing  the  binding  of  the  peptides  in  the  presence  of  the  magnesium 
chloride,  fresh  buffer  containing  EDTA  (ethylenediaminetetraacetic  acid)  was 
added,  the  system  equilibrated  and  the  binding  of  the  same  CD23 derived 
peptides tested. The data for the binding of selected peptides to immobilised 
αVβ3 and αVβ5 integrins in the absence (black lines) and presence of magnesium 
chloride (red lines) are shown in Figure 3 11. In all cases, the peptides bound to 
the  integrins  in  the  absence  of  divalent  cations  and  the  presence  of  the 
chelating agent EDTA. Addition of magnesium chloride to the system prevented 
binding of peptides to both αVβ3 and αVβ5 integrins, as shown by the lack of 
characteristic association and dissociation curves. The sensorgram traces for the 
binding  of  LP  and  P9  in  the  presence  of  chloride  (red  lines)  resembles  the 
binding traces for the control peptide P58, which does not bind to the integrins 
(grey lines).   
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Figure   3-8 BIACORE analysis of binding of CD23-derived peptides to purified 
αVβ3 integrin 
Purified αVβ3 integrin was immobilized on the chip surface. CD23-derived peptides at different 
concentrations in solution  were injected over the test and control chip surfaces. Data collected 
were standarised using control and blank injections prior to kinetic analysis, according to standard 
double referencing data subtraction methods 
170, using BIAevaluation 3.1 software (Biacore AB). 
For P9-P12 and P58, the light grey line is 5µM, the dark grey line is 10µM and the black line is 
20µM. For the LP, the light grey line is 0.25µM, the dark grey line is 0.5µM and the black line is 
1µM.   
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Figure   3-9 BIACORE analysis of the binding of CD23-derived peptides to 
purified αVβ5 integrin 
Purified αVβ5 integrin was immobilized on the chip surface. CD23-derived peptides at different 
concentrations in solution  were injected over the test and control chip surfaces. Data collected 
were standarised using control and blank injections prior to kinetic analysis, according to standard 
double referencing data subtraction methods 
170, using BIAevaluation 3.1 software (Biacore AB). 
For P9-P12 and P58, the light grey line is 5µM, the dark grey line is 10µM and the black line is 
20µM. For the LP, the light grey line is 0.25µM, the dark grey line is 0.5µM and the black line is 
1µM.   
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Table   3-1 Kinetic Constants determined for the binding of derCD23 and 
CD23-derived peptides to immobilised integrins 
 
αVβ3 
 
αVβ5 
Ligand 
 
Kd (M) 
 
Kd (M) 
 
P9 
 
8.98 ± 3.14  
x 10
 4 
 
1.30 ± 0.08 
x 10
 6 
 
P10 
 
8.13± 6.19  
x 10
 4 
 
1.55 ±0.76  
x 10
 6 
 
P11 
 
9.87 ±0.12  
x 10
 6 
 
8.92 ± 0.2  
x 10
 6 
 
P12 
 
1.07 ± 0.14 
x 10
 5 
 
3.73 ± 0.35 
x 10
 6 
 
LP 
 
2.33 ± 0.068  
x 10
 7 
 
3.68 ± 0.04  
x 10
 7 
 
derCD23 
 
6.00 ± 4.21 
x 10
 6 
 
 
6.04 ± 3.59  
x 10
 6 
 
 
Published constants for derCD23 and its other ligands
62 
 
Ligand 
 
Kd (M) 
CD21  8.70 ± 0.9 x 10
 7 
IgE  1.3 ± 0.3 x 10
 6  
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Figure   3-10 Analysis of disulphide formation in CD23-derived peptides by 
Ellman's Assay 
(A) Ellman’s reagent was used to determine disulphide bond formation in CD23-derived peptides. 
Peptide  solutions  at  10µM  were  prepared  and  stored  at  4
0C  for  a  month.  The  percentage 
disulphide  was  determined  at  specified  time  points  by  incubation  with  Ellman’s  Reagent  and 
measurement of absorbance at 450nm. (B) RKC-containing CD23 long peptide sequence contains 
a single cysteine, possibly capable of forming two disulphide-bonded dipeptide species.  
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Figure   3-11 BIACORE analysis of effect of salt concentration on binding of 
CD23-derived peptides 
Panel A shows the binding of CD23-derived peptide LP to the purified αVβ3 (Ai) and αVβ5 (Aii) 
integrins. Panel B shows the binding of CD23-derived peptide P9 to the purified αVβ3 (Bi) and 
αVβ5 (Bii) integrins. In all graphs, the black line shows the binding sensorgram for the specific 
peptide in the absence of divalent cations or chloride ions. The grey line shows the binding of 
CD23-derived P58. This peptide P58 did not bind the purified integrins and therefore is considered 
a control for absence of binding. The red line shows the binding of the specific peptide  in the 
presence of divalent cations and chloride ions. Data collected were standardized using control and 
blank injections prior to kinetic analysis, according to standard double referencing data subtraction 
methods 
170, using BIAevaluation 3.1 software. 
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3.3  DISCUSSION 
CD23  binds  to  four  members  of  the  integrin  family  of  proteins,  αMβ2,  αXβ2, 
αVβ3  and  αVβ5.  Using  cell  lines  that  express  CD23 binding  integrins  and 
commercially available purified αVβ3 and αVβ5 integrins, we investigated the 
interaction  between  CD23  and  these  integrins.  We  generated  a  library  of 
nonameric  peptides  derived  from  the  CD23  sequence  (residues  131 321)  and 
identified a set of peptides (P9 P12) which bound to integrins expressed on the 
surface of cells and purified αVβ3 and αVβ5 integrins in in vitro Biacore analysis. 
Although many protein recognition motifs are cryptic and non linear, this protein 
array technique was determined suitable for our purposes as integrins are well 
known to bind small, linear peptide motifs (RGD) 
175.  
3.3.1   RKC is a new integrin recognition motif 
Those  CD23 derived  peptides  that  bound  cells  and  integrins  were  found  to 
contain  a  common,  linear  tripeptide  recognition  sequence,  termed  the  RKC 
motif. Peptides containing this motif bound to cells expressing integrins in flow 
cytometry assays and to purified αVβ3 and αVβ5 integrins in Biacore analysis. 
The  interaction  between  RKC containing  peptides  was  determined  to  be 
independent of divalent cations, salt sensitive and not inhibited by the presence 
of  RGD containing  integrin  ligands.  Mutation  of  residues  in  the  RKC  motif 
abolished the interaction with cells and purified integrins as judged by Biacore. 
These data suggest that the RKC is a new recognition motif for αV integrins and 
that the sequence is recognised and bound by the integrin at a site distinct from 
that used for RGD binding.  
The classical integrin recognition motif is the tripeptide RGD motif, found in 
numerous  integrin  ligands.  Initial  observations  suggested  that  the  RKC  motif 
might be a new variant of the RGD motif, given that it was a tripeptide motif 
and that CD23 does not contain an RGD sequence, but is known to bind integrins. 
Integrins do bind variations of the RGD tripeptide motif at the site usually bound 
by  RGD containing  ligands,  for  example  the  KQAGDV  sequence  is  bound  by 
αIIbβ3, the LDV is bound by α4β1 and α4β7 and REDV sequence from fibronectin 
is bound by α4β1 
101, 110.   
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3.3.2   RKC binding is independent of RGD binding 
All  of  the  alternative  integrin  recognition  sequences  described previously  are 
considered variants of the RGD motif and are bound at the same site on the 
integrin at the RGD binding site. The inverse RGD sequence, DGR, does not have 
any  measurable  integrin  binding  activity.  This  is  important  in  the  context  of 
CD23, as it contains a DGR sequence and is known to interact with RGD binding 
integrins 
67. Our data support the fact that DGR is not an integrin recognition 
motif, as peptides from the CD23 sequence containing this DRG motif (P60 63) 
failed to bind to cells in our assays.  
Despite the range of sequences recognised by integrins, in most cases, those 
alternative motifs described thus far all include an Asp, or the closely related, 
Glu residue. The RGD peptide binds a shallow groove at the interface of the ß 
propeller of the α subunit and the ßA domain of the ß subunit (Figure 1.6). The 
requirement  for  the  Asp  may  be  due  to  its  ability  to  coordinate  metal  ions 
essential for integrin based ligand recognition. In addition to binding the metal 
ion at the MIDAS site, the Asp
RGD side chain makes contacts with residues Tyr122 
from the α subunit and Arg214 and Asn215 from the βA domain on the β subunit. 
The Arg
RGD residue is bound by the ß propeller groove from the α subunit, where 
the guanidinium group forms a bidentate salt bridge with Asp218 and another 
salt bridge with Asp150 (Figure 1 6). This group forms the centre of a network of 
polar interactions with the ßA residues and the MIDAS. The central Gly
RGD residue 
projects into the interface between the α and ß subunits. It interacts with the 
αV subunit, primarily via the carbonyl oxygen of Arg216.  
In view of this binding information obtained from the crystal structure of the 
αVβ3  integrin  in  complex  with  a  cyclic  RGD  containing  peptide,  the 
characteristics of the RKC make it improbable that the RKC would be bound at 
the RGD site. The RKC motif lacks the acidic residue and therefore would be 
unable to coordinate the divalent cation; indeed our data show that the RKC 
binding is independent of divalent cations and can occur in the presence of the 
chelating agent EDTA. CD23 derived peptides do not compete for binding with 
RGD containing ligands. In addition, a predicted conflict between the Arg216 
carbonyl group integral to RGD binding and the large, charged lysine group of 
the RKC means the Lys
RKC is unlikely to be accommodated in the Gly
RGD position  
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at the interface of the two subunits. Taken together, these data suggest that the 
RKC is a novel recognition sequence and is bound at a site distinct from that 
used for RGD binding.  
Although the RGD binding site is the most extensively studied interaction site on 
integrins, there are precedents for the existence of an alternative binding site 
from other studies. These alternate binding sites have been suggested by the 
binding of ligands, such as tumstatin 
114, HIV Tat protein 
109 and entactin 
115, to 
the  αVβ3  and  αVβ5  integrins  at  RGD independent  sites.  These  studies  have 
proposed  either  the  existence  of  an  additional  distinct  binding  site  or  a 
synergistic ligand recognition site that cooperates with the RGD binding site 
109, 
176, 177. In most cases, this additional non RGD site recognises basic sequences. 
Analysis of the binding of Type IV collagen indicates that this protein contains 
additional aVb5 and aVb3 binding sites 
108. Studies on the binding of tumstatin 
derived  peptides  to  aVb3  indicated  that  the  protein  contains  two  RGD 
independent  aVb3  binding  sites,  as  the  binding  of  these  peptides  was  not 
inhibited by the presence of cyclic RGD peptides 
114. Entactin was also shown to 
contain  two  distinct  RGD independent  cell  attachment  peptides.  Mutants  of 
entactin lacking the RGD motif were still capable of mediating cell attachment, 
although the integrin involved in binding remains to be identfied 
115. The α2β1 
integrin  also  recognises  a  basic  tetrapeptide  RKKH  site  in  the  protein 
jararhagin
177 and α3β1 recognises a basic sequence in laminin 
176. 
3.3.3   Substitution of the RKC affects integrin binding 
The  interaction  of  CD23/CD23 derived  peptides  and  integrins  required  the 
presence  of  the  RKC  motif.  Substitution  of  residues  in  the  RKC  tripeptide 
affected  the  interaction  between  the  peptides  and  both  the  αVβ3  and  αvB5 
integrins.    Mutation  of  any  of  the  residues  in  the  RKC  motif  abolishes  the 
interaction of these peptides with cells, while the Biacore analysis was more 
sensitive  and  reveals  that  some  of  the  mutant  peptides  retain  some  binding 
ability. P9 carrying a mutation of the Arg
RKC to a similarly charged Lys residue 
shows a reduction in binding to approximately half of that of the wild type P9, 
but  did  not  completely  prevent  binding  in  our  assays.  Mutation  of  the  same 
residue  to  a  Gln  almost  completely  abolished  any  binding  to  the  purified  
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integrin. Mutation of the Lys
RKC to Ala also results in a significant reduction in 
binding. These three mutations highlight the importance of the basic nature of 
the RKC motif in the binding to integrins. Any mutation that reduces the basic 
nature of the motif reduces the interaction. The double mutant RK￿AA mutant 
displays no binding in the context of either P9 (Figure 3 7) or P11 (data not 
shown).  
Interestingly, the P9C￿S mutant completely ablates the binding between the 
RKC containing peptides and the integrins. Analysis of the structure of the RKC 
motif in complete CD23 reveals that this residue is part of a disulphide bond 
(Figure 3 12). We investigated the abilty of the CD23 derived peptides to form 
inter peptide  disulphide  bonds  using  Ellman’s  reagent.  Our  analysis  revealed 
that  the  peptides  did  appear  to  form  disulphides,  as  indicated  by  a  lower 
concentration of free sulphydryl groups than total sulphydryls over time. This 
disulphide bonding may be important for peptide binding, indicated by the lack 
of binding in the P9C￿S mutant (which cannot form an inter peptide disulphide 
bond).  Work  from  another  member  of  the  laboratory  has  highlighted  the 
importance of the Cys
RKC to the biological role of the CD23 derived peptides in B 
cells. RKC containing peptides stimulate the proliferation of B cell precursors 
75. 
A  specific  murine  cell  line,  BAF03  requires  β mercaptoethanol  in  the  growth 
medium  for  survival.  This  fact  was  exploited  to  examine  the  role  of  the 
disulphide  bond  in  RKC  containing  peptides.  P9  was  boiled  with  β 
mercaptoethanol to reduce the disulphide bond and then tested for its ability to 
stimulate  the  growth  of  BAF03  cultures  (including  β mercaptoethanol  in  the 
medium).  Untreated  P9  was  capable  of  stimulating  cell  growth,  but  the  β 
mercaptoethanol  treated  P9  was  not  (Dr.  Mridu  Acharya,  unpublished  data). 
These data support the important role of the Cys
RKC in the binding and activity of 
these  peptides.  The  mechanism  underlying  this  characteristic  remains  to  be 
determined. It is possible that the disulphide provides a degree of structural 
rigidity to the peptides that is required for binding or activity. Alternatively, the 
dimeric  peptide  may  cause  dimerisation  of  the  integrins  to  which  it  bound. 
These are only theories at present and will need to be determined conclusively 
by crystallisation/structural analyses.  
Although the RKC motif is the core unit important for binding, the hierarchy of 
binding obtained from the Biacore analysis (both qualitative and in KD values)  
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reveals that other regions of the peptides must be important for binding. Were it 
only the RKC motif that was the critical determinant for binding, all peptides 
containing that tripeptide should bind with equivalent affinities. We observed, 
however, that peptides bound with different affinities, suggesting an important 
role for the flanking sequence in integrin binding (Table 1 1). The  LP (2.33 x   
10
 7M and 3.68 x 10
 7M for the αVβ3 and αVβ5 integrin, respectively) shows the 
highest affinity binding, higher than any of the other P9 P12 and in fact higher 
that  obtained  for  CD23  (KD  6  x  10
 6M  and  3  x  10
 7M  for  the  αVβ3  and  αVβ5 
integrin, respectively, from which all the peptides were derived). The fact that 
the LP binds more strongly to both αVβ3 and αVβ5 than the other CD23 derived 
peptides indicates that, although the RKC is required for binding, the flanking 
sequence influences the strength of that interaction. The LP contains the whole 
sequence encompassing those peptides which bind the integrins and therefore 
must  contain  the  majority  of  the  complete  binding  sequence.  The  increased 
affinity of the LP for the integrin is interesting, as the natural ligand (CD23) 
binds with lower affinity than the LP derived from it. It may be that there is 
some structural arrangement or induced fit conformation that the LP is capable 
of achieving that the full length CD23 is prevented from by steric hindrance. 
Whether this is true or has physiological relevance remains to be determined.  
The hierarchy of binding determined from the kinetic analysis is also observed 
qualitatively by looking at the relative responses of equivalent concentrations of 
CD23 derived  peptides  in  the  Biacore  sensorgrams  (Figure  3 4).  It  is  worth 
noting, however, that the kinetic parameters determined for this interaction are 
only relevant in the context of our experiment and the interaction model used to 
fit  the  data.  In  the  absence  of  knowledge  of  the  exact  mechanism  of  the 
interaction between CD23/CD23 derived peptides and αV integrins, we applied a 
simple 1:1 interaction model to calculate kinetic parameters. This may not be 
the most accurate method of fitting the data. We determined by Ellman’s assay 
that these CD23 derived peptides are capable of forming disulphide bonds. Given 
that  the  peptides  contain  only  a  single  disulphide  bond,  the  only  possible 
disulphide bonded species would be an inter peptide bond. Mutation of the C￿S 
abolishes  the  potential  to  form  a  disulphide  and  prevents  binding;  a  peptide 
treated with the reducing agent β mercaptoethanol loses its functional activity 
(Dr Mridu Acharya, unpublished data).  This suggests that a dipeptide, which 
possibly might contain 2 recognition sites (RKC) for the integrin, may be the  
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active  conformation.  Visual  observation  of  the  shape  of  the  association  and 
dissociation curves suggests a biphasic reaction (Figure 3 4). If this were correct, 
a  model  that  incorporated  this  would  give  more  accurate  kinetic  data.  This 
model would need to address the different binding scenarios that could arise 
from this, possibilities that include a ligand in solution with two binding sites for 
a single integrin molecule or a single dipeptide binding two integrin molecules.  
Further investigation of the interaction will allow re analysis of these data as 
more  information  regarding  the  interaction  between  these  species  becomes 
available. Care should be taken therefore when making assumptions about in 
vivo binding, although it does not, however, detract from the value of these 
data in comparing the in vitro interaction characteristics of the different CD23 
derived peptides and mutants thereof.  
3.3.4   RKC binding is cation independent and salt 
sensitive 
A 9 residue basic peptide derived from the HIV Tat protein was shown to bind 
the aVb5 integrin in an RGD and divalent cation independent fashion. This basic 
peptide was highly specific with respect to sequence and capable of mediating 
cell attachment 
109. The authors postulate that, although Tat contains an RGD 
motif, it is not presented in a context that allows it to bind aVb5. They suggest 
that  the  basic  peptide  binds  a  synergistic  site  on  aVb5  to  mediate  specific 
interactions 
109. The binding of this peptide may give a clue to the binding of the 
RKC motif, as there are similarities with the CD23 derived peptides. In CD23 the 
DGR is not presented in a format that can be recognised and the interaction was 
rather mediated by an interaction of the RKC with a basic domain binding site on 
the integrin. Moreover, the interaction between the basic peptide from Tat and 
the αVβ5 integrin was cation independent and salt sensitive (chloride), similar to 
that observed for the binding of RKC peptides to the αVβ3 and αVβ5 integrins in 
the Biacore analysis. The addition of the magnesium to the Biacore buffer as a 
chloride  salt  would  have  elevated  the  salt  concentration  above  physiological 
levels,  as  the  buffer  contained  150mM  sodium  chloride  prior  to  addition  of 
100mM  magnesium  chloride.  Other  similar  salt sensitive  interactions  involving 
integrins  have  been  described,  including  the  interaction  of  collagen  and 
fibronectin by the α3β1 integrin 
178.   
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3.3.5   Analysis of the structures of CD23 
Two structures of the soluble C type lectin like head of CD23, both of which 
contain the RKC motif, have been published in the literature 
62, 63. Examination 
of the structures shows that the binding sites for the three CD23 ligands, CD21, 
IgE and integrins (RKC), are independent of each other (Figure 3 12A).  
Whereas a crystal structure gives a single set of coordinates, the NMR structure 
is an average of a number of structural coordinates, due to the dynamic nature 
of  proteins  in  solution.  It  is  possible  therefore  to  isolate  each  individual 
structural file and analyse them individually. Figure 3 12B shows an image of the 
20 individual structure files that comprise the NMR structure of CD23 overlaid on 
each other using the Pymol graphics program (Delano Scientific, CA). The C type 
lectin head is displayed as ribbons and the RKC motif rendered as sticks. The 
RKC  motif  is  located  on  a  solvent exposed  disulphide bonded  loop  at  the  N 
terminal end of the C lectin head domain, between the β0 and β1 strands. The 
Cys174
RKC forms a disulphide bond with Cys163 and therefore is restricted and 
maintains its position in all of the 20 structures  comprising the NMR average 
structure. Similarly, the Lys173
RKC does not show much movement, other than a 
slight apparent rotation of the side chain. In contrast, the Arg172
RKC side chain is 
shown to sample a number of positions in the different NMR structure files which 
make up the final structure. Comparison of the relative positions of the RKC 
motif in the averaged NMR structure and crystal structure indicates that in the 
crystal structure (Figure 3.12B) the Arg172
 RKC and Lys173
RKC appear less solvent 
exposed than in the averaged NMR structure (Figure 3 12A). However, as the 
crystal structure represents a single defined structure (“snapshot in time”), it is 
possible  that  this  less  solvent exposed  conformation  is  also  observed  during 
dynamic movements of the solution CD23. The fact that it is not reflected in the 
averaged  CD23  NMR  structure  suggested  that  in  solution  this  residue  is  more 
likely to be solvent exposed than not. This apparent flexibilty in the Arg172
RKC 
may have important consequences for the binding of CD23 to its integrin ligands. 
It does not preclude the possibility of an induced fit model for CD23 binding. The 
relevance of this to the interaction will rely on the solution of a structural model 
of the interaction prior to making any conclusions in this regard.   
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Data  collected  in  this  study  suggested  that  the  interaction  between  CD23 
derived peptides and αV integrins occurs via an RKC motif in CD23 and that this 
motif is bound at an alternate binding site to that which recognises the RGD 
motif. Attempts to identify this site during this investigation were hampered by 
technical problems and it remains to be identified. Work is continuing to extend 
the analysis of this interaction. Our priority is to identify the location of the 
basic site for ligand binding on the αV integrins and to analyse the substitutions 
of the RKC motif in the full length CD23 protein.  
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Figure   3-12 Analysis of RKC motif in CD23 crystal and NMR structures 
Crystal 
94, 98 and NMR  
62, 63 structures of the C-lectin like domain of CD23 have been solved. (A) 
The binding sites for IgE (blue), CD21 (red) and integrins/RKC (yellow) on CD23 are distinct from 
each other. (B) CD23 solution structure, showing the position of the RKC motif in the 27 individual 
coordinate files that comprise the NMR structure file. The RKC motif (shown as sticks) is located on 
a solvent-exposed loop at the base of the C-lectin like head domain of CD23. The Lys
RKC and 
Cys
RKC retain similar positions in all the files, while the Arg
RKC is shown to sample a number of 
positions. RKC motif is shown in the NMR solution (C) and crystal (D) structures of CD23. Figures 
were generated using Pymol (DeLano Scientific); NMR structure PDB code is 1T8C and Crystal 
structure PDB code is 2H2R.  
106 
 
 
 
 
 
 
4  INTEGRIN-REGULATED CYTOKINE 
PRODUCTION BY MONOCYTIC CELLS  
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4.1 Introduction 
4.1.1   CD23-Integrin interactions and cytokine production 
CD23 (Blast 2, FcεRII) is a 45 kDa, Type II transmembrane glycoprotein, which 
exists  in  both  membrane  bound  and  soluble  forms 
32.  Membrane  bound  CD23 
(mbCD23) is cleaved by membrane associated metalloproteases to yield soluble 
CD23 (sCD23) fragments of 37kDa, which are subsequently cleaved to yield CD23 
species of 33kDa, 29kDa, 25kDa and 16kDa 
35,  179. These sCD23 species possess 
cytokine like  activities,  which  may  be  induced  by  interactions  with  partner 
proteins. Of particular interest in this thesis is the interaction between sCD23 
and integrins, which is important in the stimulation the production of cytokines 
by monocytes 
40, 41, 83, 84, 180. Integrins are proteins that play a critical role in cell 
adhesion  and  signalling  across  membranes.  They  control  cell cell  and  cell 
extracellular  matrix  contacts  and  participate  in  signalling  both  from  the 
cytoplasm to the exterior of the cell and vice versa. CD23 interacts with two 
classes of integrin (αV and β2) to induce cytokine synthesis in monocytes. 
4.1.1.1   CD23 and β2 integrins 
The  ß2  integrins  are  exclusively  expressed  on  leukocytes.  They  are 
heterodimeric αß integrins, formed by the non covalent association of one of 4 α 
chains  (αD,  αL,  αM  or  αX)  with  the  ß2  integrin 
88,  144.  An  absence  of the ß2 
integrin  results  in  impairment  of  a  variety  of  immune  functions,  including 
reductions  in  macrophage  oxidative  burst  and  phagocytosis  and  lymphocyte 
proliferation 
181. CD23 interacts with the alpha chains of the leukocyte integrins 
αMß2  (CD11b/CD18)  and  αXß2  (CD11c/CD18) 
74.  Membrane bound  CD23 
incorporated  into  liposomes  has  been  shown  to interact  with  αXß2  and  αMß2 
expressed  on  the  surface  of  monocytes.  Soluble  CD23  was  demonstrated  to 
induce the synthesis by monocytes of the pro inflammatory cytokines IL 1ß, IL 6 
and TNF α through interaction with αMß2 and αXß2 
41, 74, 83, 84.   
4.1.1.2   CD23 and αV integrins 
The αV family of integrins, also known as the vitronectin receptors, include the 
αV subunit in complex with one of β1, β3, β5, β6 or β8 subunits. CD23 interacts  
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with the vitronectin receptors αVß3 and αVβ5, with αVβ3 having an important 
role in cytokine production in monocytes. Integrin αVβ3 is associated with CD47, 
a 50kDa tetraspan transmembrane protein, to form the αVβ3 integrin signalling 
complex 
182, 183. The αVβ3 integrin plays a role in cytokine production through its 
interaction with sCD23, which leads to the production of TNF α and IL 1 
40. Our 
laboratory has recently identified an interaction between CD23 and αVß5, which 
is implicated in prevention of apoptosis of pre B cells 
75. The potential role of 
αVβ5 in cytokine production remains to be established.  
4.1.2   Hierarchy of integrin activity in cytokine production 
by monocytic cells 
The  role  of  CD23  in  initiating  cytokine  production  by  monocytic  cells  via  an 
interaction with one or more of its integrin receptors has been described by a 
number of groups 
40, 41, 83, 84. However, the relative importance of each of the 
individual integrin isoforms to this process has not been studied in detail. We 
aimed  to  extend  the  analysis  of  the  role  of  individual  integrins  in  cytokine 
production  by  monocytic  cells  and  to  identify  any  relative  hierarchy  of 
importance of the individual integrins with respect to cytokine production. This 
analysis  included  the  first  investigation  of  the  role  of  the  αVβ5  integrin  in 
promoting cytokine synthesis by monocytic cells.   
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4.2 Results 
4.2.1   CD23 drives cytokine production by monocytic cells 
The interaction between CD23 and integrins expressed on monocytic cells has 
been shown to induce the synthesis of cytokines, including TNF α, IL 1β, MIP 
1α/β and nitric oxide 
40, 41, 83, 84, 180. We tested our model monocytic cell line, 
THP 1, for the ability to produce cytokines in response to treatment with CD23 
(Figure 4 1A). Supernatant from THP 1 cells stimulated overnight with CD23 was 
tested for the presence of RANTES, IL 8 and MIP 1β using ELISA. CD23 stimulated 
the production of all of these cytokines by THP 1 cells (Figure 4.1A), albeit to 
different extents.  
However, CD23 binds to four members of the integrin family of proteins (αVβ3, 
αVβ5, αMβ2 and αXβ2) and often more than a single integrin isoform will be 
expressed  on  the  surface of  monocytic  cells  at  the  same time.  The  cytokine 
output of a cell, therefore, will be the net result of the interaction of CD23 with 
the range of interacting integrins expressed on that particular cell. In order to 
assess the contribution of individual integrins to the cytokine output, we used 
antibodies against specific integrin isoforms to attempt to identify a hierarchy of 
importance  amongst  the  different  CD23 binding  integrins  with  respect  to 
monocyte stimulation (Figure 4 1B).   
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Figure   4.1 Cytokine production by CD23-integrin interaction in monocytes 
(A) THP-1 cells were incubated overnight alone (white bars) or with 5µg/mL sCD23 (grey bars) 
Cytokines released into the supernatant were detected by ELISA. (B) The response of a monocytic 
cell to CD23 treatment is due to the combined effect of binding to any of 4 possible CD23 binding 
integrins.  The  use  of  antibodies  raised  against  specific  integrins  allowed  identification  of  the 
contribution of individual integrin isoforms and/or subunits to the cytokine output of the monocyte.  
111 
4.2.2   Qualitative analysis of the cytokine output in 
response to integrin binding 
In  order  to  investigate  the  global  cytokine  production  profile  induced  by 
stimulating  integrins  on  monocytic  cells,  we  used  a  commercially  available 
cytokine  array  technique  (Figure  4 2).  This  method  uses  a  combination  of 
sandwich  ELISA,  Western  blotting  and  chemiluminescent based  detection  to 
simultaneously analyse a sample for the presence of 36 different cytokines in 
duplicate.  The  protein  array  itself  comprises  a  nitrocellulose  membrane  with 
antibodies  conjugated  to  it  at  defined  locations  in  a  grid  (Figure  4 2B).  This 
membrane was incubated with the sample (in our case cleared supernatant from 
stimulated  cells)  and  then  non specific  sites  on  the  membrane  were  blocked 
with  BSA.  Cytokines  in  the  sample/supernatant  bound  to  their  corresponding 
antibody  on the  membrane.  The  bound  cytokines  were  then  detected  with  a 
biotinylated  primary  antibody  against  that  specific  cytokine  (to  form  the 
antibody  “sandwich”).  The  binding  of  biotinylated  primary  antibody  was 
detected  using  streptavidin conjugated  to  HRP,  the  nitrocellulose  membrane 
incubated with chemiluminescent substrate and a signal pattern recorded on X 
ray  film.  The  membrane  is  orientated  by  the  location  of  the  positive  and 
negative  samples  and  the  location  of  the  signal  relative  to  that  identifies  a 
particular  cytokine,  as  indicated  by  the  grid  (Figure  4 2B  and C).  The  global 
cytokine output for a particular stimulus can be determined semi quantitatively 
using  densitometry  and  standardisation  of  the  signal  strength  of  individual 
cytokines against the positive control signals (Figure 4 2D).  
We  selected  a  specific  cytokine  array  that  would  allow  us  to  analyse  the 
production of a range of inflammatory cytokines. We validated the use of this 
technique for our purposes by first investigating the response of THP 1 cells to 
stimulation  with  IgG1,  LPS  and  CD23.  LPS  and  CD23  are  known  inducers  of 
cytokine production 
41, 184 186 and IgG1 was used as a negative control for ligating 
(but not cross linking) of Fcγ receptors (certain members of which are known to 
induce cytokine production in phagocytes). Figure 4 2C shows the cytokine array 
membrane for cleared supernatants from untreated THP 1 cells and THP 1 cells 
treated overnight with IgG1, LPS and CD23. All of these arrays displayed the 
expected  patterns  for  the  positive  and  negative  control  signals  on  the 
membranes. These are shown as a block of four signal dots at the top right and  
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bottom right of each of the blots (positive controls), separated by a space that 
shows  no  signal  (negative  control),  indicating  that  the  array  had  performed 
according to manufacturer’s instructions. 
The  blot  using  the  supernatant  from  untreated  THP 1  cells  showed  positive 
signals  in  certain  positions.  These  signals  correspond  to  cytokines  that  are 
produced constitutively by the cell line, such as the chemokine RANTES. THP 1 
cells are derived from a patient suffering from acute myelogenous leukaemia 
and therefore the changes associated with this disease may be responsible for 
this  constitutive  production  of  certain  cytokines.  IgG1 treated  THP 1  cells 
showed a similar profile in cytokine production as the untreated cells and in 
some cases lower levels of constitutive cytokine production. LPS and CD23, both 
known  to  induce  cytokine  production  by  monocytes,  produced  a  number  of 
positive signals, indicating the presence of a range of cytokines in the THP 1 
supernatant. Strong positive signals were obtained for RANTES, MIP 1α/β, IL 8, 
VEGF, IL 4 and IL 12p40 in response to LPS and sCD23 treatment.  
The array technique is, however, qualitative and therefore could only be used to 
illustrate the presence or absence of a certain cytokine but not to determine its 
concentration. Additionally, the chemiluminescent based signal detection meant 
that  there  was  the  potential  for  membrane to membrane  variation  in  signal 
intensity due to exposure times. As such, the signal intensity for each cytokine 
was standardised against the positive control signals on each individual blot. The 
positive and negative control signal intensities are independent of concentration 
and therefore ideal for use as an internal standard to normalise cytokine signal 
intensity for exposure differences. This produced a set of data that could be 
used  for  comparison  between  different  blots.  The  standardised  data  for  the 
signal intensity of 36 cytokines produced in response to negative (untreated and 
IgG1)  and  positive  (LPS  and  IgG1)  treatments  are  shown  in  Figure  4 2D.  This 
chart  shows  the  cytokine  signal  intensity  determined  by  densitometry  and 
represented  as  a  ratio  relative  to  the  signal  intensity  of  the  positive  control 
signal intensity on that same membrane. The signal ratios of the 36 cytokines 
produced in response to a particular treatment are shown together on the chart. 
This  gives  a  global  view  of  the  effect  of  the  particular  treatment;  allowing 
identification of those treatments which are most stimulatory with respect to 
cytokine production. The chart shows that although there is some constitutive  
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production  of  cytokines  observed  in  the  untreated  supernatant  or  the  IgG1 
treated cells, there is a large increase in the number of positive signals when the 
THP 1 cells are treated with LPS or CD23.  
Using this semi quantitative approach, we analysed the response of THP 1 cells 
to antibodies directed against individual CD23 binding integrins (Figures 4 3 and 
4 4). THP 1 cells express high levels of the αVβ3, αVβ5 and αXβ2 integrins but 
only low levels of the αMβ2 integrin. The difference in expression levels of the 
different CD23 binding integrins with respect to cytokine production is discussed 
later in the chapter (Figure 4 8). We selected pairs of antibodies against the four 
CD23 binding  integrins  (αVβ3,  αVβ5,  αMβ2  and  αXβ2)  and  the  two  common 
integrin  chains  (αV  and  β2).  The  antibodies  were  selected  to  recognise  the 
different families of integrin (αV or β2), distinct heterodimer isoforms within 
those families (αV, αVβ3 or αVβ5) or different epitopes on a specific heterodimer 
(Table  4 1).  We  used  these  antibodies  to  determine  the  difference  in  the 
cytokine response to binding of the αV integrins as opposed to the β2 integrins, 
to analyse the role of different isoforms within a particular family (αV or β2), 
and to investigate the role of different epitopes on a specific integrin.  
Figure  4 3  shows  the  global  cytokine  profile  for  THP 1  cells  treated  with 
antibodies against CD23 binding integrins from the αV family. The cytokine array 
membrane  signal  pattern  is  shown  in  Figure  4 3B  and  the  associated 
densitometry data are displayed in the bar chart in Figure 4 3C. The untreated 
and  IgG1 treated  THP 1  supernatants  did  not  produce  significantly  different 
signals, other than certain cytokines, such as RANTES, which were constitutively 
expressed  by  the  THP 1  cell  line.  LPS  treatment  led  to  the  expression  of  a 
number of cytokines, leading to a large change of signals represented in the 
densitometry chart. This indicated that LPS induced the production of a range of 
cytokines by THP 1 cells, including TNF α, RANTES, IL 8 and MIP 1β. Comparing 
the cytokine arrays for the treatment of THP 1 cells with antibodies (Figure 4 
3Bii) showed that THP 1 cells produced cytokines, including RANTES, IL 8 and 
MIP 1β,  in  response  to  anti αV  antibodies.  Stimulation  of  THP 1  cells  with 
antibodies against αV (using AMF7) and αVβ3 (23C6) and αVβ5 (15F11) produced 
a similar qualitative cytokine profile, although αV and αVβ5 ligation were less 
effective  than  αVβ3.  The  anti αVβ3  antibody  was  the  most  effective  at  
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stimulating cytokine production by THP 1 cells and induced the greatest range of 
cytokines of the anti αV antibodies (Figure 4 3C). 
Figure 4 4 shows the equivalent data for the global cytokine profile for THP 1 
cells treated with antibodies against CD23 binding integrins from the β2 family. 
Stimulation  of  THP 1  cells  with  antibodies  to  members  of  the  β2  family  of 
integrins resulted in the production of a range of cytokines. Ligation of the β2 
subunit  using  the  antibody  MEM48  did  not  produce  a  change  in  the  profile 
compared with untreated or IgG1 treated THP 1 cells. Treatment with the anti 
αMβ2 antibody Clone44 and anti αXβ2 antibody HC1.1 induced the production of 
a similar range of cytokines to that observed with LPS treatment. Of the two 
treatments, the anti αXβ2 antibody produced the greater cytokine response and 
was most similar to the LPS induced response (Figure 4 4D).  
Analysis of the qualitative cytokine data collected for stimulation of the αV and 
β2 integrins indicated that a similar profile of cytokines is produced, irrespective 
of the family of integrin targeted. Rather than a change in the identity of the 
cytokines,  the  concentration  of  individual  cytokines  produced  in  response  to 
stimulation  of  integrins  was  seen  to  vary.  Using  the  qualitative  information 
obtained from the global cytokine arrays, a number of cytokines that had been 
secreted as a consequence of integrin binding were  selected for quantitative 
analysis.  The  chemokines  MIP 1β,  IL 8  and  RANTES  were  selected  for  the 
majority of further analysis. In certain cases the production of other cytokines 
and growth factors, including but not limited to IL 4 or VEGF, were analysed.    
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Figure   4.2 Validation of cytokine arrays for the simultaneous detection of 36 
cytokines 
(A)  Schematic  diagram  of  the  cytokine  array  process.  Supernatant  from  stimulated  cells  was 
cleared  by  centrifugation  and  incubated  with  the  cytokine  array  membrane.  The  nitrocellulose 
membrane has antibodies for specific cytokines attached at defined positions, as shown by the 
template guide. (B) The membrane was incubated with cleared supernatant for 2 hours, washed 
and  incubated  with  biotinylated  antibodies  to  specific  cytokines.  Binding  of  these  biotinylated 
primary antibodies was detected using streptavidin conjugated to HRP. The blot was incubated 
with chemiluminescent substrate and the membrane exposed to x-ray film. (C) Cytokine arrays 
showing the global cytokine array responses for positive (LPS and CD23) and negative (Untreated 
cells  and  IgG1  stimulation)  controls.  The  patterns  were  recorded  and  analysed  using  ImageJ 
software. Signal intensity was calculated as a ratio relative to the positive control signal intensity, to 
standardize for exposure differences (D). The response to IgG1 is included as a representative 
example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses 
equivalent to IgG1.   
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Table   4-1 Antibody pairs used to determine response to integrin binding 
 
INTEGRIN 
 
ANTIBODY 
 
EPITOPE* 
 
 
AMF7 
 
Non-RGD 
 
 
αV   
LM142 
 
Non-RGD 
 
 
23C6 
 
RGD 
 
 
αVβ3   
LM609 
 
RGD** 
 
 
P1F6 
 
RGD 
 
 
αVβ5   
15F11 
 
Non-RGD 
 
 
PAH9 
 
Non-RGD 
 
 
β2   
MEM48 
 
Non-RGD 
 
 
Clone44 
 
RGD 
 
 
αMβ2   
ICO-GMI 
 
Non-RGD 
 
 
Clone3.9 
 
RGD 
 
 
αXβ2   
HC1.1 
 
RGD 
 
 
*RGD signifies that the antibody inhibits or blocks the adhesive function of the integrin; Non-RGD 
indicates that the antibody does not inhibit adhesion 
** Blocks adhesion via an allosteric site, i.e. does not bind directly to the RGD site 
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Figure   4.3 Cytokine Arrays for THP-1 treated with antibodies to αV integrins  
(A)  Cytokine  array  template  showing  location  of  antibodies  to  specific  cytokines  on  the 
nitrocellulose membrane. (B) Cytokine array profile of the cleared supernatant from THP-1 cells 
treated  with  controls  (Bi)  or  antibodies  to  members  of  the  αV  integrin  family  (Bii).  The  integrin 
isoform targeted in each array is indicated above the blot, while the clone name corresponding to 
the antibody used is detailed below the individual blots. Cytokines bound to the membrane were 
detected with specific biotinylated antibodies, which in turn were detected using HRP-congujated 
streptavidin and chemiluminescent based detection. (C) Densitometric analysis of cytokine array 
pattern, showing the ratio of all of the individual cytokine signal intensities to the positive control 
signal. All 36 cytokines are displayed together in the bar chart to yield a global, semi-quantitative 
representation  of  the  response  to  each  treatment.  The  response  to  IgG1  is  included  as  a 
representative  example.  All  antibody  isotypes  were  tested  (IgG1,  IgG2a,  IgG2b  and  IgG3)  and 
gave responses equivalent to IgG1.   
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Figure   4.4 Cytokine Arrays for THP-1 treated with antibodies to β2 integrins 
(A)  Cytokine  array  template  showing  location  of  antibodies  to  specific  cytokines  on  the 
nitrocellulose membrane. (B) Cytokine array profile of the cleared supernatant from THP-1 cells 
treated  with  controls  (Bi)  or  antibodies  to  members  of  the  β2  integrin  family  (Bii).  The  integrin 
isoform targeted in each array is indicated above the blot, while the clone name corresponding to 
the antibody used is detailed below the individual blots. Cytokines bound to the membrane were 
detected with specific biotinylated antibodies, which in turn were detected using HRP-congujated 
streptavidin and chemiluminescent based detection. (C) Densitometric analysis of cytokine array 
pattern, showing the ratio of all of the individual cytokine signal intensities to the positive control 
signal. All 36 cytokines are displayed together in the bar chart to yield a global semi-quantitative 
representation  of  the  response  to  each  treatment.  The  response  to  IgG1  is  included  as  a 
representative  example.  All  antibody  isotypes  were  tested  (IgG1,  IgG2a,  IgG2b  and  IgG3)  and 
gave responses equivalent to IgG1.   
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4.2.3   Quantitative analysis of the cytokine output in 
response to integrin binding 
ELISAs  were  used  to  detect  the  presence  of  MIP 1β,  IL 8  and  RANTES  in  the 
supernatant of THP 1 cells treated with antibodies against integrins (Table 4 1). 
The  ELISAs  were  validated  for  our  purpose  using  positive  and  negative 
stimulations in a dose response experiment (Figure 4 5). The response of THP 1 
cells  to  treatment  with  an  isotype  control  (IgG1),  RGDS  and  vitronectin  was 
tested. The positive control selected was the 23C6 antibody specific for αVβ3 
that gave a large signal in the global cytokine array. A dose dependent increase 
in cytokine production was observed for 23C6 (anti αV antibody) but not for any 
of  the  other  stimulations.  The  THP 1  cultures  did  not  produce  a  significant 
amount  of  IL 8  and  MIP 1β  in  response  to  treatment  with  IgG1  or  the  RGDS 
peptide or the ECM protein, vitronectin, even at the highest concentrations of 
5 g/mL.  A  high  constitutive  level  of  RANTES  production,  as  detected  in  the 
cytokine  arrays,  was  observed  with  untreated  THP 1  cells  and  was  slightly 
enhanced by stimulation of THP 1 cells with anti αVβ3 antibody but not with any 
of the other treatments (Figure 4 5). 
We used these ELISAs to evaluate the role of different integrin families, subunits 
and epitopes in cytokine production using specifically selected antibodies. Figure 
4 6 shows the production of IL 8, MIP 1β and RANTES by the model monocytic 
cell line THP 1 after stimulation with antibodies against individual integrins. The 
data are displayed as stimulation index, which represents the fold elevation of 
cytokine  production  over  the  untreated  cells  (accounting  for  any  constitutive 
expression).  A  fold  stimulation  value  below  1  indicates  a  decrease  in  the 
cytokine output in response to a specific stimulus compared to the untreated 
control,  while  a  fold  stimulation  value  above  1  indicates  an  increase  in  the 
cytokine output in response to a specific stimulus compared to the untreated 
cells. THP 1 cells constitutively produced RANTES, but not IL 8 or MIP 1β. The 
concentration ranges for cytokines produced in response to stimulations were as 
follows:  RANTES  1  000 10  000  pg/mL;  IL 8  100 1  000pg/mL  and  MIP 1β  200 2 
000pg/mL.  
Figure 4 6 shows the production of IL 8 (A), MIP 1β (B) and RANTES (C) by THP 1 
cell cultures in response to stimulation with anti integrin antibodies (Table 4 1).  
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The responses of THP 1 cells to antibodies against the αV integrin family are 
shown in the left hand panel (labelled Ai, Bi and Ci) and those to antibodies 
against the β2 family are shown on the left hand panel (labelled Aii, Bii, and 
Cii). No stimulation of cytokine production was observed with any of the control 
treatments  for  THP 1.  IgG1,  RGDS  peptide  and  vitronectin  failed  to  induce 
cytokine production and therefore have a fold stimulation equal to or below 1.  
Figure 4 6Ai shows the production of IL 8 by THP 1 cells induced by antibodies 
directed against members of the αV integrin family. Treatment of THP 1 cells 
with antibodies AMF7 and LM142, which are directed against the common αV 
subunit, produced a statistically significant increase in the production of IL 8 
production. Both treatments induced a similar fold stimulation of ~8 fold and 
~11 fold for AMF7 and LM142, respectively. For the αVβ3 and αVβ5 integrins, 
only one of the pairs of antibodies induced a significant response from the THP 1 
cells.  For  the  αVβ3  integrin,  a  fold  stimulation  of  ~9 fold  was  obtained  for 
treatment with the 23C6 antibody, whereas the LM609 clone did not produce a 
statistically significant increase in IL 8 production by THP 1 cells. For the αVβ5 
heterodimer,  the  P1F6  antibody  induced  an  equivalent  ~9 fold  increase  over 
baseline  IL 8  levels,  while  the  15F11  antibody,  whilst  still  producing  a 
statistically significant increase in IL 8 secretion, induced a much lower response 
(~3 fold stimulation).  
Figure 4 6Aii shows the IL 8 responses of THP 1 cells following stimulation with 
antibodies against members of the β2 family of integrins. THP 1 cells did not 
show any increase in IL 8 concentration over baseline in response to antibodies 
directed  against  the  common  β2  subunit.  Neither  the  P4H9  nor  the  MEM48 
antibody  induced  any  production  of  IL 8.  An  increase  in  the  levels  of  IL 8 
produced  was  observed  for  treatment  of  the  THP 1  cells  with  the  Clone44 
antibody (directed against αMβ2) and the Clone 3.9 antibody (directed against 
αXβ2). The fold stimulations were ~7 fold and ~22 fold, respectively. The other 
antibody  directed  against  αMβ2  (ICO GM1)  did  not  induce  a  statistically 
significant increase in IL 8 production.   
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Figure 4 6B shows the data for the production of MIP 1β by THP 1 cells under 
exactly the same set of conditions. A striking similarity is observed for the fold 
stimulation pattern of THP 1 cells in response to αV and β2 antibodies for the 
production of IL 8 and MIP 1β (compare Figures 4 6A and B). Exactly the same 
trend in stimulation is observed for IL 8 and MIP 1β production by stimulated 
THP 1 cells. A  large increase in MIP 1β production was observed when THP 1 
cells were treated with AMF7, LM142, 23C6 and P1F6 antibodies (~5 fold, ~9 
fold, ~6 fold and ~7 fold, respectively). THP 1 cells also significantly increased 
production of MIP 1β in response to Clone44 (~10 fold), and Clone3.9 (~28 fold). 
In  this  case,  the  response  to  ICO GMI  was  determined  to  be  statistically 
significant,  although  it  was  much  lower  than  that  observed  for  Clone44  or 
Clone3.9 treatment. Again, treatment of THP 1 cells with antibodies against β2 
integrins  resulted  in  a  greater  response,  although  the  range  of  response  was 
more limited than that observed with the αV antibodies.  
Figure  4 6C  shows  the  production  of  RANTES  by  THP 1  cells  in  response  to 
integrin binding. No statistically significant increase in cytokine production was 
seen with any of the controls for THP 1 cells. THP 1 cells were shown previously 
to produce RANTES constitutively. There was no significant stimulation over this 
background level in response to stimulation with any of the negative controls  
IgG1,  RGDS  or  vitronectin.  Treatment  with  the  anti αV  antibodies,  AMF7  and 
LM142,  and  the  anti αVβ3  antibody,  23C6,  produced  small  yet  significant 
increases in RANTES production. Treatment with the anti αXβ2 integrin antibody 
Clone3.9 induced a small but significant increase in RANTES production. Analysis 
of RANTES production was complicated by the high constitutive production by 
THP 1 cells. 
Overall, treatment of THP 1 cells with anti αXβ2 antibody Clone3.9 lead to the 
greatest  increase  in  IL 8  and  MIP 1β  production  (~22 fold  and  ~28 fold 
respectively),  although  the  cells  responded  to  a  greater  range  of  antibodies 
directed against the αV family of integrins than the β2 family of integrins. The 
THP 1 cells failed to produce IL 8 or MIP 1β in response to binding the common 
β2 chain of the β2 family of integrins, but ligation of the common αV subunit 
stimulates cytokine release to a level similar that noted following binding of 
antibodies to the heterodimers αVβ3 or αVβ5.   
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Figure 4 7 shows the data for the production of IL 8, MIP 1β and RANTES by U937 
cells treated in the same manner as the THP 1 cell experiments. U937 cells did 
not  show  a  statistically  significant  increase  in  IL 8  levels  in  response  to 
treatment  with  any  of  the  anti αV  antibodies.  A  modest  increase  in  IL 8 
production of approximately 2 fold was observed after treatment with the αXβ2 
antibody, Clone3.9. Treatment of U937 cells with the LM142 and 23C6 antibodies 
resulted  in  statistically  significant  increases  in  MIP 1β  (2 fold  and  4 fold 
respectively).  U937  cells  did  not  show  a  significant  increase  in  RANTES 
production in response to treatment with antibodies against αV or β2 integrins.  
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Figure    4.5  Cytokine  production  by  THP-1  cells  is  not  induced  by  binding 
controls 
THP-1 cells were treated overnight as indicated below and the presence of RANTES (A), MIP-1β 
(B)  and  IL-8  (C)  in  the  cleared  supernatant  determined  by  ELISA.  Untreated  cells:black  bars; 
Vitronectin:white bars; RGDS:light grey bars; IgG1:dark grey bars; diagonal-striped bars:anti-αVβ3 
23C6 Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of 
at least 3 separate experiments. The error bars indicate standard deviations (SD). The response to 
IgG1 is included as a representative example. All  antibody isotypes  were tested (IgG1, IgG2a, 
IgG2b and IgG3) and gave responses equivalent to IgG1.   
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Figure    4.6  Cytokine  production  by  THP-1  cells  in  response  to  integrin 
ligation 
Supernatants  from  THP-1  cells  stimulated  with  anti-αV  antibodies  (Ai,  Bi  and  Ci)  or  anti-β2 
antibodies (Aii, Bii and Cii) were tested for the presence of IL-8 (Ai and Aii; white bars), MIP-1β (Bi 
and Bii; grey bars) and RANTES (Ci and Cii; black bars) using ELISA. Fold-stimulation represents 
the ratio of the cytokine concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells.  Unt:Untreated cells; 
IgG1:Isotype  control;  RGDS:  RGDS  peptide;  VN:vitronectin;  AMF7:anti-αV;  LM142:anti-αV; 
23C6:anti-αVβ3;  LM609:  anti-αVβ3;  15F11:anti-αVβ5;  P1F6:anti-αVβ5;  P4H9:anti-β2;  MEM48: 
anti-β2;  Clone44:anti-αMβ2;  ICO-GM1:anti-αMβ2;  Clone3.9:anti-αXβ2.  Statistical  analysis  was 
performed  using  Student’s  t-test  *p<0.05.  Data  are  representative  of  at  least  3  separate 
experiments. The response to IgG1 is included as a representative example. All antibody isotypes 
were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
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Figure   4.7 Cytokine production by U937 cells in response to integrin binding 
Supernatants from U937 cells stimulated overnight with anti-αV antibodies (Ai, Bi and Ci) or anti-β2 
antibodies (Aii, Bii and Cii) were tested for the presence of IL-8 (Ai and Aii; white bars), MIP-1β (Bi 
and Bii; grey bars) and RANTES (Ci and Cii; black bars) using ELISA. Fold-stimulation represents 
the ratio of the cytokine concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells.  Unt:Untreated cells; 
IgG1:Isotype  control;  RGDS:  RGDS  peptide;  VN:vitronectin;  AMF7:anti-αV;  LM142:anti-αV; 
23C6:anti-αVβ3;  LM609:  anti-αVβ3;  15F11:anti-αVβ5;  P1F6:anti-αVβ5;  P4H9:anti-β2;  MEM48: 
anti-β2;  Clone44:anti-αMβ2;  ICO-GM1:anti-αMβ2;  Clone3.9:anti-αXβ2.  Statistical  analysis  was 
performed  using  Student’s  t-test  *p<0.05.  Data  are  representative  of  at  least  3  separate 
experiments. The response to IgG1 is included as a representative example. All antibody isotypes 
were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
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4.2.4   Effect of integrin expression levels on cytokine 
production by THP-1 and U937 cells 
THP 1 and U937 cells were tested for their cytokine responses to stimulation by 
CD23 binding integrins (Figures 4 6 and 4 7). Stimulation of different integrins 
induced distinct patterns of production of IL 8, RANTES and MIP 1β by the two 
cell lines. To establish whether this was due to the levels of these integrins on 
the cell lines we examined the integrin expression levels on THP 1 and U937 
cells and related this to the levels of cytokines produced in response to binding a 
specific heterodimer (Figure 4 9).  
Figure 4 9A shows the expression of the four CD23 binding integrin heterodimers 
on the surface of U937 (Figure 4 9Ai) and THP 1 cell lines (Figure 4 9Aii). THP 1 
and U937 cells express similar levels of these integrin heterodimers. There was 
no significant difference between the different cell lines. Within an individual 
cell  line,  the  most  highly  expressed  integins  were  the  αVβ3,  αVβ5  and  αXβ2 
heterodimers, with only low levels of αMβ2 integrin expressed. However, the 
cytokine production in response to stimulation of a particular heterodimer was 
markedly  different  between  the  cell  lines  (despite  the  equivalent  integrin 
expression levels). 
Figure  4 9B  shows  the  relationship  between  the  relative  expression  of  the 
different  integrins  on  THP 1  cells  (Figure  4 9Bi)  and  the  levels  of  cytokines 
produced by stimulating them (Figure 4 9Bii). Of the β2 integrins, the β2 subunit 
is  expressed  to  the  highest  level  on  the  surface  of  THP 1  cells  (black  line), 
followed by the αXβ2 isoform (blue line) and then the αMβ2 heterodimer (red 
line). The hierarchy of cytokine production indicated that stimulation of cells 
with anti αXβ2 antibodies (Clone3.9, blue arrow) resulted in the highest level of 
MIP 1β  release.  Stimulation  of  the  cells  with  anti αMβ2  (Clone44,  red  arrow) 
induced a moderate level of MIP 1β production, while binding of the β2 subunit 
did not result in the production of detectable levels of MIP 1β (black arrows). 
Integrin  expression  level  alone  in  this  case  was  unlikely  to  be  the  major 
determinant  of  concentrations  of  cytokines  produced  in  response  to  integrin 
stimulation, either between cell lines or within different integrin isoforms on the 
same cell line.  
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Figure   4.8 Integrin expression level alone does not determine cytokine output 
(A) Expression levels of integrins on U937 (Ai) and THP-1 cells (Aii) was determined by flow cytometry. (B)  Expression levels of different isoforms of β2 integrins on THP-1 
cells was determined by flow cytometry. Integrin staining is shown as a solid black line and isotype staining is shown as grey shading (Bi) and the corresponding levels of 
MIP-1β production by binding those isoforms was determined by ELISA (Bii). Red line/arrow:αMβ2; Blue line/arrow:αXβ2; Black line/arrow:β2.Data are representative of at 
least 3 separate experiments. The error bars indicate standard deviations (SD).  
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4.2.5   Cytokine response after differentiation of THP-1 cells  
A difference in cytokine production in response to the same stimulus was observed 
between  the  two  cell  lines  THP 1  and  U937.  These  two  cell  lines  represent 
monocytic cell lines at different maturation stages. U937 is more similar to an early 
blood monocyte 
166, whereas the THP 1 cell line is more monocyte/macrophage in 
nature 
165. To investigate further the role of cell differentiation state on integrin 
mediated cytokine production, we treated THP 1 cells with differentiating agents 
and compared the cytokine response to antibody mediated stimulation of specific 
integrins.  
THP 1 cells were treated for 3 days with macrophage colony stimulating factor (M 
CSF/CSF 1),  granulocyte/macrophage  colony  stimulating  factor  (GM CSF)  and 
dibutryl cyclic  adenosine  monophosphate  (db cAMP).  The  cells  were  washed  and 
integrin  expression  and  cytokine  production  in  response  to  integrin  binding 
determined (Figures 4 9, 4 10 and 4 11, respectively). Expression of integrins was 
determined by flow cytometry. The integrin staining observed for untreated cells is 
shown in grey shading and the equivalent staining for M CSF, GM CSF or db cAMP 
differentiated  cells  is  shown  as  a  black  line.  The  cytokine  production  was 
determined  by  ELISA  and  is  represented  as  fold stimulation.  This  represents  the 
ratio  of  the  cytokine  (RANTES,  IL 8  or  MIP 1β)  concentration  produced  by  the 
integrin stimulated sample after treatment with the differentiating agent relative 
to the integrin stimulated untreated cells.  
Figure 4 9 shows the comparison of the integrin expression levels (Figure 4 9A) and 
cytokine production level (Figure 4 9B) from untreated and M CSF treated THP 1 
cells. THP 1 cells that were treated with 10ng/mL M CSF for 3 days did not show 
any appreciable change in the expression levels of the αVβ3, αVβ5, αMβ2 or αXβ2 
integrins  (Figure  4 9A).  A  slight,  non specific  increase  was  observed  for  RANTES 
production by untreated cells and  in response to all stimulations. There  was no 
increase in the IL 8 levels in response to any of the stimulations.  An increase in the 
fold stimulation  for  the  production  of  MIP 1β  was  observed  in  response  to 
stimulation with the anti αMβ2 antibody, but not with any of the other stimulations.   
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Figure 4 10 shows the effect of treatment of THP 1 cells with 1ng/mL GM CSF for 3 
days.  Treatment  of  THP 1  cells  with  GM CSF  did  not  considerably  alter  the 
expression of any of the CD23 binding integrins compared to the untreated cells 
(Figure 4 10A). There was no substantiated increase in the production of RANTES, 
IL 8 or MIP 1β for any of the stimulations tested (Figure 4 10B). 
Figure 4 11 shows the expression levels and cytokine production characteristics of 
THP 1 cells that had been treated with db cAMP for 3 days prior to stimulation.  An 
increase in the expression levels of the αXβ2 integrin upon treatment with db cAMP 
was  noted,  while  there was no change in expression  of αVβ3,  αVβ5  or  αMβ2.  A 
general reduction in the secretion of RANTES was observed for untreated cells and 
in response to all stimulations. There was an increase in the fold stimulation for   
IL 8 and MIP 1β production in response to αVβ5 binding, but not for stimulation with 
any other integrin directed antibody.   
Differentiation of THP 1 cells with db cAMP led to changes in expression levels of 
specific  integrin  heterodimers.  This  change  in  expression,  however,  did  not 
necessarily correlate with the  levels  of  cytokines  produced  as a  consequence  of 
integrin  stimulation.  For  example,  treatment  of  THP 1  cells  with  M CSF  did  not 
influence the expression levels of integrins compared to untreated THP 1 cells, but 
led to an increase in the production of IL 8 in response to 23C6 treatment. Although 
the expression levels of αVβ5 did not change, treatment of the THP 1 cell line with 
db cAMP led to an increase  in the production  of IL 8 and  MIP 1β in  response  to 
stimulation  with  the  anti αVβ5  antibody.  The  cell  line  U937  had  similar  surface 
expression  of  integrins  to  the  THP 1  line,  but  responded  differently  to  integrin 
stimulation (i.e. did not produce cytokines).  
Integrins play an important role in modulating the effects of other surface receptors 
and so we analysed the expression of other surface receptors after treatment of 
THP 1  cells  with  M CSF,  GM CSF  or  db cAMP.  We  hypothesised  that  cytokine 
production involved an additional receptor (apart from the integrin) and that the 
levels of this receptor may explain the discrepancies between expression level and 
cytokine  production.  The  Fcγ  receptors  are  immunoreceptors  that  recognise  the 
constant  region  of  immunoglobulins  and  have  an  important  role  in  cytokine  
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production by monocytes. We also assessed the levels of CD47 (integrin associated 
protein). CD47 is part of the αVβ3 signalling complex and therefore its expression 
levels might influence cytokine production.  
Figure 4 12 shows the expression of the Fcγ receptors, CD16, CD32, CD64 and the 
integrin associated protein CD47, on U937 cells and on THP 1 cells before and after 
treatment with M CSF, GM CSF or db cAMP.  There was no change in the expression 
of CD16, CD32, CD64 or CD47 by THP 1 cells that had been treated with M CSF 
(Figure 4 12B), GM CSF (Figure 4 12C) or db cAMP (Figure 4 12D) compared with 
untreated  THP 1  cells  (Figure  4 12A).  There  was,  however,  a  difference  in  the 
expression levels of the Fcγ receptors on the U937 cell line compared with the THP 
1 cell line. U937 cells did not express CD16 or CD32 and only expressed low levels of 
CD64 and CD47, compared with the THP 1 cells. We also tested the primary blood 
monocytes for the expression of these receptors. The cells stained positive for all 4 
receptors, although at lower levels than found on THP 1 cells.   
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Figure    4.9  Integrin  expression  and  cytokine  profile  of  THP-1  cells  after 
differentiation with M-CSF 
THP-1  cells  were  cultured  with  or  without  10ng/mL  M-CSF  for  3  days  before  analysis  of  integrin 
expression and cytokine production. (A) Untreated cells (grey shading) and M-CSF treated cells (black 
line)  were  stained  for  integrin  expression  by  flow  cytometry.  (B)  The  cytokine  production  was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed  using  Students  t-test.  Data  are  representative  of  at  least  3  separate  experiments.  The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
132 
   
Figure    4.10  Integrin  expression  and  cytokine  profile  of  THP-1  cells  after 
differentiation with GM-CSF 
THP-1  cells  were  cultured  with  or  without  1ng/mL  GM-CSF  for  3  days  before  analysis  of  integrin 
expression  and  cytokine  production.  (A)  Untreated  cells  (grey  shading)  and  GM-CSF  treated  cells 
(black line) were stained for integrin expression by flow cytometry. (B) The cytokine production was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed  using  Students  t-test.  Data  are  representative  of  at  least  3  separate  experiments.  The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
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Figure    4.11  Integrin  expression  and  cytokine  profile  of  THP-1  cells  after 
differentiation with dibutryl-cyclic AMP (db-cAMP) 
THP-1  cells  were  cultured  with  or  without  100mM  db-cAMP  for  3  days  before  analysis  of  integrin 
expression  and  cytokine  production.  (A)  Untreated  cells  (grey  shading)  and  db-cAMP  treated  cells 
(black line) were stained for integrin expression by flow cytometry. (B) The cytokine production was 
determined by ELISA and is represented as fold stimulation. This represents the ratio of the cytokine 
(RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated sample after treatment 
with the differentiating agent relative to the integrin-stimulated untreated cells. Statistical analysis was 
performed  using  Students  t-test.  Data  are  representative  of  at  least  3  separate  experiments.  The 
response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
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Figure   4.12 Expression of integrin associated receptors on monocytic cells 
THP-1  cells  (with  or  without  treatment  with  differentiating  agents),  U937  and  CD14
+PBMC  were 
assessed for their expression of Fcγ receptors (CD16, CD32 and CD64) and CD47 (integrin associated 
protein) by flow cytometry. Isotype control staining is shown as grey shading and antibody staining is 
shown  as  a  solid  black  line.  The  identity  of  the  protein  detected  is  indicated  above  the  individual 
histograms. A: THP-1 cells in OptiMEM, B: THP-1 cells in OptiMEM with M-CSF, C: THP-1 cells in 
OptiMEM with GM-CSF D: THP-1 cells in OptiMEM with db-cAMP, E: U937 in OptiMEM, F: CD14
+ 
blood monocytes.  
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4.2.6   Cooperation between different integrin heterodimers 
The  data  in  Figures  4 2  to  4 11  have  shown  that  specific  integrins  can  regulate 
cytokine  production  by  monocytic  cells  when  stimulated  with  antibodies  against 
specific  integrin  isoforms,  subunits  and  epitopes.  Cross talk  amongst  different 
integrins has been reported and so we investigated the response of monocytes to 
simultaneous stimulation with antibodies against multiple integrins. The production 
of RANTES, MIP 1β and IL 8 was monitored by ELISA after overnight stimulation with 
multiple antibodies as indicated in figure legends.  
We selected the anti αVβ3 antibody 23C6 and the anti αXβ2 antibody Clone3.9 for 
these  analyses  as  they  had  induced  high  levels  of  cytokine  production  in  the 
previous experiments. We examined the ability of the two antibodies to influence 
the cytokine production of the other when supplied at a suboptimal concentration. 
Figure  4 13A  shows  the  response  of  THP 1  cells  to  incubation  with  increasing 
concentrations  of  Clone3.9  (0.2  –  1.0   g/mL)  in  the  absence  (white  bars)  or 
presence (black bars) of a fixed suboptimal concentration of 23C6 (0.4 g/mL). The 
sub optimal concentration of 23C6 was titrated in a dose response experiment. The 
concentration  of  23C6  at  which  cytokine  production  was  half  of  the  maximum 
concentration  of  cytokine  produced  by  the  cell  line,  was  selected  as  the  sub 
optimal concentration (data not shown). A dose dependent increase in the levels of 
RANTES, IL 8 and MIP 1β was observed with the increasing Clone3.9 concentration. 
Cytokine  production  was  enhanced  at  all  concentrations  by  the  addition  of 
0.4 g/mL 23C6 antibody. Figure 4 13B shows the data for the reverse situation, 
where THP 1 cells were stimulated with increasing concentrations of 23C6 antibody 
alone (white bars) or in the presence of concentration of Clone3.9 (0.4 g/mL; black 
bars) and tested for the production of RANTES, IL 8 and MIP 1β. A dose dependent 
increase in the production of all of these cytokines was observed with increasing 
23C6  concentration.  The  levels  of  RANTES,  IL 8  and  MIP 1β  produced  at  all 
concentrations of 23C6 were enhanced by the addition of suboptimal concentrations 
of Clone3.9. These data indicated that simultaneous binding of the αVβ3 and αXβ2 
integrins  enhanced  cytokine  production,  and  so  we  tested  if  any  of  the  other 
integrins could influence the levels of cytokines produced in response to 23C6 or 
Clone3.9 stimulation.   
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Figure 4 14 shows the effect of incubation of THP 1 cells with the 23C6 antibody 
(0.2 g/mL) and increasing concentrations of antibodies against other αV integrins 
(anti αV  antibodies  AMF7  and  LM142  and  anti αVβ5  antibody  P1F6).  Figure  4 15 
shows the response of THP 1 cells to stimulation with 23C6 (anti αVβ3 antibody) in 
conjunction with antibodies against members of the  β2 integrin family (anti αβ2 
antibodies  Clone44  and  ICO GMI  and  anti β2  antibody  P4H9).  The  data  are 
represented as stimulation index (SI). The stimulation index is the fold stimulation 
of cytokine production when using 23C6 and another antibody together, over the 
level of cytokine produced by treatment with 23C6 alone. There was no statistically 
significant  enhancement  or  inhibition  of  the  levels  of  RANTES,  IL 8  or  MIP 1β 
produced by THP 1 cells in response to 23C6 when co incubated with any of the 
antibodies  AMF7  (αV),  LM142  (αV)  or  P1F6  (αVβ5).  Similarly,  there  was  no 
statistically significant increase or decrease in stimulation index for the production 
of RANTES, IL 8 and MIP 1β when cells were treated with 23C6 (αVβ3) and the β2 
family  antibodies,  ICO GMI  (αMβ2),  Clone44  (αMβ2)  and  P4H9  (β2).  The  co 
stimulation of THP 1 cells with 23C6 and the anti αMβ2 antibody ICO GMI did appear 
to  cause  a  modest,  dose dependent  increase  in  the  stimulation  index  for  the 
production of IL 8, although these data were outside the confidence interval to be 
statistically significant (p=0.055 using Student’s t test).  
Figure 4 16 and Figure 4 17 show the equivalent data for the treatment of THP 1 
cells  with  Clone  3.9  (αXβ2)  and  other  antibodies  against  αV  and  β2  integrins, 
respectively.  THP 1 cells were treated with the Clone3.9 antibody (0.2 g/mL) and 
increasing  concentrations  of  antibodies  against  αV  integrins  (anti αV  antibodies 
AMF7  and  LM142  and  anti αVβ5  antibody  P1F6)  and  β2  integrins  (anti αMβ2 
antibodies  Clone44  and  ICO GMI  and  anti β2  antibody  P4H9).  The  data  are 
represented as stimulation index (SI). The stimulation index is the fold stimulation 
of  cytokine  concentration  determined  when  treating  cells  with  Clone3.9  in 
conjunction with another antibody over the concentration of cytokine produced by 
treatment with Clone3.9 alone. There was no statistically significant change in the 
stimulation index for IL 8, RANTES or MIP 1β when THP 1 cells were stimulated with 
Clone3.9 in conjunction with any of the antibodies tested (Figures 4 16 and 4 17).    
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Figure   4.13 Cytokine production in response to simultaneous ligation of αVβ3 
and αXβ2 
THP-1 cells were stimulated overnight with (A) 0.4 g/mL 23C6 (anti αVβ3 antibody) alone (white bars) 
or  with  varying  concentrations  of  Clone3.9  (anti-αXβ2  antibody)  (black  bars)  or  (B)  0.4 g/mL  of 
Clone3.9  (anti  αXβ2  antibody)  alone  (white  bars)  or  varying  concentrations  of  23C6  (anti-αVβ3 
antibody)  (black  bars).  Cleared  supernatants  were  tested  for the  presence  of  cytokines  by  ELISA. 
Statistical analysis was performed using Student’s t-test *p<0.05. Data are representative of at least 3 
separate experiments.  The error bars indicate standard deviations (SD).  
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Figure   4.14 Effect of simultaneous ligation of αVβ3 and other αV integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with 23C6 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) AMF7 (anti-αV antibody), (B) LM142 
(anti αV antibody) or (C) P1F6 (anti-αVβ5 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-test. 
Data are representative of at least 3 separate experiments   
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Figure   4.15 Effect of simultaneous ligation of αVβ3 and β2 integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with 23C6 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) ICO-GMI (anti-αXβ2 antibody), (B) 
Clone44 (anti αMβ2 antibody) or (C) P4H9 (anti-β2 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments.  
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Figure   4.16 Effect of simultaneous ligation of αXβ2 and αV integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with Clone3.9 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) AMF7 (anti-αV antibody), (B) 
LM142 (anti αV antibody) or (C) P1F6 (anti-αVβ5 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments.  
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Figure   4.17 Effect of simultaneous ligation of αXβ2 and other β2 integrins on cytokine production by THP-1 cells 
THP-1 cells were incubated overnight with Clone3.9 (0.2µg/mL) alone or in conjunction with increasing concentrations of (A) ICO-GMI (anti-αXβ2 antibody), (B) 
Clone44 (anti αMβ2 antibody) or (C) P4H9 (anti-β2 antibody). Cytokine production was analysed by ELISA. Statistical analysis was performed using Student’s t-
test. Data are representative of at least 3 separate experiments.  
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4.2.7   Effect of serum on cytokine production by integrin 
stimulation 
All of the integrin stimulation experiments described thus far have been conducted 
in serum free, OptiMEM medium. Given the role of integrins in cell adhesion and 
the presence of adhesive integrin ligands (such as vitronectin) in serum, we tested 
the effect of serum on cytokine production by 23C6 (αVβ3) and Clone3.9 (αXβ2).  
Figure 4 18 shows the production of RANTES, IL 8, MIP 1β and VEGF by THP 1 cells 
stimulated with increasing concentrations of 23C6 in OptiMEM alone (white bars) or 
OptiMEM  supplemented  with  5%  serum  (white  bars).  Serum  does  not  negatively 
affect cytokine production by THP 1 cells in response to 23C6 treatment. In most 
cases, except for the production of RANTES, serum has a positive effect on cytokine 
production, leading to a slight but statistically significant increase in the levels of 
IL 8, MIP 1β and VEGF.  
Figure 4 19 shows the corresponding data for the stimulation of THP 1 cells with 
increasing concentrations of Clone3.9 in OptiMEM alone (white bars) or OptiMEM 
supplemented  with  FCS (grey  bars).  The  presence of  serum  does  not inhibit the 
production of RANTES, IL 8, MIP 1β and VEGF by THP 1 cells in response to Clone3.9 
stimulation.  In the case  of  MIP 1β  and  VEGF, inclusion of  serum in the reaction 
leads  to  a  statistically  significant  increase  in  concentration  in  response  to 
stimulation by Clone3.9. 
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Figure   4.18 Effect of serum on αVβ3 induced cytokine production 
THP-1 cells were stimulated with increasing concentrations of 23C6 (anti-αVβ3 antibody) in the presence (grey bars) and absence (white bars) of 5% FCS and 
cytokine production detected by  ELISA.  Statistical analysis  was performed using  Student’s t-test *p<0.05. Data  are representative of at  least 3 separate 
experiments. The error bars indicate standard deviations (SD).  
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Figure   4.19 Effect of serum on αXβ2 induced cytokine production 
THP-1 cells were stimulated with increasing concentrations of Clone3.9 (anti-αXβ2 antibody) in the presence (grey bars) and absence (white bars) of FCS and 
cytokine production detected by  ELISA.  Statistical analysis  was performed using  Student’s t-test *p<0.05. Data  are representative of at  least 3 separate 
experiments. The error bars indicate standard deviations (SD).  
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4.2.8   Analysis of the responses to integrin stimulation in 
primary human monocytes 
The THP 1 and U937 cells are cell lines derived from patients with leukaemia 
165, 166. 
The changes associated with these diseases may influence the cytokine responses of 
the cells. To confirm that integrin stimulation results in cytokine production under 
non diseased, physiological conditions, we tested the responses of primary human 
CD14
+  monocytes  and  human  primary  bone  marrow  monocytes.  Primary  CD14
+ 
human  monocytes  from  peripheral  blood  (CD14
+PBMC)  and  bone  marrow derived 
monocytes  (BMDM)  were  cultured  in  RPMI 1640  medium  supplemented  with  1% 
serum  and  10ng/mL  M CSF  for  3  days  before  staining  for  surface  expression  of 
integrins and determination of integrin induced cytokine production.  
Figure 4 20 shows the expression of CD23 binding integrins on primary BMDM and 
CD14
+PBMC as determined by flow cytometry. The BMDM and the CD14
+PBMC both 
expressed the αVβ3, αMβ2 and αXβ2 integrins, while CD14
+PBMC also expressed the 
αVβ5 integrin. 
Figures 4 21 and 4 22 show the responses of primary human BMDM and CD14
+PBMC 
to  integrin  stimulation.  The  primary  cells  were  stimulated  under  the  same 
conditions  used  for  stimulation  of  THP 1  cells  and  cytokines  released  into  the 
supernatant  quantified  by  ELISA.  The  cytokine  production  is  shown  as  fold 
stimulation over the untreated sample, where a fold stimulation of 1 indicates that 
there  was  no  cytokine  produced  over  constitutive  levels  (BMDM  and  CD14
+PBMC 
constitutively produced high levels of IL 8).   
Integrin stimulation had no effect on the levels of RANTES and IL 8 produced by 
CD14
+PBMC. There was a statistically significant increase in the TNF α production 
by CD14
+PBMC in response to stimulation with Zymosan and with antibodies against 
the β2 heterodimers, αMβ2 (Clone44) and αXβ2 (Clone3.9). The CD14
+PBMC did not 
produce TNF α in response to stimulation with an antibody against the common β2 
chain  (P4H9).  There was  no  TNF α  response  observed  for  CD14
+PBMC  stimulated 
with any of the anti αV antibodies.    
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The BMDM showed a similar IL 8 profile to the CD14
+PBMC; there was no effect on 
IL 8 levels by any of the integrin treatments. A statistically significant increase in 
the levels of RANTES, MIP 1β and TNF α was observed for BMDM treated with the 
anti αVβ3 antibody (23C6) and the anti αXβ2 antibody (Clone3.9). αMβ2 stimulation 
with  the  ICO GMI  antibody  also  led  to  a  statistically  significant  increase  in  the 
production of MIP 1β. The BMDM were the most similar to the THP 1 cell line in 
their cytokine responses to integrin stimulation.   
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Figure   4.20 Expression of integrins on primary human bone marrow and CD14+ 
blood monocytes 
Primary human monocytes from bone marrow (A) or peripheral blood (B) were incubated with anti-
integrin  antibodies  on  ice  and  binding  of  these  primary  antibodies  was  detected  by  binding  of  a 
secondary antibody conjugated to PE. The integrin heterodimer targeted is indicated in the top right 
corner of the plot. Isotype control is shown as grey shading and the antibody binding is shown as a 
black line.  
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Figure   4.21 Production of cytokines by primary human bone monocytes in response to integrin stimulation  
Primary human bone marrow monocytes were stimulated overnight with antibodies against integrins. The cytokine production was detected by ELISA and is 
represented as fold stimulation. This represents the ratio of the cytokine (TNF-α, RANTES, IL-8 and MIP-1β) concentration produced by the integrin-stimulated 
sample relative to the unstimulated/untreated cells. IgG1:Isotype control; RGDS:RGDS peptide; VN:vitronectin; AMF7:anti-αV; LM142:anti-αV; 23C6:anti-αVβ3; 
LM609:anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48:anti-β2; Clone44:anti-αMβ2; ICO-GM1:anti-αMβ2; Clone3.9:anti-αXβ2. Statistical 
analysis was performed using Student’s t-test *p<0.05. The response to IgG1 is included as a representative example. All antibody isotypes were tested (IgG1, 
IgG2a, IgG2b and IgG3) and gave responses equivalent to IgG1.   
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Figure   4.22 Cytokine production by primary CD14+ blood monocytes 
Primary  human  CD14
+  peripheral  blood  monocytes  were  stimulated  overnight  with  antibodies 
against  integrins.  The  cytokine  production  was  detected  by  ELISA  and  is  represented  as  fold 
stimulation.  This  represents  the  ratio  of  the  cytokine  (TNF-α,  IL-8  and  MIP-1β)  concentration 
produced  by  the  integrin-stimulated  sample  relative  to  the  unstimulated/untreated  cells. 
IgG1:Isotype  control;  RGDS:RGDS  peptide;  VN:vitronectin;  AMF7:anti-αV;  LM142:anti-αV; 
23C6:anti-αVβ3; LM609:anti-αVβ3; 15F11:anti-αVβ5; P1F6:anti-αVβ5; P4H9:anti-β2; MEM48:anti-
β2;  Clone44:anti-αMβ2;  ICO-GM1:anti-αMβ2;  Clone3.9:anti-αXβ2.  Statistical  analysis  was 
performed using Student’s t-test *p<0.05. The response to IgG1 is included as a representative 
example. All antibody isotypes were tested (IgG1, IgG2a, IgG2b and IgG3) and gave responses 
equivalent to IgG1.   
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4.3 Discussion 
CD23 induces cytokine production by monocytic cells through an interaction with 
integrins 
40,  41,  84. There are four integrins which bind CD23, two from the αV 
family, namely αVβ3 and αVβ5, and two from the β2 family, namely αMβ2 and 
αXβ2.  We  have  investigated  the  individual  contribution  of  these  integrins  to 
cytokine  production  by  monocytes,  using  antibodies  directed  against  these 
integrins. This approach has been used to a limited extent by some laboratories 
to investigate the role of the β2 integrins 
41,  84, but has not been previously 
performed for the role of CD23 binding αV integrins.  
Antibodies were selected to investigate the role of the different integrin families 
(e.g. αV vs β2 integrins); to analyse the role of different heterodimer isoforms 
(e.g. αV vs αVβ3 vs αVβ5); and to investigate the role of specific epitopes within 
a  particular  isoform  (e.g.  different  antibody  clones  against  the  same 
integrin/subunit) (Table 4 1). We used two monocytic cell lines to address the 
role of cell differentiation state on cytokine production.  
The preliminary analysis was conducted using a global cytokine array technique. 
This  allowed  the  detection of  36  different  cytokines  in  one  supernatant in  a 
simultaneous assay. We selected the particular cytokine array based on previous 
investigations into the types of cytokines produced by monocytes in response to 
CD23.  Although  this  technique  was  qualitative,  it  was  possible  to  use 
densitometry  to  produce  standardised  data  that  allowed  comparison  of  the 
responses  of  different  stimulating  antibodies.  Visual  observation  alone  of  the 
arrays could be misleading due to exposure differences between individual blots, 
which influenced signal intensity. The positive control signals on each blot are 
independent of integrin treatment and therefore were used to standardise the 
signal intensity between blots.  
At the outset of the analysis, we were uncertain whether each treatment would 
result in a very different cytokine profile. We therefore used the cytokine arrays 
to perform the preliminary qualitative analysis and assess the production of a 
wide  range  of  cytokines,  from  which  we  could  subsequently  select  specific 
cytokines for quantitative analysis. Analysis of the cytokine array profiles from 
THP 1 cells treated with antibodies against CD23 binding integrins indicated that  
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the  cytokine  profile  produced  did  not  differ  significantly  between  different 
integrin  families  or  isoforms.  We  did  not  find  that  one  family  regulated  a 
particular  group  or  groups  of  cytokines,  as  we  may  have  hypothesised.  Our 
analyses  suggested  that,  although  the  cytokine  profile  may  be  similar,  the 
concentration of cytokines produced was influenced by integrin family, integrin 
isoform and integrin epitope targeted.  
We  selected  three  chemokines  RANTES,  IL 8  and  MIP 1β  for  the  quantitative 
analysis. These chemokines were selected on the basis of the qualitative arrays 
and also because they have similar roles in the biology of the immune system. 
They are all chemotactic cytokines involved in the recruitment and activation of 
immune cells to the site of infection and, in the case of RANTES and MIP 1β, 
they share a common receptor (CCR5). We attempted to define a hierarchy of 
importance for the CD23 binding integrins in the production of these cytokines 
by monocytic cells.  
Using the quantitative ELISAs, we determined that cytokine production by THP 1 
cells in response to integrin binding results in the production of physiologically 
relevant levels of cytokines. The concentrations of cytokines detected in our 
analyses  were  similar  to  the  concentrations  observed  in  human  serum  in 
physiological  and  pathological  conditions  (Table  6 2).  The  interaction  was 
specific and influenced by the integrin family, the subunit composition of the 
heterodimer and by the epitope bound on the heterodimer. It was not simply 
sufficient  to  have  a  high  level  of  expression  of  a  particular  heterodimer  to 
induce cytokine production; a precise signal was required.  
4.3.1   Role of integrin family on cytokine production 
Both  CD23 binding  members  of  the  αV  and  β2  family  of  integrins  induced 
cytokine synthesis by THP 1 cells. Cytokine production in response to binding of 
αVβ3, αMβ2 and αXβ2 have been published previously by other groups 
40, 74. Our 
group has recently identified the αVβ5 integrin as a new receptor for CD23 
75. 
This  thesis  is  the  first  to  identify  cytokine  production  by  monocytic  cells  in 
response to stimulation with antibodies against the αVβ5 integrin. Stimulation of 
THP 1 cells with an antibody against αVβ5 (P1F6) induced synthesis of RANTES, 
IL 8 and MIP 1β.   
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Using  antibodies  against  different  isoforms  within  the  αV and  β2  families  we 
investigated the role of individual heterodimer isoforms in cytokine production. 
Within  the  αV  family  of  integrins,  both  antibodies  selected  against  the  αV 
subunit (AMF7 and LM142) were able to induce synthesis of RANTES, IL 8 and 
MIP 1β. Antibodies 23C6 and P1F6 directed against αVβ3 and αVβ5, respectively, 
were able to induce cytokine synthesis. Similarly, antibodies against the αMβ2 
and  αXβ2  integrins  induced  cytokine  production  (antibodies  Clone44  and 
Clone3.9,  respectively).  However,  stimulation  of  THP 1  cells  with  antibodies 
against the common β2 subunit using antibodies MEM48 or P4H9 failed to induce 
synthesis of cytokines. Taken together, these data suggest that the important 
determinant of integrin mediated cytokine production could be the integrin α 
subunit.  All  of  the  stimulations  involving  the  α  subunit  of  the  heterodimer 
resulted  in  cytokine  production,  even  if  only  the  α  subunit  (i.e.  not  the 
heterodimer)  was  targeted.  Ligation  of  the  α  subunit  alone  was  sufficient  to 
induce cytokine production, while the β subunit alone was not. The binding site 
for CD23 on integrins remains to be identified, although a number of groups have 
suggested  that  the  binding  site  for  CD23  on  integrins  and  thus  the  site 
responsible for inducing cytokine production, is located on the α chains of the 
integrins 
40, 83. This may be important in regulating the signalling pathways that 
arise from integrin ligation, as both the α and β subunits contact cytoplasmic 
signalling  molecules  and  are  capable  of  inducing  signalling  cascades  in  the 
cytoplasm. In the case of αVβ3, the phosphorylation of the β3 tail relies on the 
presence of the αV subunit 
187.  
It  was  interesting  to find  two  distinct  families  of  integrins  (αV and  β2)  both 
influencing cytokine production by monocytic cells. The production of cytokines 
is specific and therefore it is possible that these different families of integrin 
regulate  cytokine  production  under  different  conditions  or  environments.  For 
example, the β2 integrin family is expressed exclusively on leukocytes and not 
on other cell types in the body. As such, β2 mediated cytokine production may 
be important for processes that are specific to leukocytes, such as extravasation 
and oxidative burst. The αV integrins, however, are expressed by a variety of 
cell types, such as fibroblasts, in addition to leukocytes. Therefore, their role in 
cytokine production will not be limited to those functions related to leukocytes. 
The αV mediated cytokine production may substitute for β2 integrins on other 
cell  types.  The  expression  pattern  of  particular  integrins  is  developmentally  
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regulated and specific to certain cell types. Therefore, the ability of individual 
integrins to induce cytokine production may be regulated at the level of integrin 
expression. Additionally, integrins are known to cooperate with other receptors, 
including other integrins, as we have shown with the αVβ3 and αXβ2 integrins 
(See  Figures  4 12  to  4 16).  Stimulation  of  cells  with  antibodies  against  both 
integrins led to an increase in cytokine production over the levels produced by 
stimulation of a single integrin. Therefore, the cytokine output of a particular 
cell will also be influenced by the different types of integrins expressed on the 
cell surface.  
4.3.2   Role of integrin isoform 
Cytokine output was influenced by the heterodimer within the integrin family 
that was targeted. Stimulation of the cells with antibodies against the αVβ3 and 
αVβ5 integrins induced similar cytokine responses by monocytic cells. The αVβ3 
and αVβ5 integrins were expressed at comparable levels and induced a similar 
increase  in  the  fold  stimulation  of  cytokine  production  by  THP 1  cells.  In 
contrast,  the  αMβ2  integrin  induced  lower  levels  of  cytokines  than  the  αXβ2 
integrin.  THP 1  cells  express  significantly  lower  levels  of  αMβ2  than  αXβ2, 
although the expression level alone of a particular integrin was not sufficient to 
influence the production of cytokines. In the presence of the correct signal to 
induce  cytokine  production,  however,  expression  levels  may  influence  the 
concentration  of  cytokines  released.  This  may  account  for  the  difference 
observed  in  the  concentrations  of  cytokine  produced  by  stimulation  of  αMβ2 
versus  αXβ2.  Although  treatment  of  the  THP 1  cells  with  GM CSF  led  to  an 
increase in the expression of αMβ2, we did not observe an increase in αMβ2 
mediated cytokine production. This may indicate, again, that expression levels 
of an integrin are not the major determinant of its ability to induce cytokine 
production. We cannot exclude the possibility though that there may have been 
changes other than in αMβ2 expression in the cell line after GM CSF treatment 
that  we  did  not  observe,  but  which  would  explain  the  discrepancy  between 
integrin level and cytokine production.   
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4.3.3   Role of integrin epitope 
We investigated the role of the integrin epitope on the production of cytokines 
by integrin stimulation using paired antibodies against the same heterodimer. 
We observed that there was an epitope effect, since for both the αV and β2 
heterodimers, only one of the paired antibodies elicited a response. Therefore, 
the  site  at  which  the  integrin  is  bound  is  important  for  inducing  cytokine 
production. This comparison is independent of concentration as both antibodies 
bind  the  same  heterodimer  and  gives  an  indication  of  the  specificity  of  the 
interaction.  For  the  αVβ3  integrin,  the  23C6  antibody  induced  high  levels  of 
cytokine synthesis by THP 1 cells. The other αVβ3 antibody used in the analysis, 
LM609, failed to induce the production of the cytokines studied. This suggests 
that  the  23C6  clone  may  recognise  the  site  on  the  heterodimer  required  to 
activate this integrin to induce cytokine production, while LM609 did not. The 
mechanism of this interaction will need to be determined; 23C6 may activate 
αVβ3 by binding to the critical site or through an  allosteric mechanism. This 
remains  to  be  determined.  In  addition,  an  analysis  of  the  affinities  of  the 
individual  antibodies  should  be  undertaken,  to  ensure  that  the  responses 
observed are not solely due to the strength of the interaction.  
4.3.4   Role of cell differentiation status 
We  tested  two  monocytic  cells  lines,  THP 1  and  U937,  for  their  ability  to 
produce cytokines in response to integrin binding. THP 1 cells are derived from 
the peripheral blood of a patient suffering with acute myeloid leukaemia 
165. 
U937 cells were derived from a patient with histiocytic lymphoma 
166. Both cell 
lines  are  routinely  used  as  model  cell  systems  for  analysis  of 
monocytic/macrophage responses.  
The two lines expressed similar levels of CD23 binding integrins, but responded 
differently to equivalent stimulation. This suggests that cell differentiation state 
may  influence  cytokine  production  in  response  to  integrin  stimulation.  These 
data were supported by the studies involving the differentation of THP 1 cells 
using M CSF, GM CSF and db cAMP. In these cases, a change in the expression 
level of the integrins did not correlate with an increase in cytokine production in 
response to integrin binding. It may be however, that THP 1 cells are already too  
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differentiated  to  observe  any  changes  in  response  to  treatment  with  the 
different agents. These experiments should have rather been conducted on the 
less differentiated U937 cell line.  
It is possible that there was an increase in integrin activation without a change 
in expression levels that led to the increases in cytokine production. This is a 
difficult parameter to measure in the context of this interaction. The integrin 
stimulation in these experiments was performed using soluble ligands with cells 
in  suspension  and  therefore  it  is  difficult  to  define  integrin  activation  under 
these conditions. Most analyses define integrin activation in terms of adhesion, 
and  consequently  the  reagents  available  for  the  study  of  integrin  activation 
(conformational antibodies), are based on the adhesive/RGD binding abilities of 
integrins. We anticipate that the site on the integrin that modulates cytokine 
production is independent of the RGD site, although we have yet to identify it. It 
seems  unlikely  therefore,  that  activation  of  an  integrin  in  the  “classical 
adhesion based”  sense  would  enhance  cytokine  production.  Our  hypothesis  is 
supported by the fact that the inclusion of FCS (which contains RGD containing 
ligands) does not inhibit or dampen the cytokine response. Inclusion of FCS in 
the  medium  led  to  a  statistically  significant  increase  in  cytokine  production. 
Chemokines are known to activate integrins, this may lead to RGD binding and 
enhancement  of  the  cytokine  response.  ECM  proteins  alone  cannot  induce 
cytokine response in solution. Alternatively, it may simply be due to the fact 
that the cells are better adapted and less stressed in media containing serum. 
The  possible  interplay  between  adhesive  and  non adhesive  integrin  signalling 
will be addressed as more information regarding the role of integrins in non 
adhesion based signalling becomes available. 
4.3.5   Cooperation between integrins and other receptors 
The role of integrins as modulators of the activity of other surface receptors is 
an  example  of  adhesion independent  integrin based  signalling.  Integrins  are 
signalling  molecules  in  their  own  right,  but  have  also  been  shown  to  show 
synergy  with  other  surface  receptors.  Cell  differentiation  is  often  associated 
with changes in activity and changes in the expression levels of surface proteins. 
The production of cytokines by integrins, therefore, may rely on the expression 
of an additional surface receptor that is developmentally regulated.   
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We analysed the expression of the Fcγ receptors, a family of immunoreceptors 
which  play  a  key  role  in  cytokine  production  by  monocytes 
188.  Three  Fcγ 
receptors are expressed on monocytes, CD16, CD32 and CD64. CD64 is the high 
affinity receptor, which is capable of binding monomeric IgG, while the CD16 
and CD32 receptors only bind IgG as part of an immune complex. Fc receptors 
have an important role in a number of integrin mediated immune functions 
189 
192, which might influence cytokine production. As we were using antibodies, it 
was plausible that Fcγ receptors may be involved in the interaction.  
We did not find any change in the levels of Fcγ receptors on the differentiated 
THP 1  cells  that  could  explain  the  discrepancies  between  integrin  expression 
levels and cytokine production. Interestingly, U937 cells, which did not produce 
significant  quantities  of  cytokines  in  response  to  integrin  binding,  did  not 
express CD16 or CD32 and only expressed low levels of CD64. The precise role of 
the  Fcγ  receptors  in  integrin induced  cytokine  production  would  need  to  be 
addressed using the corresponding Fab fragments that lack the Fc portion of the 
antibody, as opposed to whole immunoglobulin molecule. Isotype controls were 
used  to  control  for  the  contribution  of  Fcγ  receptors,  although  they  are  not 
necessarily a true representation of the immune complexes required to induce 
cytokine production by Fcγ receptors. A better approach would have been to use 
Fcγ  receptor  blockers  in  conjunction  with  the  specific  antibodies.    However, 
even  if  Fcγ  receptors  are  involved  in  the  mechanism  of  integrin mediated 
cytokine production, the interaction was still specific, as it was only observed in 
specific cases (such as 23C6), not with any antibody (such as LM609).  
We also analysed the expression of CD47 on the differentiated THP 1 cells. CD47 
is a component of the αVβ3 signalling complex and therefore an increase in CD47 
levels may lead to an increase in αVβ3 mediated signalling without altering αVβ3 
levels. There was no change in the expression of CD47 on the differentiated 
THP 1 cells or U937 cells that could explain the differences between change in 
expression level and cytokine production. It is still possible, however, that an 
additional, as yet unidentified, receptor is regulating integrin mediated cytokine 
production.  
We did not observe cooperativity between different  integrins during cytokine 
production. Co stimulation of THP 1 cells with the 23C6 and Clone3.9 antibody  
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led to higher levels of cytokine production, than when used alone at equivalent 
concentrations. This indicates that the pathways that lead from αVβ3 and αXβ2 
integrins  during  cytokine  production  are  not  opposing  and  lead  to  a  similar 
outcome. We would anticipate that both integrins activate the same pathway, 
possibly via a common co receptor, although we do not currently have the data 
to support this conclusion. To observe cooperativity between the integrins, we 
would  have  expected  an  antibody  that  did  not  normally  induce  cytokine 
production (such as P4H9) to enhance the cytokine production of a suboptimal 
level of 23C6 or Clone3.9. We did not observe a statistically significant effect 
with any of the co stimulations tested.  
4.3.6   Integrin-mediated cytokine production by primary 
cells 
Although used as a model for monocytic cells, the THP 1 cell line is derived from 
a  patient  suffering  from  acute  myeloid  leukaemia  and  carries  the  MLL AF9 
mutation 
165. It may be a better model for integrin mediated cytokine production 
during  pathology  than  in  physiological  conditions.  We  analysed  the  cytokine 
responses of primary cells (BMDM and CD14
+PBMC) to integrin stimulation. The 
CD14
+PBMC produced cytokines upon β2 ligation, but did not produce cytokines 
in response to stimulation with antibodies against αV integrins. The BMDM gave 
the most similar response to THP 1 cells and produced cytokines in response to 
both αV and β2 antibodies. This was unexpected as THP 1 cells are routinely 
used  as  a  model  for  macrophage/monocytic  cells  and  therefore  it  was 
anticipated that the CD14
+PBMC would be the most similar in response to THP 1. 
These data would suggest that in fact, THP 1 cells are more similar to BMDM in 
their  integrin mediated  cytokine  responses.  These  data  further  suggest  that 
differentiation state is crucial for integrin mediated cytokine synthesis.  
We  have  analysed  the  importance  of  stimulation  of  different  CD23 binding 
integrins in cytokine production by monocytic cells. This analysis has indicated 
that integrin mediated cytokine production is specific and influenced by integrin 
family, isoform and epitope targeted. The production of these chemokines may 
have a role in the biology of the immune system and the monocytes themselves. 
CD23 itself also induces maturation/activation of monocytes via its interactions 
with β2 integrins 
74, 193.   
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5  ROLE OF αVβ3 INTEGRIN IN MONOCYTE 
DIFFERENTIATION  
159 
5.1  Introduction 
5.1.1   The αVβ3 integrin 
The  αVβ3  integrin  is  a  member  of  the  vitronectin  receptor  family,  integrins 
which all contain the αV subunit in a non covalent association with one of 5 β 
chains, namely β1, β3, β5, β6 or β8, and have the capacity to bind vitronectin 
194. The αVβ3 integrin is expressed at low levels in most normal tissues including 
intestinal,  vascular  and  smooth  muscle,  although  in  general,  the  other  αV 
isoforms  are  more  widely  expressed  in  normal  tissues.  High  levels  of  αVβ3 
expression  in  vivo  are  observed  in  bone,  placenta,  inflammatory  sites  and 
invasive  malignancies  (including  melanoma,  glioma,  ovarian  and  breast 
tumours). Specifically, cell types which express high levels of the αVβ3 integrin 
are  mature  osteoclasts  (bone  resorbing  cells),  activated  macrophages, 
angiogenic endothelial cells and migrating smooth muscle cells 
195.  
The  aVβ3  integrin  is one of  the  most  well  studied  of  the  integrins,  with  the 
recent information on the general structure and conformational regulation of 
integrin  activation  being  based  on  the  published  crystal  structures  of  the 
extracellular  domain  of  the  αVβ3  integrin 
94,  98.  The  αVβ3  integrin  plays  an 
important role in adhesion and non adhesion based interactions in cells.  As a 
cell  adhesion  receptor  it  binds  a  wide  range  of  ECM  proteins  in  addition  to 
vitronectin, including fibronectin, fibrinogen, osteopontin and thrombospondin. 
These interactions are mediated via recognition of the RGD motif in the various 
ECM  proteins.  These  adhesive  interactions  are  important  during 
osteoclastogenesis and in the case of metastatic cancers. The αVβ3 integrin also 
functions as a receptor for a number of viruses during entry into cells. These 
interactions are both RGD dependent and RGD independent (Table 6 1). 
In addition to its role in cell adhesion and migration processes, αVβ3 associates 
with  and  modulates  the  activity  of  a  number  of  growth  factor  receptors, 
including  the  platelet derived  growth  factor  (PDGF)  receptor 
196 198,  basic 
fibroblast growth factor (BFGF) receptor 
137, 199 203, transforming growth factor β 
(TGFβ) receptor 
204 206, insulin growth factor (IGF) receptor
140,  207 and vascular 
endothelial growth factor (VEGF) receptor 
137, 196, 197, 208. The αVβ3 integrin has 
also been shown to associate with the M CSF receptor, c FMS, during osteoclast  
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development  and  macrophage  activation 
142,  209,  210.  The  combined  expression 
patterns and functions of αVβ3 make it an attractive target for therapies against 
a number of inflammatory disorders, rheumatic diseases and cancers 
194, 211 216.   
5.1.2   Macrophage differentiation and activation  
Macrophages  are  a  highly  heterogeneous  population  that  fulfil  a  range  of 
functions  in  the  immune  system.  They  are  the  precursors  for  a  number  of 
terminally differentiated cells with specialised functions in the body, including 
osteoclasts  and  dendritic  cells.  Macrophages  develop  when  blood  monocytes 
move  into  the  tissues  in  response  to  cues  from  the  local  environment. 
Macrophages can be activated by a number of different stimuli, each of which 
results  in  a  macrophage  that  is  polarised  to  exhibit  specific  characteristics. 
Activated macrophages can be classified as having undergone either a classical 
or alternative programme of activation.  
5.1.2.1   Classically Activated Macrophages (M1) 
Classically activated macrophages develop in response to treatment with IFN γ 
and TNF α. These macrophages are pro inflammatory and produce high levels of 
pro inflammatory  cytokines,  including  TNF α,  IL 1  and  IL 6 
217.  This  type  of 
macrophage  is  traditionally  associated  with  Th1  responses  that  result  in 
inflammation and the destruction and clearance of intracellular pathogens and 
tumour cells 
217.  
5.1.2.2   Alternatively Activated Macrophages (M2) 
Alternatively activated macrophages are generally classed as anti inflammatory 
and are usually identified due to their high expression of IL 10 and lack of IL 12 
expression 
6. M2 macrophages can be further sub classified into M2a (also known 
as alternatively activated), M2b (also known as type II activated) and M2c (also 
known as deactivated) macrophages, according to the activating signals under 
which  they  arise  and  their  subsequent  cytokine  production  profiles.  M2a 
macrophages develop in response to treatment with agents including IL 4, IL 13 
and glucocorticoids, while M2b develop in response to TLR or IL 1R ligation and 
immune  complexes,  and  M2c  macrophages  develop  in  response  to  IL 10  
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treatment.  M2  macrophages  are  associated  with  anti inflammatory,  tissue 
remodelling and pro cancer activity. M2b macrophages are distinct in that they 
continue to produce the pro inflammatory cytokine TNF α, in addition to the 
anti inflammatory IL 10 
16.   
5.1.3   Activated macrophages and disease 
Activated  macrophages  play  an  important  role  in  the  development  and 
progression  of  a  number  of  diseases 
2.  Both  pro inflammatory  M1  activated 
macrophages and anti inflammatory M2 macrophages can contribute to human 
disease. Pro inflammatory M1 activated macrophages are a hallmark of a number 
of inflammatory diseases, including rheumatoid arthritis 
194, 217. The production 
of cytokines (such as TNF α, IL 6 and IL 1) by M1 macrophages is responsible for 
inflammation  observed  during  these  diseases.  Anti inflammatory  M2 
macrophages  also  have  a  role  in  human  pathology,  most  likely  as  tumour 
associated  macrophages  (TAM) 
218.  TAMs  are  a  M2  population  of  activated 
macrophages  recruited  to  tumour  sites,  which  do  not  destroy  tumours,  but 
rather  contribute  to  their  survival  and  development.  TAMs  aid  in  the 
establishment of a favourable tumour microenvironment by the release of pro 
tumourgenic and pro angiogenic mediators, including factors like VEGF and IL 8 
219.   
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5.2  Results 
5.2.1   Integrin signalling during cytokine production  
Stimulation of THP 1 cells with an anti αVβ3 antibody 23C6 led to the production 
of  high  levels  of  cytokines.  We  examined  the  early  signalling  events  that 
occurred in the THP 1 cells after integrin stimulation with 23C6. Activation of 
the β3 integrin has been shown to induce phosphorylation of the cytoplasmic tail 
at different sites 
220 224. To test if 23C6 was inducing cytoplasmic signalling by 
the αVβ3 (i.e., 23C6 was activatory as opposed to inhibitory), we examined the 
phosphorylation  state  of  the  β3  tail  in  THP 1  cells  after  treatment  with 
increasing  concentrations  of  23C6.  Figure  5 1  shows  Western  blots  for  the 
phosphorylation of the β3 cytoplasmic domain at residues Tyr773 or Tyr785. In 
the absence of treatment, there was no phosphorylation of the β3 tail at either 
residue  (Tyr773  or  Tyr785).  Ligation  of  αVβ3  with  the  23C6  antibody  led  to 
detectable phosphorylation of the β3 tail at Tyr773 at concentrations ranging 
from 0.25 g/mL – 5 g/mL antibody. There was no detectable phosphorylation of 
Tyr785 of the β3 cytoplasmic tail at any concentration of 23C6 treatment.  
Integrins  are  known  to  activate  the  mitogen activated  protein  kinase  (MAPK) 
pathway in many cell lineages 
84,  225 228. We tested if treatment of THP 1 cells 
with  the  anti αVβ3  antibody  23C6  in  solution  led  to  activation  of  the  MAPK 
pathway and subsequent phosphorylation of extracellular signal regulated kinase 
(ERK). Figure 5 2 shows the Western analysis for the phosphorylation of ERK in 
THP 1  cells  treated  with  23C6.  Actin  was  used  as  a  loading  control  and 
densitometry was performed using the ImageJ program, although using total ERK 
levels as a loaded control would have been more accurate. Figure 5 2A shows 
the phosphorylation of ERK in THP 1 cells treated with increasing concentrations 
of 23C6 for 30 min. Figure 5 2B shows the response of THP 1 cells treated with 
1 g/mL of 23C6 at different time points. Phosphorylation of ERK was observed 
when THP 1 cells were stimulated with 23C6.   
163 
We analysed the importance of ERK activation in integrin mediated production 
of cytokines using the mitogen activated ERK kinase (MEK) inhibitor U0126. MEK 
directly  phosphorylates  ERK  during  MAPK  signalling 
229.  THP 1  cells  were 
stimulated  to  induce  cytokine  production  using  LPS  (positive  control),  23C6 
(anti αVβ3 integrin) or Clone3.9 (anti αXβ2) in the absence and presence of the 
MEK inhibitor U0126, and cytokines (RANTES, MIP 1β and IL 8) released into the 
supernatant were detected by ELISA (Figure 5 3). THP 1 cells stimulated with 
LPS, 23C6 or Clone3.9 in the absence of U0126 produced high levels of RANTES 
(Figure 5 3A white bars), IL 8 (Figure 5 3B white bars) and MIP 1β (Figure 5 3C 
white  bars).  THP 1  cells  were  stimulated  with  the  same  treatments  in  the 
presence  of  the  MEK  inhibitor,  U0126.  Inclusion  of  the  MEK  inhibitor  in  the 
reaction  lead  to  a  statistically  significant  reduction  in  the  concentrations  of 
RANTES (Figure 5 3A grey bars), IL 8 (Figure 5 3B grey bars) and MIP 1β (Figure 
5 3C grey bars) produced in response to integrin stimulation with either 23C6 or 
Clone3.9.  LPS induced  RANTES  production  was  statistically  reduced  by  U0126 
treatment,  while  LPS induced  IL 8  and  MIP 1β  concentrations  did  not  differ 
significantly  in  the presence  or absence  of  U0126.  The  MEK inhibitor did  not 
completely inhibit cytokine production, as low levels of RANTES, IL 8 and MIP 1β 
were  still  released  in  the  presence  of  U0126.  In  general,  αXβ2 stimulated 
cytokine production was inhibited to a greater degree than the αVβ3 mediated 
cytokine production. Interestingly, treatment of cells with U0126 also inhibted 
the constitutive expression of RANTES observed previously with THP 1 cells.   
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Figure    5.1  Phosphorylation  of  β3  tail  in  response  to  binding  of  anti-αVβ3 
antibody to THP-1 cells 
THP-1  cells  were  incubated  with  increasing  concentrations  of  23C6  (anti-αVβ3)  antibody  for 
30mins. Lysates prepared were resolved by SDS-PAGE and probed for the presence of specific 
phosphorylation  of  the  β3  integrin  using  antibodies  to  residues  phosphotyrosine  773  and 
phosphotyrosine 785. Actin was used as a loading control. Data are representative of at least 3 
separate experiments. 
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Figure   5.2 Integrin binding induces ERK phosphorylation 
 (A) THP-1 cells in OptiMEM were stimulated with increasing concentrations of 23C6 (anti-αVβ3 
antibody) for 30mins. (B) THP-1 cells in OptiMEM were incubated with 1 g/mL of 23C6 (anti-αVβ3 
antibody) and samples taken at specific time points. Cell lysates were analysed for expression of 
phosphorylated  ERK  and  actin  (loading  control)  by  SDS-PAGE  and  Western  blotting.  Signal 
intensity was quantified by densitometry and represented as a ratio of pERK:Actin to standardise 
for loading inaccuracies. Data are representative of at least 3 separate experiments. 
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Figure   5.3 Inhibition of MEK blocks integrin-mediated cytokine production 
Cytokine  production  by  THP-1  cells  was  determined  in  the  presence  (grey  bars)  and  absence 
(white bars) of the MEK inhibitor U0126 (10  M). Cytokines released into the supernatant were 
detected  by  ELISA.  Unt:untreated;  IgG1:isotype  control;  LPS:positive  control;  23C6:anti-αVβ3 
antibody; 3.9:anti-αXβ2 antibody. Statisitical analysis was performed using Student’s t-test*p<0.05. 
Data are representative of at least 3 separate experiments. The response to IgG1 is included as a 
representative  example.  All  antibody  isotypes  were  tested  (IgG1,  IgG2a,  IgG2b  and  IgG3)  and 
gave responses equivalent to IgG1.   
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5.2.2    Analysis of the effects of cytokines produced by 
integrin ligation upon migration of THP-1 cells 
RANTES, IL 8 and MIP 1β are all involved in migratory responses of leukocytes in 
vivo and in vitro 
12, 230 234. We therefore analysed the chemotactic ability of the 
supernatant  containing  chemokines  produced  by  THP 1  cells  in  response  to 
integrin binding.  
THP 1  cells  were  treated  with  different  agents  overnight  and  cleared 
supernatants  collected.  These  supernatants  were  subsequently  used  as  the 
chemotactic  stimulus  in  transwell  migration  assays  using  unstimulated  THP 1 
cells. The concentrations of IL 8, RANTES, VEGF and MIP 1β in the supernatants 
were  quantified  prior  to  use  in  the  transwell  assays.  Consistent  levels  of 
cytokines  were  detected  in  all  supernatants  used  in  the  analysis  (data  not 
shown). The transwell migration assays are conducted in multiwell plates that 
contain an upper and lower chamber separated by a polycarbonate membrane. 
Supernatants  from  THP 1  cells  treated  with  stimulating  agents  (LPS,  23C6  or 
Clone3.9)  were  cleared  by  centrifugation  and  filtration  and  the  levels  of 
RANTES, IL 8 and MIP 1β quantified by ELISA. Untreated THP 1 cells in OptiMEM 
were  placed  in  the  upper  chamber  of  the  transwell  plate  and  cleared 
supernatants in the lower chamber. The plate was incubated for 3 hours at 37
0C 
and cells that had migrated from the upper chamber across the membrane into 
the lower chamber were collected and quantified by flow cytometry.  
The migration of unstimulated THP 1 cells across the transwell membrane was 
tested  in  response  to  OptiMEM  or  supernatant  from  stimulated  THP 1  cells 
(Figure 5 4). A small number of cells migrated in response to OptiMEM. This can 
be  considered  due  to  random  migration.  There  was  a  statistically  significant 
increase in the number of migratory cells when cleared supernatant from 23C6 
stimulated or Clone3.9 stimulated cells was used instead of OptiMEM (Figure 5 
4A). There was no statistically significant increase in migration observed with 
cleared  supernatant  from  LPS stimulated  supernatants  over  OptiMEM  alone. 
23C6 stimulated supernatant induced the greatest migration of THP 1 cells.   
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To  determine  if  the  increase  in  migration  was  due  to  the  concentration  of 
chemokines in the supernatant, we analysed the migratory response of THP 1 
cells to serial dilutions of the cleared supernatant from 23C6 stimulated THP 1 
cells. Cleared supernatant from 23C6 treated THP 1 cells was diluted (1 in 2, 1 
in 5 and 1 in 10) with fresh OptiMEM and used in transwell migratory assays. 
Figure  5 4B  shows  that  THP 1  cells  migrated  in  response  to  undiluted 
supernatant  from  23C6 treated  cells  (dilution  factor=1).  The  dilution  of  the 
cleared supernatant in the transwell assay led to a statistically significant, dose 
dependent decrease in migration of THP 1 cells.  The greater the dilution of the 
supernatant, the fewer cells migrated across the membrane, although, even at 
10 fold dilution, an increase in migration over the background (OptiMEM) was 
observed. 
As  migration  across  the  membrane  is  an  active  process  involving  adhesion 
reactions,  we  measured  the  effect  of  coating  the  transwell  polycarbonate 
membrane with proteins on the migration of THP  1 cells to the same stimulus 
(Figure 5 4C). The transwell plate was incubated with the coating proteins at 
37
0C for 1 hour. The chambers were washed with OptiMEM and used in transwell 
migration  assays  using  cleared  supernatant  from  23C6 treated  cells  as  the 
chemotactic stimulus. Bovine serum albumin (BSA) was used to control for the 
presence of non specific protein on the membrane. This was compared with the 
migration  of  THP 1  cells  across  polycarbonate  membranes  coated  with  foetal 
calf serum (FCS), vitronectin (VN) or fibrinogen (FBGN). A statistically significant 
increase  in  migration  was  observed  for  membranes  coated  with  FCS  and  VN, 
compared  to  BSA.  The  membrane  coated  with  FBGN  did  not  lead  to  a 
statistically significant increase in cell migration across the membrane compared 
with BSA (Figure 5 4C).  
We tested the ability of the supernatants to influence the migration of other 
cells in the immune system. We compared the migration of THP 1 cells with the 
T  cell  line,  Jurkat,  and  the  B  cell  line,  IB4.  Figure  5 5  shows  that  cleared 
supernatant from THP 1 cells treated with 23C6 could positively influence the 
migration of Jurkat and IB4 cell lines in addition to THP 1 cells (Figure 5 5A). 
Although the greatest number of migratory cells was observed with THP 1 cells 
compared  to  Jurkat  or  IB4  cells,  the  fold  stimulation  over  the  number  of 
randomly migrating cells was similar for all the cell lines (Figure 5 5B).   
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Figure   5.4 Migration of THP-1 cells in transwell assays 
(A) Migration of cells towards Optimem (OPT) or cleared supernatants from LPS, 23C6 (anti-αVβ3) 
or  3.9  (anti-αXβ2)  treated  cells.  (B)  Effect  of  dilution  of  23C6  (anti-αVβ3)  supernatant  on  cell 
migration.  (C)  Effect  of  coating  of  transwell  polycarbonate  membrane  with  proteins  on  cell 
migration. Wells were coated with bovine serum albumin (BSA), foetal calf serum (FCS), vitronectin 
(VN) or fibrinogen (FBGN) for at least 1 hour at 37
0C prior to migration assays. Cells (1x10
-5) were 
placed in the upper transwell chamber and cleared supernatant from treated THP-1 cultures was 
placed in the lower chamber of transwell plates. The plates were incubated at 37
0C, in 5% CO2 for 
3 hours, whereupon cells that had migrated across the membrane into the lower chamber were 
collected by centrifugation, washed and resuspended in equivalent volumes of PBS/formalin. Cell 
counts  in  duplicate  were  determined  by  flow  cytometry.    Data  represent  mean  of  at  least  3 
independent experiments. Statistical analysis was performed using Students t-test, *p<0.05. The 
error bars indicate standard deviations (SD).  
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Figure   5.5 Comparison of migration of different cell types in transwell assay 
(A) Migration of THP-1 (black bars), Jurkat (white bars) and IB4 (grey bars) cell lines to untreated 
Optimem  medium  (OPT)  or  cleared  supernatant  (SN)  from  23C6  (anti-αVβ3)  treated  THP-1 
cultures. (B) The migration index, representing fold-stimulation of migration in response to 23C6 
(anti-αVβ3)  supernatant  relative  to  migration  in  response  to  Optimem.  Migration  of  cells  was 
measured using transwell plate assays. Cells that had migrated across the membrane into the 
lower chamber were collected by centrifugation, washed and resuspended in equivalent volumes of 
PBS/formalin. Cell counts in duplicate were determined by flow cytometry. Data represent mean of 
at least 3 separate experiments. Statistical analysis was performed using Students t-test, *p<0.05. 
The error bars indicate standard deviations (SD).  
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5.2.3    αVβ3-mediated monocyte differentiation/activation 
Monocytic cells are the precursors for a number of essential cells in the body. 
Monocytes  develop  into  cells  such  as  macrophages,  dendritic  cells  and 
osteoclasts  when  treated  with  different  stimuli.  CD23  has  been  shown  to 
mediate monocyte activation via an interaction with β2 integrins 
74, 193.  
We had previously analysed the response of THP 1 cells to acute (<24 hours) 
stimulation with anti integrin antibodies. Stimulation of THP 1 cells with specific 
antibodies led to the production of cytokines over this time period. We were 
therefore interested in investigating the potential activation of THP 1 cells in 
response to chronic stimulation with these antibodies (>3 days).  
Monocyte activation requires multiple signals, one of which is often a priming 
step  induced  by  cytokines  such  as  M CSF.  We  tested  the  ability  of  selected 
antibodies  to  induce  monocyte  activation  in  conjunction  with  the  myeloid 
growth  factor,  M CSF  (Figure  5 6).  THP 1  cells  were  incubated  in  OptiMEM 
supplemented  with  10ng/mL  M CSF  and  selected  antibodies  for  5  days  and 
observed for changes in morphology associated with monocyte activation (such 
as increases in size and adherence).  Any changes in cell morphology associated 
with  monocyte  differentiation  were  recorded  by  phase  contrast  microscopy 
(Figure 5 6).  
Unstimulated  cells  cultured  in  OptiMEM/M CSF  retained  a  small,  rounded 
morphology, although there was a minor increase in the degree of adherence to 
the plastic culture dish observed (Figure 5 6A). LPS treatment was used as a 
positive control for monocyte activation. LPS stimulated THP 1 cells cultured in 
OptiMEM/M CSF  displayed  an  altered  morphology  characterised  by  a  larger, 
adherent  phenoytpe  with  a  number  of  spiky  cytoplasmic  extensions 
characterisitc of activated macrophages (Figure 5 6B).  There was no change in 
morphology for THP 1 cells treated with IgG1, MEM48 (β2) or P1F6 (αVβ5) in the 
presence of M CSF (Figure 5 6C, D and F, respectively). The cells treated in this 
manner appeared similar to the untreated cells (Figure 5 6A). Treatment of THP 
1  cells  with  the anti integrin antibodies  Clone44  (αMβ2)  and  Clone3.9  (αXβ2) 
induced  a  degree  of  change  in  THP 1  morphology  that  was  similar  but  less 
extreme than that observed for the LPS treated THP 1 cells (Figure 5 6 G and H,  
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respectively).  By contrast, 23C6 induced a significant change in the morphology 
of THP 1 cells. These changes were more pronounced than those observed for 
LPS treated  THP 1  cells.  The  THP 1  cells  became  adherent  and  increased 
significantly  in  size,  with  a  large  number  of  spiky  cytoplasmic  extensions.  In 
certain cases, 23C6/M CSF treated cells were observed to have multiple nuclei 
by Giemsa staining.  Given this pronounced phenotype, we elected to analyse 
further the 23C6 mediated activation of THP 1 cells.  
We investigated whether 23C6 could mediate this activation in the absence of 
the  M CSF  growth  factor.  THP 1  cells  in  OptiMEM  were  incubated  with  23C6 
alone or in conjunction with the cytokine M CSF for 3 7 days and observed for 
any changes in morphology (Figure 5 7). Stimulation of THP 1 cells with anti 
αVβ3 antibody alone led to the distinct changes in morphology. The THP 1 cells, 
which are usually small, rounded suspension cells (Figure 5 7A) formed clumps in 
solution and a number of cells became adherent and enlarged, with significant 
spiky processes. Treatment with 23C6 alone was sufficient to induce this change 
in morphology of THP 1 cells (Figure 5 7C), although the number of cells showing 
the  differentiated  morphology  and  the  extent  of  the  differentiation  was 
enhanced by the presence of M CSF (Figure 5 7D). Equivalent concentrations of 
M CSF  alone  caused  changes  in  morphology  of  the  cells  associated  with 
maturation  of  monocytic  cells  to  a  more  macrophage like  phenotype.  Cells 
became  slightly  larger  and  adherent,  but  lacked  the  large  number  of  spiky 
protuberances  observed  with  the  23C6 treated  cells.  The  23C6 treated  cells 
(with and without M CSF) were significantly larger, more adherent and had a 
greater number of spiky extensions compared to those treated with M CSF alone. 
The cytoplasm appeared to be highly granular or vesicular in nature (Figure 5 7).  
We investigated the effect of 23C6 and M CSF on the morphology of primary 
human monocytes derived from peripheral blood (CD14
+PBMC) or bone marrow 
(BMDM). Figure 5 8 shows the differentiation of BMDM in response to M CSF (A 
and B), 23C6 and M CSF (C and D) and LPS and M CSF (E and F). Treatment of 
BMDM  with  M CSF  led  to  a  change  in  morphology  associated  with  a  more 
macrophage like phenotype, with cells being adherent, rounded and flattened in 
appearance. Treatment of BMDM with 23C6 in conjunction with M CSF led to a 
similar adherent phenotype, together with the development of numerous spiky 
processes. A similar change in morphology was observed with BMDM treated with  
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LPS  and  M CSF,  although  in  this  case,  the  LPS  treated  cells  had  fewer  spiky 
processes than the 23C6 treated cells. 
Figure 5 9 shows the differentiation of CD14
+PBMC in OptiMEM alone (Figure 5 
9A) or supplemented with M CSF (Figure 5 9B), 23C6 (Figure 5 9C) or 23C6 and 
M CSF (Figure 5 9D). The difference in morphology is less obvious, as CD14
+PBMC 
are adherent even when unstimulated. However, closer observation of cultures 
suggested a change in morphology when CD14
+PBMC were treated with 23C6, 
either  in  the  presence  or  absence  of  M CSF.  Treatment  with  23C6  in  the 
presence or absence of M CSF induced a change in morphology, where the cells 
became enlarged, with a stellate morphology and a number of projections. A 
number  of  cells  appeared  to  have  multiple  nuclei.  Cells  treated  with  M CSF 
alone generally had an enlongated morphology.     
Monocytic cells are known to differentiate into a number of different cell types, 
including but not limited to macrophages, dendritic cells and osteoclasts. The 
morphological changes observed in the THP 1 cells upon treatment with 23C6 
and M CSF were potentially consistent with the differentiation of the monocytic 
cells into one of these cell types. Each of these cell types has a characteristic 
set of surface markers and cytokine outputs that are defined by their nature.  
We first investigated whether the THP 1 cells were acquiring an osteoclast like 
phenotype.  Osteoclasts  are  large,  adherent,  multinuclear  cells  derived  from 
macrophages.  The  αVβ3  integrin  and  the  cytokine  M CSF  are  associated  with 
osteoclast development in vivo and in vitro. Therefore, given the morphology of 
the  23C6/M CSF treated  cells  (large,  adherent,  multinucleated),  and  the 
stimulus  used  to  induce  differentiation  (anti αVβ3  antibody  and  M CSF),  we 
hypothesised that the THP 1 cells may developing into osteoclasts. Osteoclasts 
can be identified by staining for the osteoclast marker, tartrate resistant acid 
phosphatase (TRACP), which should give a pink colour due to the activity of the 
TRACP enzyme. Figure 5 10 shows the TRACP staining for 23C6/M CSF treated 
cells.  The  cells  stained  yellow  with  the  TRACP  assay.  No  pink  colour  was 
observed,  even  with  the  large,  multinucleated  cells  (Figure  5 10B).  This 
suggested  that  the  stimulated  THP 1  cells  did  not  acquire  an  osteoclast like 
nature, as defined by TRACP staining.   
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In light of the above result, we proposed that the change in morphology of the 
THP 1  cells  was  an  indication  of  macrophage  activation.  Macrophages  are  a 
naturally heterogeneous population and there are multiple mechanisms which 
lead  to  macrophage  activation 
7,  8,  235.  Each  of  these  mechanisms  defines  a 
specific type of macrophage, each of which has a characteristic expression of 
surface markers and cytokine profiles (summarised in Table 5 1). To investigate 
whether  23C6/M CSF  treatment  of  THP 1  cells  was  initiating  a  specific 
programme of activation, we analysed the changes in surface marker expression 
and monitored the cytokine profile of the differentiated cells  during a 5 day 
stimulation. 
After stimulation with M CSF and 23C6 for 5 days, the THP 1 cells were assessed 
for the presence of specific cell surface markers by flow cytometry (Figure 5 
11). These markers have been correlated with a specific type of macrophage 
activation mechanism (Table 5 1) 
7. The expression levels of selected markers on 
untreated  THP 1  cells  cultured  in  OptiMEM  for  5  days  (Figure  5 11A)  was 
compared to the expression of the same markers after treatment of cells with 
23C6 and M CSF for 5 days (Figure 5 11B). A general increase in the background 
staining was observed for 23C6/M CSF treated cells compared to untreated cells. 
There was no significant change in the expression levels of CD86, HLA DR, CD23 
or CD14 between untreated THP 1 cells and 23C6/M CSF stimulated THP 1 cells. 
There was also no change in the expression level of CD25, IFNγ R1, TLR 2, CD64 
or CD47. 23C6/M CSF stimulated THP 1 cells expressed lower levels of the Fcγ 
receptors CD16 and CD32, but slightly upregulated expression of the chemokine 
receptor CCR5. Figure 5 12 shows the expression of integrins on unstimulated 
and 23C6/M CSF stimulated THP 1 cells. THP 1 cells treated with 23C6/M CSF 
expressed  lower  levels  of  the  αV  subunit  and  the  individual  αVβ3  and  αVβ5 
heterodimers. The expression of the β1 integrin, β2 integrin, αMβ2 and αXβ2 
were roughly equivalent between the stimulated and unstimulated THP 1 cells  
Figure  5 13  shows  the  production  of  RANTES,  MIP 1β,  IL 8,  TNF α,  IFN γ,  IL 
12p40, IL 10, IL 4 and VEGF by the 23C6/M CSF treated THP 1 cultures over the 
5 day stimulation period. THP 1 cells in OptiMEM were treated for 5 days with 
23C6  and  M CSF  and  supernatant  samples  were  analysed  for  the  presence  of 
cytokines by ELISA at specific time points.The cytokines IL 12p40 and IL 4 were 
not detected in the cell supernatant at any time during the stimulation.  The  
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stimulated THP 1 cells produced high levels of RANTES, MIP 1β, IL 8, TNF α and 
VEGF  during  differentiation.  For  all  these  cytokines,  there  was  a  sustained 
proportional increase in cytokine production with the length of stimulation. The 
stimulated cultures transiently released IFN γ and IL 10. A peak in IFN γ and IL 
10 levels was observed after 24 hours, but levels were reduced to zero after 48 
hours after stimulation and did not increase later in the experiment.  
The data from the above analyses are summarised in Table 5 1, along with the 
corresponding data collected for specific types of macrophage activation. Table 
5 1 indicates the details determined for different mechanisms of macrophage 
activation, classical (M1) and alternative (M2 which can be sub divided in M2a, 
M2b and M2c). The cytokine profile and surface marker expression of 23C6/M 
CSF treated THP 1 cells did not correlate significantly with any of the specific 
macrophage  activation  mechanisms.  However,  the  upregulation  of  other 
markers,  such  as  CCR5,  and  the  production  of  cytokines,  suggests  that  the 
stimulated THP 1 cells may still be classified as activated macrophages.   
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Figure   5.6 Screen of antibodies for monocyte activation 
Antibodies known to induce cytokine production were screened for their ability to induce monocyte 
activation  in  the  presence  of  M-CSF.  Monocyte  activation  was  measured  by  morphological 
changes, including increased size and adherence. THP-1 cells were treated with 10ng/mL M-CSF 
along with A: untreated, B: LPS, C: IgG1, D: MEM48, E: 23C6, F: P1F6, G: Clone44, H: Clone3.9. 
Data are representative of at least 3 separate experiments. The response to IgG1 is included as a 
representative  example.  All  antibody  isotypes  were  tested  (IgG1,  IgG2a,  IgG2b  and  IgG3)  and 
gave responses equivalent to IgG1.   
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Figure   5.7 Integrin-mediated activation of THP-1 cells 
THP-1  cells  were  grown  for  5  days  in  Optimem medium  (A)  without  supplementation,  (B)  with 
10ng/mL M-CSF, (C) with 1µg/mL 23C6 (anti-αVβ3) antibody or (D) 10ng/mL M-CSF and 1µg/mL 
23C6  (anti-αVβ3)  antibody.  Phase  contrast  photomicrographs  (magnification  x320)  of  cell 
morphology were taken using the Zeiss Axiovert microscope. Data are representative of at least 3 
independent experiments. 
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Figure   5.8 Differentiation of bone marrow derived monocytes in response to 
treatment with 23C6 and M-CSF 
Bone marrow monocytes were stimulated with 5ng/mL M-CSF (A and B), 5ng/mL M-CSF and 23C6 
(C and D) and LPS (E and F). Pictures A, C and E are 200x magnification and B, D and F are 320x 
magnification.  Cells were fixed and stained with Giemsa stain and images captured using a Canon 
EOS300 digital camera attached to a Zeiss Axiovert S100 microscope. 
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Figure    5.9  Differentiation  of  CD14+  blood  monocytes  in  response  to 
treatment with 23C6 and M-CSF 
CD14+ peripheral blood monocytes were cultured in OptiMEM with 1% FCS (A) or OptiMEM with 
1% FCS supplemented with 10ng/mL M-CSF (B) or 23C6 1 g/mL (C) or a combination of 10ng/mL 
M-CSF  and  1 g/mL  23C6  (D).  Phase  contrast  photomicrographs  (magnification  x320)  of  cell 
morphology were taken using the Zeiss Axiovert microscope. 
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Figure   5.10 Staining of 23C6/M-CSF treated THP-1 cells for the osteoclast 
marker TRACP 
THP-1 cells were treated with 23C6 and M-CSF for 5 days before being fixed and stained for the 
osteoclast  marker, TRACP.  Images  at  different magnifications  (A  is  x200  and  B is x320)  were 
captured using a Canon EOS300 digital camera attached to a Zeiss Axiovert S100 microscope.   
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Figure   5.11 Analysis of THP-1 cells for surface markers of macrophage 
activation 
THP-1 cells were grown in OptiMEM (A) or OptiMEM supplemented with 23C6 and M-CSF for 5 
days (B) and then analysed for the expression of markers characteristic of macrophage activation 
by flow cytometry.  Isotype control staining is shown as grey shading and antibody staining as a 
black line. The antigen targeted is indicated above the individual plots. Data are representative of 
at least 3 separate experiments. 
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Figure   5.12 Analysis of expression of integrins on THP-1 cells before and 
after treatment with 23C6 and M-CSF 
THP-1 cells were grown in OptiMEM (A) or OptiMEM supplemented with 23C6 and M-CSF for 5 
days and then analysed for the expression of integrins by flow cytometry.  Isotype control staining 
is shown as grey shading and antibody staining as a black line. The antigen targeted is indicated 
above the individual plots. Data are representative of at least 3 separate experiments. 
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Figure   5.13 Cytokine production during THP-1 differentiation/activation by M-CSF and 23C6 
THP-1 cells were stimulated with M-CSF and 23C6 for 5 days. Supernatant samples were collected at intervals and assessed for the production of cytokines by 
ELISA. Data are representative of at least three independent experiments.   
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Table   5-1 Characteristics of activated macrophages (adapted from
6, 7, 16, 236) 
 
ALTERNATE (M2) 
 
 
DETAIL 
 
 
 
CLASSICAL 
(M1) 
 
 
 
M2a 
 
M2b 
 
M2c 
 
INTEGRIN 
MEDIATED 
 
Activating 
signals 
 
IFN γ 
TNF α 
 
IL 4  
glucocorticoids 
 
Immune 
complexes/ 
TLR/IL 1R 
ligands 
 
 
IL 10 
 
αVβ3 binding 
M CSF 
 
Cytokines 
secreted 
 
TNF α 
IL 12 
IL 1 
IL 6 
 
IL 1RA 
IL 10 
 
TNF α 
IL 10 
IL 6 
 
 
TGF β 
IL 10 
 
TNF α 
Transient IL10 
Transient IFN γ 
 
Growth 
factors 
   
VEGF*** 
 
VEGF*** 
 
 
VEGF*** 
 
VEGF 
 
 
Markers 
 
 
UP: 
 
MHC II 
CD86 
 
 
 
 
DOWN: 
 
Mannose 
receptor 
 
 
UP: 
 
MHC II 
Mannose 
receptor 
Scavenger 
receptor 
CD23 
 
DOWN: 
 
CD14 
CD163 
MS 1 
 
 
UP: 
 
MHC II 
CD86 
 
 
 
 
DOWN: 
 
Mannose 
receptor 
 
 
UP: 
 
SLAM 
Mannose 
receptor 
 
 
 
DOWN: 
 
CD14 
CD163 
MS 1 
 
 
 
UP 
 
CCR5 
 
UNCHANGED: 
 
CD86 
CD14 
CD23 (not 
expressed) 
HLA DR 
 
NOT 
ANALYSED: 
 
Mannose 
receptor 
Scavenger 
receptor 
CD163 
MS 1 
 
 
Killer 
molecules 
 
 
NO, O2
  
 
NONE 
 
None/*NO, 
O2
  
 
NONE 
 
NONE 
 
 
Chemokines 
 
MCP 1 
MIP 1 
IP 10 
 
AMAC 
 
**ND 
 
AMAC 
 
IL 8 
RANTES 
MIP 1β 
 
* High levels of IL 10 block radicals 
**ND   not determined  
***in the context of tumour associated macrophages (TAM)
236 238    
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5.2.4   Role of the receptors αVβ3, c-FMS and TLR-2 during 
macrophage activation 
Toll like receptors (TLRs) are immunoreceptors that play in important role in the 
innate immune response, particularly with respect to detection of pathogens. 
Binding of TLRs on macrophages can lead to their activation, either directly or 
via  TLR induced  cytokine  production.  These  TLRs  often  associate  with  other 
surface  receptors,  including  integrins,  to  achieve  these  functions.  The  LPS 
signalling  complex,  for  example,  is  composed  of  CD14,  TLR 4  and  the  CD18 
integrin. We hypothesised that the αVβ3 mediated macrophage activation and 
cytokine production involved a similar signalling complex that included TLR 2 
and the M CSF receptor c FMS. 
THP 1 cells were shown to be activated by stimulation of the αVβ3 integrin with 
the 23C6 antibody (Figure 5 1). This activation was enhanced by the presence of 
the  cytokine  M CSF.  M CSF  is  known  to  exhibit  its  effects  by  binding  to  its 
receptor, c FMS. We had previously shown that THP 1 cells express the αVβ3 
integrin and so we examined the cells for the expression of the M CSF receptor 
c FMS. Figure 5 14 shows the western blot and densitometric analysis using actin 
as a loading control of the expression of c FMS in THP 1 and U937 whole cell 
lysates. THP 1 was shown to express the c FMS receptor, as indicated by a band 
at ~170 kDa. The U937 cell lysate did not express the c FMS receptor. U937 cells 
failed to differentiate under treatment conditions similar to those causing the 
morphology changes in THP 1 cells. U937 cells did not respond with an altered 
morphology, but instead the cultures failed to survive for the 3 7 day treatment 
with 23C6 and M CSF (data not shown).  
The stimulatory effect of 23C6 and M CSF on THP 1 cells was determined to be 
dose dependent,  with  respect  to  both  23C6  concentration  and  M CSF 
concentration  (Figure  5 15).  Figure  5 15  shows  the  dose dependent 
differentiation of the THP 1 cells in response to changing concentrations of 23C6 
and a constant M CSF concentration (Ai), and to changing concentrations of M 
CSF and a fixed concentration of 23C6 (Bi). Cells were treated with the indicated 
concentrations of 23C6 and M CSF and the number of cells exhibiting the altered 
morphology  per  microscope  field  was  counted.  Three  fields  were  randomly 
selected  and  the  number  of  differentiated  cells  counted  in  duplicate  wells    
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(Figure 5 15 A and B ii). An increase in either 23C6 concentration at a fixed M 
CSF concentration (Figure 5 15A) or M CSF at a fixed 23C6 concentration (Figure 
5 15B) led to an increase in the number of differentiated cells per field and an 
increase in the degree of change of morphology.  
We  continued  to  examine  the  relationship  between  23C6  and  M CSF  in  the 
processes of cytokine production and activation of the THP 1 cells. The 23C6 
antibody was previously shown to induce high levels of cytokines in THP 1 cells, 
which  could  be  responsible  for  the  morphological  changes  and  monocyte 
differentiation phenotype. We observed a dose dependent enhancement of THP 
1  differentiation  as  measured  by  changes  in  cell  morphology  in  response  to 
suboptimal concentrations of 23C6 or M CSF by M CSF and 23C6, respectively. 
We  therefore  examined  the  effect  of  M CSF  on  23C6 mediated  cytokine 
production (Figure 5 16) and ERK phosphorylation (Figures 5 17 and 5 18).  
Figure 5 16 shows the enhancement of 23C6 mediated RANTES, IL 8 and MIP 1β 
production  stimulated  by  increasing  concentrations  of  M CSF  (Figure  5 16A,  B 
and C respectively). M CSF alone (white bars) did not induce release of RANTES, 
IL 8 or MIP 1β by THP 1 cells at any concentration tested. Cytokine production 
by THP 1 cells treated with a suboptimal level of 23C6 (when M CSF is absent) 
was  enhanced  by  the  addition  of  M CSF  (5 25ng/mL),  in  a  dose dependent 
manner (black bars). Increasing concentrations of M CSF led to an increase in the 
cytokine output for the fixed concentration of 23C6.  
The enhancement of cytokine production was associated with an enhancement 
of 23C6 mediated ERK phosphorylation by the presence of M CSF. We previously 
determined  that  23C6  induces  a  signalling  pathway  that  involves  ERK 
phosphorylation in THP 1 cells. Figures 5 17 and 5 18 show data collected to 
examine the effect of M CSF on this ERK phosphorylation.  
Figure 5 17 shows the western blot (A) and densitometry analysis (B) for the 
effect of increasing M CSF concentrations on ERK phosphorylation. THP 1 cells 
were treated with increasing concentrations of M CSF with or without 23C6 for 
30 min and lysates probed for the phosphorylation of ERK by Western blotting. 
M CSF  treatment  alone  led  to  phosphorylation  of  ERK  at  a  concentration  of 
50ng/mL, but not at the lower concentrations (0 20ng/mL). Treatment of THP 1 
cells  with  23C6  alone  at  a  concentration  of  0.5 g/mL  induced  ERK    
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phosphorylation.  This  23C6 mediated  ERK  phosphorylation  was  enhanced  by 
addition of M CSF, even at the lower concentrations of 10ng/mL and 20ng/mL, 
where M CSF alone failed to induce ERK phosphorylation.  
We analysed the kinetics of ERK phosphorylation in response to 23C6 and M CSF 
treatment  (Figure  5 18).  THP 1  cells  were  incubated  with  M CSF  alone,  23C6 
alone or a combination of 23C6 and M CSF for different time periods. Lysates 
were probed for phosphorylation of ERK by Western blot using actin as a loading 
control. Treatment of THP 1 cells with M CSF alone led to phosphorylation of 
ERK that was observed after 10 min of treatment and peaked at 60 min after 
stimulation. Treatment of THP 1 cells with 23C6 led to weak phosphorylation of 
ERK that was observed after 5 min of treatment and peaked at 60 min after 
stimulation. Treatment of THP 1 cells with 23C6 and M CSF led to a stronger 
phosphorylation of ERK that was observed after 5min of treatment and peaked at 
30 min after stimulation.  
We next examined the expression of TLR 2 on THP 1 and U937 cell lines. Both 
THP 1 and U937 expressed high levels of TLR 2 (Figure 5 19). We compared the 
morphology of the 23C6/M CSF treated THP 1 cells with THP 1 cells activated by 
a TLR 2 ligand, yeast zymosan. Figure 5 20 shows the morphology of untreated 
THP 1 cells (A and B), compared with THP 1 cells treated with zymosan (C and 
D) and 23C6/M CSF treated THP 1 cells (E and F). Untreated THP 1 cells were 
small, non adherent and rounded in culture. Zymosan and 23C6/M CSF treated 
cells  both  acquired  a  similar  morphology,  large  and  adherent,  with  spiky 
projections.  The 23C6/M CSF treatment appeared to induce larger cells with a 
greater  number  of  projections  than  zymosan treated  cells.  We  assessed  the 
ability of the TLR 2 ligand zymosan to induce cytokine production by THP 1 cells 
(Figure 5 21). Zymosan treated cells produced high levels of MIP 1β and IL 8, as 
observed with 23C6 and 23C6/M CSF treatment. This suggested that a TLR 2 
induced  response  was  consistent  with  the  activation  and  cytokine  profile 
observed for 23C6 treated THP 1 cells.  
We  had  previously  established  that  the  M CSF  receptor  was  essential  for  the 
23C6 mediated THP 1 activation, as U937 cells which did not express c FMS did 
not activate/differentiate in response to 23C6 or 23C6/M CSF treatment (data 
not shown). We attempted to identify the role of TLR 2 in cytokine production    
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using  a  blocking  antibody.  THP 1  cells  were  pre treated  with  a  neutralising 
antibody against TLR 2 or an RGDS peptide and then stimulated with the 23C6 
antibody.  Cytokines  released  into  the  supernatant  were  quantified  by  ELISA 
(Figure  5 22).  The  production  of  MIP 1β,  RANTES,  IL 8  and  VEGF  was  not 
inhibited by the pre incubation and inclusion of the RGDS peptide. The inclusion 
of  the  neutralising  TLR 2  antibody,  however,  led  to  a  statistically  significant 
reduction in the production of all four cytokines. This supported a role for TLR 2 
in the 23C6 mediated cytokine production by THP 1 cells.  
TLRs are capable of two signalling mechanisms, one dependent on the MyD88 
(myeloid differentiation factor 88) molecule and the other independent of this 
protein. TLR 2 based signalling is dependent on MyD88; no MyD88 independent 
signalling pathway has been identified for TLR 2. We therefore investigated the 
effect  of  blocking  MyD88  signalling  on  cytokine  production  by  THP 1  cells  in 
response  to  23C6  binding  (Figure  5 23).  THP 1  cells  were  incubated  with  the 
MyD88  inhibitory  peptide
239  or  control  peptide  for  24  hours  or  anti TLR 2 
antibody for 1 hour prior to stimulation with 23C6 or the TLR 2 ligand zymosan. 
Treatment of the THP 1 cells with the control peptide did not inhibit release of 
IL 8,  RANTES  or  MIP 1β  produced  in  response  to  23C6  or  zymosan  treatment 
(Figure  5 23,  black  bars).  Pre incubation  of  THP 1  cells  with  the  neutralising 
TLR 2 antibody led to a statistically significant reduction in RANTES, IL 8 and 
MIP 1β concentrations in response to stimulation with either 23C6 or zymosan 
(Figure 5 23, white bars). Treatment of THP 1 cells with the MyD88 inhibitory 
peptide caused a statistically significant reduction in the levels of IL 8 and MIP 
1β,  but  not  RANTES,  produced  in  response  to  zymosan  treatment.  MyD88 
inhibition did not affect the production of IL 8, MIP 1β or RANTES in response to 
23C6 stimulation (Figure 5 23, grey bars).  
We extended this analysis to test the effect of the anti TLR 2 antibody and the 
MyD88 peptide on the transcription of the cytokine genes. Using IL 8 as a model, 
we  investigated  the  production  of  mRNA  in  response  to  23C6 mediated 
stimulation using semi quantitative PCR. Total RNA was extracted from THP 1 
cells that had been stimulated with 23C6 or zymosan after being incubated with 
the anti TLR 2 antibody or the MyD88 inhibitory peptide. The RNA was used in 
semi quantitative RT PCR reactions for the detection of IL 8 transcripts, using 
GAPDH as an internal standard (Figure 5 24). RNA from untreated THP 1 cells did    
189 
not contain any detectable IL 8 transcript. Transcripts for IL 8 were observed in 
cells treated with the control peptide and the MyD88 inhibitory peptide, and 
stimulated  with  23C6  or  zymosan.  The  signal  for  the  IL 8  transcript  was  not 
reduced compared to the control cells treated with zymosan. Pre treatment of 
THP 1  cells  with  the  anti TLR 2  antibody  prior  to  stimulation  with  23C6  or 
zymosan led to a decrease in the expression of the IL 8 transcript relative to the 
GAPDH  signal.  These  data  were  consistent  with  the  reduction  in  cyoktine 
production by inhibition of TLR 2, but not by inhibition of MyD88, observed in 
the ELISA analysis (Figure 5 23). 
As  TLR  signalling  leads  to  activation  of  the  NFκB  transcription  factors,  we 
investigated  whether  23C6/M CSF  treatment  could  lead  to  activation  of  this 
pathway.  We  performed  gel  shift  assays  (EMSAs)  to  detect  the  presence  of 
activated transcription factors in nuclear extracts from THP 1 cells treated with 
23C6. Nuclear extracts were prepared from untreated THP 1 cells, THP 1 cells 
treated with 23C6, and THP 1 cells treated with 23C6 and anti TLR 2 antibody. 
These extracts were assessed for their ability to bind the radioactively labelled 
NFκB consensus oligonucleotide in electrophoretic mobility shift assays/EMSAs 
(Figure 5 25A). Untreated THP 1 nuclear extract did not bind the NFκB oligo. 
Nuclear extracts from THP 1 cells treated with 23C6 or 23C6 and M CSF antibody 
bound the radioactively labelled NFκB consensus oligonucleotide, as indicated by 
the presence of a low mobility band on the autoradiogram (Figure 5 25A, arrow). 
This  was  deemed  to  be  a  specific  interaction,  as  it  could  be  prevented  by 
competition  with  a  cold/unlablled  NFκB  consensus  oligonucleotide.  We  were 
unable to identify the member of the NFκB family by supershift analysis, but we 
attempted  to  analyse  the  translocation  of  p65  to  the  nucleus  using 
immunofluorescence staining and confocal microscopy (Figure 5 25B). There was 
no difference observed for the expression levels or subcellular localisation of p65 
in untreated or 23C6/M CSF treated THP 1 cells (Figure 5 25B).      
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We next examined the activation of the signalling pathway leading to activation 
of the NFκB transcription factors. The TLR mediated pathway involves signalling 
factors such as TRAF 6 and IRAK 1. We examined the expression of IRAK 1 in 
response  to  23C6,  M CSF  and  zymosan  treatment  by  confocal  microscopy. 
Untreated THP 1 cells or THP 1 cells treated with M CSF alone did not express 
detectable levels of IRAK 1. Treatment of THP 1 cells with 23C6 induced low 
levels  of  IRAK 1,  which  was  enhanced  by  the  addition  of  M CSF.  The  IRAK 1 
staining for 23C6 and M CSF was similar to that observed for the TLR 2 ligand 
zymosan, which induced a strong IRAK signal in THP 1 cells (Figure 5 26).   
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Figure   5.14 Expression of c-FMS by THP-1 and U937 cell lines 
Expression of the M-CSF receptor c-FMS in THP-1 and U937 cell lines as determined by western 
blotting. Whole cell lysates from THP-1 and U937 cells were resolved by SDS-PAGE and c-FMS 
detected by Western blotting (A) and the signal quantified by densitometry against an actin loading 
control  using  the  ImageJ  program  (B).  The  data  are  representative  of  at  least  3  independent 
experiments.  
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Figure   5.15 Integrin-mediated differentiation and activation of THP-1 is dose-
dependent 
THP-1 cells were grown for 5 days in Optimem medium (A) with M-CSF (10ng/mL) and increasing 
concentrations of 23C6 (anti-αVβ3) antibody or (B) with 23C6 (anti-αVβ3) antibody at 0.5µg/mL 
and increasing concentrations of M-CSF. Numbers in the top right corners indicate concentrations 
of  23C6  (anti-αVβ3)  antibody  in  µg/mL  (A)  or  M-CSF  in  ng/mL  (B).  (A)i  and  (B)i  show 
photomicrographs of cell morphology and (A)ii and (B)ii show the quantitation of the numbers of 
differentiated  cells  with  increasing  concentration  of  23C6  (anti-αVβ3)  antibody  and  M-CSF, 
respectively. Data shown are representative of at least three independent experiments. Statistical 
analysis was performed using Students t-test, *p<0.05. The error bars indicate standard deviations 
(SD).    
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Figure   5.16 Enhancement of 23C6-mediation cytokine production by M-CSF  
Cells were incubated with increasing concentrations of M-CSF alone (white bars) or M-CSF with a 
fixed  concentration  of  0.5µg/mL  of  23C6  (anti-αVβ3)  antibody  (black  bars)  overnight  at  37
0C. 
Cytokines released into the supernatant were quantified by ELISA. Data are representative of at 
least 3 independent experiments. Statistical analysis was performed using Students t-test, *p<0.05. 
The error bars indicate standard deviations (SD).    
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Figure    5.17  Enhancement  of  ERK  phosphorylation  by  M-CSF  for  a  given 
concentration of 23C6. 
Cells  were  incubated  with  increasing  concentrations  of  M-CSF  alone  or  M-CSF  with  a  fixed 
concentration of 0.5µg/mL of 23C6 (anti-αVβ3) antibody for 30min at 37
0C. ERK phosphorylation 
was detected by SDS-PAGE and Western blotting, with actin as a loading control. Band intensity 
was quantified by densitometry using ImageJ graphics software. Data are representative of at least 
3 independent experiments.  
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Figure   5.18 Kinetics of ERK phosphorylation in 23C6/M-CSF-treated cells 
Cells were incubated with M-CSF alone (50ng/mL), 23C6 alone (0.5µg/mL) or a combination of M-
CSF (50ng/mL) and 23C6 (0.5µg/mL) at 37
0C. Samples were collected at time points indicated and 
ERK phosphorylation was detected by SDS-PAGE and Western blotting, with actin as a loading 
control. Band intensity was quantified by densitometry using ImageJ graphics software. Data are 
representative of at least 3 independent experiments.  
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Figure   5.19 Expression of TLR-2 by THP-1 and U937 cell lines 
THP-1 and U937 cells were incubated with anti-TLR-2 antibody (black line) or isotype matched 
control (grey shading). Primary antibody binding was detected by secondary antibody conjugated 
to the fluorescent label PE. The data are representative of at least 3 independent experiments.  
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Figure   5.20 Comparison of morphologies of zymosan-treated and 23C6/M-
CSF-treated THP-1 cells 
THP-1 cells were grown for 5 days in Optimem medium (A and B) without supplementation, (C and 
D)  with  10 g/mL  Zymosan  A  (E  and  F)  with  10ng/mL  M-CSF  and  1µg/mL  23C6  (anti-αVβ3) 
antibody. Phase contrast photomicrographs (magnification x320) of cell morphology were taken 
using  the  Zeiss  Axiovert  microscope.  Data  are  representative  of  at  least  3  independent 
experiments.     
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Figure   5.21 Cytokine responses of THP-1 cells to the TLR-2 ligand, Zymosan  
THP-1 cells (1x10
6/mL) in Optimem were exposed to increasing concentrations of yeast zymosan 
A  and  incubated  overnight  at  37
0C  in  5%  CO2.  Cytokines  released  into  the  supernatant  were 
quantified by ELISA. The data are representative of at least 3 independent experiments. The error 
bars indicate standard deviations (SD). 
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Figure   5.22 Reduction in 23C6 induced cytokine levels in response to anti-
TLR-2 antibody, but not RGDS peptide 
THP-1 cells were incubated with increasing concentrations of anti-TLR-2 antibody or β3 blocking 
peptide for 30min prior to stimulation with 23C6 (anti-αVβ3) antibody (1µg/mL) overnight at 37
0C 
and  5%  CO2.  Cytokines  released  into  the  supernatant  were  quantified  by  ELISA.  Data  are 
representative  of  at  least  3  independent  experiments.  Statistical  analysis  was  performed  using 
Students t-test, *p<0.05. The error bars indicate standard deviations (SD).    
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Figure   5.23 Cytokine production in cells treated with anti-MyD88 peptide 
THP-1 cells were incubated with control peptide (black bars), anti-TLR2 antibody (white bars), anti-
MyD88 signalling peptide (grey bars) before being stimulated with zymosan or 23C6. MIP-1β (A), 
IL-8 (B) and (C) RANTES released into  the supernatant  were  detected  using ELISA. Data are 
representative  of  at  least  3  independent  experiments.  Statistical  analysis  was  performed  using 
Students t-test, *p<0.05. The error bars indicate standard deviations (SD).    
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Figure   5.24 Reduction in integrin induced IL-8 mRNA expression by blocking  
TLR-2, but not MyD88 
(A)  THP-1  cells  were  untreated  or  treated  with  either  anti-MyD88  peptide  or  TLR-2  blocking 
antibody prior to stimulation with 23C6 (anti-αVβ3) antibody or TLR-2 ligand, zymosan for 6 hours 
at 37
0C. Total RNA was Trizol extracted and used in semi-quantitative RT-PCR reactions to detect 
the presence of IL-8 and GAPDH mRNA. Densitometric analysis of bands was acheived using 
ImageJ software. The data are representative of at least 2 independent experiments.  
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Figure   5.25 Analysis of NFκB activation in 23C6-treated THP-1 cells 
(A) Nuclear extracts were prepared from untreated THP-1 cells, THP-1 cells treated overnight with 
23C6 and THP-1 cells treated overnight with 23C6 and M-SF and assessed for the activation of 
NFκB by EMSA. (B) Localisation and expression of p65 before and after 23C6 /M-CSF treatment 
was analysed by confocal microscopy. Primary anti-p65 was detected using Secondary antibody 
conjugated to FITC. DAPI was used to stain nuclei and images captured using the Zeiss LSM 510 
Microscope (magnification x320).  
 
    
203 
 
Figure   5.26 IRAK-1 expression in response to anti-αVβ3 integrin and M-CSF 
treatment 
THP-1 cells were treated with agents indicated in left panel for 3 hours at 37
0C, prior to being fixed 
with acetone/methanol and stained for the presence of IRAK-1. Primary anti-IRAK-1 was detected 
using Secondary antibody conjugated to FITC. DAPI was used to stain nuclei and images captured 
using the Zeiss LSM 510 Microscope (magnification x320).  
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5.3  Discussion 
Treatment of THP 1 cells with the αVβ3 antibody 23C6 was shown to induce high 
levels of cytokine release by these cells. We analysed further the role of the 
23C6 antibody in monocyte differentiation. We observed that 23C6 ligation led 
to  the  phosphorylation  of  the  β3  cytoplasmic  tail  and  activation  of  the  ERK 
signalling  pathway  in  THP 1  cells  during  cytokine  production.  Chemokines 
produced  by  αVβ3  ligation  with  23C6  were  capable  of  inducing  monocyte 
migration  in  vitro  and  possibly  contributed  to  23C6 mediated  monocyte 
activation. Treatment of THP 1 cells with the 23C6 antibody was enhanced by 
the addition of M CSF and led to distinct changes in cell morphology, consistent 
with  a  more  macrophage like  phenotype.  The  23C6/M CSF activation  and 
cytokine production of THP 1 cells was influenced by the presence of the M CSF 
receptor c FMS and partially inhibited by the blockage of the TLR 2 receptor 
using  an  anti TLR 2  antibody,  but  not  an  inhibitor  of  MyD88 dependent 
signalling.  
5.3.1    23C6 treatment of THP-1 cells induces signalling  
The 23C6 antibody induced the production of high levels of cytokines by THP 1 
cells. Antibodies may be defined as neutralising if they block the function of the 
antigen receptor to which they bind, or activating if they stimulate the function 
of  their  target  antigen.  We  analysed  the  signalling  events  induced  by  αVβ3 
ligation by 23C6.  
Binding of the anti αVβ3 integrin antibody 23C6 to THP 1 cells was shown to 
induce  phosphorylation  of  the  β3  cytoplasmic  domain  on  the  Tyr773  residue. 
Phosphorylation of this residue activates the integrin and is required for firm 
adhesion of αVβ3 to vitronectin 
220 222. This is considered to be an early event in 
the  adhesion  of  leukocytes  and  is  associated  with  the  activation  of  the  Rho 
signalling pathway and reorganisation of the actin cytoskeleton to form adhesive 
contacts. The phosphorylation of the β3 tail at this residue is consistent with the 
morphological  changes  associated  with  long  term  exposure  of  THP 1  cells  to 
23C6. Under these conditions, the THP 1 cells became enlarged and adhered to 
the plastic tissue culture dish. The stimulation of THP 1 cells  with 23C6 was 
conducted in a short time period (30 min), during which the cells were still in    
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suspension and had not acquired an adherent morphology. This indicated that a 
soluble ligand for αVβ3, namely the 23C6 antibody in solution, was capable of 
activating the adhesive function of the integrin. Phosphorylation of β3 on this 
site is known to activate the Rho/ROCK signalling pathway, which would account 
for the morphological changes observed 
222, although further analysis would be 
required to conclusively link 23C6 ligation with an activation of the Rho/ROCK 
pathway. However, these data suggest that the effects of ligation of αVβ3 are 
due to direct signalling via this integrin, as opposed to indirect activation of 
other signalling pathways (i.e. where neutralisation of αVβ3 allows signalling via 
an alternative pathway to proceed). 
Ligation of αVβ3 by the 23C6 antibody in THP 1 cells led to the activation of the 
MAPK pathway and ERK phosphorylation. An increase in ERK phophorylation was 
observed with increasing concentrations of 23C6 and with increased length of 
stimulation.  Cytokine  production  by  THP 1  cells  in  response  to  23C6  binding 
required  ERK  phosphorylation,  as  treatment  of  cells  with  the  MEK  inhibitor 
U0126  reduced  cytokine  production  in  response  to  stimulation  with  this 
antibody.  Cytokines  also  induce  activation  of  MAPK  pathways  via  interactions 
with  their  receptors  on  cells,  although,  the  ERK  phosphorylation  assays  were 
conducted over a 30 time period, prior to any detectable cytokine release in the 
supernatant. This indicated that the ERK phosphorylation observed was not a 
result  of  cytokine  activation  of  THP 1  cells  but  rather  due  to direct  integrin 
ligation by 23C6.  
Integrin mediated  activation  of  ERK  can  occur  by  activation  of  the 
Ras/Raf/MEK/ERK  pathway.  This  pathway  can  be  activated  either  by  FAK 
dependent activation of SFKs in focal adhesions or by activation of Grb2 and Sos 
directly  by  SFK,  such  as  Fyn  and  Shc.  Both  pathways  are  involved  in  the 
activation of genes controlling cell differentiation and cytokine production and 
are  linked  to  the  integrin mediated  phosphorylation  of  focal  adhesion  kinase 
(FAK). We attempted to detect FAK phosphorylation in the 23C6 stimulated THP 
1  cells.  Although  we  were  unable  to  identify  any  phosphorylated  FAK  upon 
treatment of THP 1 cells with the 23C6 antibody, it is possible that activation of 
FAK did occur upon αVβ3 ligation with 23C6 and that the levels of FAK were 
below  our  detection  limits,  due  to  low  expression  levels  in  suspension  cells 
which lack focal adhesions. Phosphorylated FAK can also activate Src which can    
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activate  p190RhoGAP  and  inactivates  its  GAP  function.  P190RhoGAP  catalyses 
the conversion of active RhoGTP to inactive RhoGDP and thus its inactivation 
could lead to an increase in active RhoGTP pools. This RhoGTP activates ROCK, 
which  subsequently  leads  to  reorganisation  of  the  cytoskeleton,  integrin 
clustering  and  adhesion.  This  mechanism  would  explain  the  signalling  events 
from β3 phosphorylation by the binding of 23C6 to the activation of the ERK 
pathway in THP 1 cells.  
Other  pathways,  such  as  the  JNK,  p38  MAPK  and  PI3K  pathways  have  been 
implicated in cytokine production by integrin ligation 
240 244. We are currently 
analysing the potential role of these pathways in the signalling from the αVβ3 
integrin in this system. Preliminary investigations suggest that signalling via the 
PI3K  pathway  is  not  as  important  during  integrin mediated  production  of 
cytokines by THP 1 cells, as we have been unable to detect phosphorylated Akt 
in  response  to  23C6  treatment  of  THP 1  cells  or  to  inhibit  23C6 mediated 
cytokine production by THP 1 cells using an inhibitor of PI3K (data not shown). 
Further analysis of these signalling events is underway.  
5.3.2    The role of αVβ3-induced cytokines in monocyte 
migration 
Treatment of THP 1 cells with 23C6 led to the production of a range of cytokines 
(as detailed in the previous chapters). A number of these cytokines, including IL 
8,  RANTES  and  MIP 1β,  are  chemotatic  cytokines  known  as  chemokines.  
Chemokines are cytokines capable of influencing the migration of immune cells 
and are  used  in  the body  to  recruit  cells  to  specific  sites at  which  they are 
required.  This  suggested  a  possible  role  for  αVβ3 induced  cytokines  in  the 
regulation of migration of immune cells. However, different chemokine isoforms, 
concentrations  and  combinations  will  have  different  chemotactic  abilities. 
Therefore,  it  was  necessary  to  analyse  the  chemotactic  ability  of  23C6 
stimulated THP 1 supernatants and not to merely assume that the presence of a 
specific  chemokine  equates  to  a  high  chemotactic  effect.  The  ability  of 
supernatants  from  23C6 treated  THP 1  cells  to  influence  the  migration  of 
virgin/unstimulated cells was analysed in vitro using transwell migration assays. 
Cleared supernatants from THP 1 cells stimulated with 23C6 were capable of 
inducing the migration of unstimulated THP 1 monocytic cells, Jurkat T cells and    
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IB4 B cells.  Chemokines are known to activate integrins to lead to adhesion and 
extravasation. Therefore, it is possible that the soluble signalling via the αVβ3 
integrin induces the production of chemokines which are subsequently capable 
of  activating  the  adhesive  functions  of  other  integrins,  as  indicated  by  an 
increase in the migration of THP 1 cells across FCS or VN coated membranes 
transwells, as opposed to BSA coated membranes. The increased migration of 
THP 1 cells on vitronectin to 23C6 treated supernatant suggests activation of the 
adhesive  functions  of  αV  integrins.  The  use  of neutralising  antibodies  against 
different chemokines should have been included in the analysis. This would have 
allowed identification of the chemokine responsible for mediating cell migration 
under these conditions.  
The  ability  of  chemokines  produced  by  αVβ3  ligation  to  induce  migration  of 
immune cells may be important in vivo in physiological immune system function 
during infections and pathological states in which inflammation and infiltration 
of immune cells contributes to the pathology of inflammatory diseases, such as 
rheumatoid arthritis and certain cancers.  
5.3.3    The role of αVβ3 and c-FMS during monocyte 
differentiation/ activation 
CD23  stimulation  of  monocytic  cells  leads  to  the  production  of  cytokines  in 
response to interaction with its integrin receptors (αVβ3, αVβ5, αMβ2 and αXβ2). 
Acute stimulation (< 24 hours) with antibodies against these integrins can mimick 
the effect of CD23 and induce cytokine production in monocytic cells (Chapter 4) 
40,  41,  84. CD23 is also known to induce monocyte activation via its interactions 
with the β2 integrins, αMβ2 and αXβ2 
74, 193. The ability of selected anti integrin 
antibodies in conjunction with M CSF to induce monocyte activation was tested 
over a 5 day assay period (chronic stimulation).  
Long term exposure of THP 1 to the anti β2 antibodies, Clone44 and Clone3.9, 
led to changes in the THP 1 morphology to a more macrophage like phenotype. 
The  cells,  originally  small,  rounded  and  in  suspension,  became  enlarged  and 
adherent with a number of spiky processes/extensions. A similar morphology was 
observed with LPS treated THP 1 cells. CD23 is known to stimulate monocyte 
activation  via  an  interaction  with  the  β2  integrins,  αMβ2  and  αXβ2 
74,  193.    
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Therefore the morphological changes associated with treatment of THP 1 cells 
with the anti β2 antibodies (and LPS) may have mimicked the effects of CD23 
and led to activation of the THP 1 cells. LPS also binds to β2 integrins, as part of 
the LPS signalling complex 
143, 245, 246.  
Treatment  of  THP 1  cells  with  the  23C6  antibody  led  to  similar  distinct 
morphological  changes  to  those  observed  with  anti αXβ2,  anti αMβ2  and  LPS 
treatment. However, the changes in the morphology of 23C6 treated cells were 
more pronounced than those observed with either LPS stimulation or treatment 
with the anti β2 heterodimer antibodies. The 23C6 treated cells were larger and 
had a greater number and degree of cytoplasmic extensions than THP 1 cells 
treated with LPS, Clone3.9 or Clone44. Indeed, 23C6 alone (without M CSF) was 
sufficient to induce the morphological changes in THP 1 cultures, while M CSF 
was required for LPS and β2 mediated activation of THP 1 cells. It is possible 
that the cytokines produced in response to integrin ligation contributed to the 
development  of  the  activated  phenotype,  especially  considering  THP 1  cells 
express at least some of the receptors for those cytokines (i.e., CCR5 and IFNγR) 
and that cytokine production preceded monocyte activation. However, it seems 
likely that there are other events controlling these morphological changes in the 
monocytic cells, as antibodies that induced a similar cytokine release profile did 
not induce the same level of monocyte activation. For example, the 23C6 and 
Clone3.9 antibodies induced the release of high levels of cytokines by THP 1 
cells, but the 23C6 treated THP 1 cells acquired a more severe phenotype than 
the Clone3.9 treated cells. These morphological changes were associated with 
the continued synthesis of cytokines (TNF α) and chemokines (IL 8, RANTES and 
MIP 1β), which indicated that the cells continued to be viable during the 5 day 
period. 
There are few reports in the literature of the role of the αVβ3 integrin in the 
activation of monocytic/macrophage cells. The αVβ3 integrin is important in the 
development of osteoclasts, terminally differentiated bone resorbing cells that 
arise  from  macrophages.  Osteoclasts  upregulate  αVβ3  as  they  develop  from 
macrophages  under  the  influence  of  M CSF  and  receptor  activator  for  NFκB 
ligand (RANKL). Osteoclast can be identified as large, adherent, multinuclear 
cells  that  express  high  levels  of  the  osteoclast  marker,  TRACP.  The 
morphological  changes  observed  with  23C6 treatment  of  THP 1  cells  were    
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consistent with the development of osteoclasts (a number of cells with multiple 
nuclei  were  also  observed  in  the  THP 1  cells  stained  with  Giemsa  stain). 
However, 23C6 treated THP 1 cells were consistently negative for the osteoclast 
marker TRACP and, as opposed to upregulating αVβ3 as would be expected for 
developing  osteoclasts,  the  cells  appeared  to  downregulate  this  heterodimer 
during  the  5  day  assay  period.  However,  TRACP  staining  can  be  technically 
difficult  and  in  the  absence  of  a  positive  control  it  is  not  possible  to  state 
conclusively that the cells are not osteoclasts. Measurement of the levels of IL 6 
and TGF β produced by these cells would also have aided in their identification.   
An  alternative  hypothesis  was  that  these  morphological  changes  were  an 
indication  of  the  activation  of  the  THP 1  cells  into  an  activated  macrophage 
phenotype  in  response  to  23C6/M CSF  treatment.  Monocyte/macrophage 
activation  can  occur  via  a  number  of  mechanisms,  each  of  which  leads  to  a 
macrophage of a particular function and phenotype. These macrophages can be 
identified by the surface markers they express and their characteristic cytokine 
profiles.  We  analysed  the  expression  of  specific  surface  markers  and  the 
cytokine production profiles of 23C6/M CSF treated THP 1 cells, to identify the 
nature  of  this  23C6 mediated  activation  of  THP 1  cells  with  reference  to 
published  markers  of  macrophage  activation
7,  8,  247,  248.  Table  5 1  shows  a 
summary of the cytokine profile and surface marker expression of THP 1 cells 
treated  with  23C6  and  M CSF,  compared  with  characteristics  of  specific 
populations  of  activated  macrophages.  The  expression  of  selected  surface 
markers on THP 1 cells did not correlate with the surface marker profile for a 
particular type of macrophage activation.  
Specific  cytokine  profiles  are  also  associated  with  macrophage  activation 
mechanisms. Classical activation of macrophages (M1) is induced by treatment 
with IFN γ and TNF α and is characterised by the production of pro inflammatory 
cytokines such as TNF α and IL 12. Alternative activation of macrophages (M2) is 
characterised by the production of high levels of IL 10 and not IL 12 or TNF α in 
response  to  exposure  to  stimuli  such  as  IL 4,  IL 10  and  glucocorticoids.  M2 
macrophages can be further sub divided into M2a, M2b and M2c sub populations 
of alternatively activated macrophages (Table 5 1). M2a and M2c are similar in 
that they both produce high levels of anti inflammatory agents, such as IL 10 
and IL 1RA. M2b macrophages are a distinct population that develop in response    
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to exposure to immune complexes and to TLR ligation, and produce TNF α in 
conjunction with high levels of IL 10 and low levels of IL 12.  
THP 1  cells  treated  with  23C6  and  M CSF  for  5  days  produced  a  range  of 
cytokines.  High  levels  of  TNF α,  RANTES,  IL 8,  MIP 1β  and  VEGF  were 
continuously  released  during  the  5  day  assay  period.  There  was  a  transient 
release of IFN γ and IL 10 detected after 24 hours, which had declined to zero 
after 48 hours. It is possible that this decline to zero was a result of autocrine 
uptake of these cytokines by the stimulated THP 1 cells. THP 1 cells express the 
receptor  for  IFN γ  (data  not  shown).  Other  authors  have  reported  some 
morphological changes in THP 1 cells after treatment with IFN γ and M CSF 
249. It 
is also possible that release of IFN γ and IL 10 was inhibited after 24 hours due 
to changes associated with the activation of THP 1 cells by 23C6 and M CSF. No 
IL 4 or IL 12p40 was detected at any time during the 5 day assay.  
The  cytokine  profiles,  similar  to  the  cell  surface  markers,  did  not  correlate 
absolutely with a specific mechanism of macrophage activation.  The cytokines 
produced in response to 23C6/M CSF may provide autocrine activating signals for 
the cells or may be the consequence of a specific programme of macrophage 
activation.  
It seems unlikely that the 23C6/M CSF treated THP 1 cells had undergone an M2a 
or  M2c  programme  of  alternative  macrophage  activation.  The  lack  of  IL 4 
production, the transient IL 10 production and the levels of TNF α produced by 
23C6/M CSF treated  THP 1  cells  suggested  that  these  are  not  M2a  or  M2c 
alternatively  activated  macrophages.  Similarly,  although  the  23C6/M CSF 
treated THP 1 cells produced IFN γ (albeit transiently) and TNF α, there was no 
production of IL 12, reactive nitrogen species (RNS) or reactive oxygen species 
(ROS)  as  would  be  expected  of  a  classically  activated  macrophage  (M1) 
population.  
Based on the data, it was hypothesised that the 23C6/M CSF activated THP 1 
cells  were  most  similar  in  their  profile  to  M2b  activated  macrophages.    The 
levels of TNFα, lack of production of ROS and RNS, transient IL 10 production 
and  lack  of  IL 12  production  suggested  this  was  the  most  likely  macrophage 
activation phenotype for the 23C6/M CSF treated THP 1 cells. These data were 
supported  by  the  fact  that  M2b  macrophage  activation  is  induced  by  IgG    
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complexes and TLR ligands. It is possible that 23C6 antibody binding involved a 
TLR receptor (discussed later). In addition, the production of VEGF and IL 8 by 
the  23C6/M CSF treated  THP 1  cells  is  also  observed  with  tumour associated 
macrophages (TAM), which are defined as an M2 macrophage population. TAM 
are a major component of many tumours and are proposed to actively contribute 
to the development, survival and metastasis of cancers.  
Further analysis will be required to conclusively identify if these cells are indeed 
an activated macrophage population and that αVβ3 ligation in conjunction with 
M CSF  leads  to  macrophage  activation.  The  data  herein  have  tentatively 
identified  23C6/M CSF differentiated  THP 1  cells  as  most  similar  to  M2b 
macrophages. However, macrophages are a highly heterogenous population and 
it is plausible that not all the mechanisms leading to their activation have been 
described  and  that  integrin mediated  activation  represents  a  new  type  of 
macrophage activation mechanism. Similarly, it is equally possible that these in 
vitro experiments are lacking specific (unknown) factors that would result in the 
development of surface markers and cytokine profiles for 23C6/M CSF treated 
THP 1 cells identical to a specific type of activated macrophage. It may also be 
that  these  23C6/M CSF treated  THP 1  cells  are  arrested  at  a  particular 
developmental point (such as a pre osteoclast or osteoclast like cell that has yet 
to  express  the  TRACP  osteoclast  marker)  and  therefore,  would  differentiate 
further given the correct in vivo or in vitro environment. This, however, does 
not  take  away  from  the  fact  that  ligation  of  the  αVβ3  integrin  by  the  23C6 
antibody in the presence or absence of the myeloid growth factor M CSF has a 
profound effect on the morphology and activity of THP 1 cells. 
5.3.4    Role of TLR-2 and c-FMS during αVβ3-mediated 
cytokine production by THP-1 cells 
Chronic  stimulation of  THP 1  cells  with the  anti αVβ3  antibody,  23C6,  led  to 
morphological changes within the THP 1 cells. This 23C6 mediated activation in 
THP 1 cells was enhanced by simultaneous addition of M CSF. This was reflected 
in the increased degree of the morphological changes induced by the presence of 
M CSF. In addition, 23C6 mediated signalling via the MAPK pathway and cytokine 
production by THP 1 cells was enhanced by the addition of M CSF.  Treatment of 
THP 1 cells with 23C6 alone did not induce the expression of M CSF mRNA as    
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measured by semi quantitative RT PCR (data not shown). This enhancement of 
ERK phosphorylation and cytokine production by the combination of suboptimal 
concentrations of 23C6 and M CSF suggests a synergistic relationship between 
the αVβ3 integrin and the M CSF receptor c FMS. 
The  importance  of  the  c FMS  receptor  (even  in  the  absence  of  exogenously 
supplied  M CSF)  was  revealed  by  the  fact  that  U937  cells,  which  express 
equivalent levels of the αVβ3 integrin to THP 1 cells but do not express c FMS, 
failed to differentiate in response to 23C6 or 23C6/M CSF treatment.  The αVβ3 
integrin  and  c FMS  receptors  have  been  shown  to  associate  with  each  other 
during osteoclast development from macrophages. It is possible that αVβ3 and c 
FMS  also  associate  during  other  macrophage  differentiation  events,  such  as 
macrophage activation.  
The authors who identified the interaction between αVβ3 and c FMS proposed 
that  the  αVβ3/c FMS  association  is  part  of  a  larger  signalling  complex  which 
includes  other,  as  yet  unidentified,  receptors.  Data  presented  herein  suggest 
that the 23C6/M CSF treated THP 1 cells acquired a phenotype most similar to 
M2b  activated  macrophages.  The  mechanism  of  activation  of  M2b  activated 
macrophage  involves  binding  of  TLR  ligands  (Table  5 1).  Thus,  it  was 
hypothesised that one of the unidentified receptors in the αVβ3/c FMS signalling 
complex was one of the TLR family of receptors. The LPS signalling complex is 
comprised  of  a  similar  group  of  receptors.  This  complex  contains  the  LPS 
receptor, CD14, the αXβ2 integrin and the TLR 4 isoform. β2 integrins contain 
binding  sites  for  LPS.  Therefore,  given  the  existence  of  this  complex,  it  is 
plausible to suggest the existence of other integrin/TLR complexes. 
Zymosan, a yeast derived ligand for TLR 2, also binds β2 integrins. Treatment of 
THP 1 cells with zymosan induced the production of similar cytokines to those 
observed with 23C6/M CSF treatment of THP 1 cells. We observed similarities 
between the morphology of 23C6/M CSF treated cells and THP 1 cells treated 
with the TLR 2 ligand, zymosan, which led us to hypothesise that TLR 2 might be 
involved. A neutralising antibody against TLR 2 reduced the levels of 23C6/M 
CSF induced  RANTES,  IL 8,  MIP 1β  and  VEGF  to  approximately  half  of  those 
observed in the absence of the TLR 2 antibody, although the anti TLR 2 antibody 
did not completely abolish cytokine production. Production of RANTES, IL 8 and    
213 
MIP 1β by THP 1 cells in response to 23C6/M CSF treatment was inhibited by 
treatment of the cells with anti TLR 2 but was not inhibited by the inclusion of 
an  inhibitor  of  MyD88 based  signalling.  This  was  unexpected,  as  all  TLR 2 
signalling pathways described to date are dependent on the MyD88 molecule. 
The production of IL 8 and MIP 1β by THP 1 cells in response to zymosan was 
inhibited by the anti TLR 2 antibody and by the inhibitor of MyD88 signalling 
(albeit to a lesser extent than the inhibition observed with the antibody). The 
levels of IL 8 mRNA detected in THP 1 cells treated with 23C6/M CSF or zymosan 
were not inhibited by the MyD88 inhibitor but were inhibted by the anti TLR 2 
antibody.  
Treatment of THP 1 cells with 23C6 or 23C6/M CSF led to the activation of NFκB 
transcription factor, as indicated by EMSA analysis. We were unable to detect a 
supershift using an anti p65 antibody and also failed to observe translocation of 
p65 to the nucleus after 23C6/M CSF treatment. Therefore, it was not possible 
to identify the individual NFκB protein involved in the analysis, although it was 
unlikely to be p65. We were able to detect increases in the levels of the TLR 
signalling molecule IRAK 1 in the cytoplasm of 23C6, 23C6/M CSF and zymosan 
treated THP 1 cells compared with M CSF treated or untreated THP 1 cells. 
The data described above suggest that cytokine production by THP 1 cells in 
response to 23C6 and M CSF treatment was reduced by binding of the exterior of 
the  TLR 2  receptor  but  not  by  blocking  the  MyD88  molecule  at  the  top 
(upstream) of the cytoplasmic TLR 2 signalling pathway. This may be due to the 
antibody  blocking  an  association  between  αVβ3,  c FMS  and  TLR 2.  However, 
increases in the expression of the IRAK 1 protein downstream of MyD88 in this 
pathway and activation of NFκB transcription factors were observed in 23C6/M 
CSF and zymosan treated cells, suggesting that signalling was proceeding via the 
TLR 2 pathway, despite the lack of dependence on MyD88.  
Taken together, these data might suggest the possibility of a MyD88 independent 
pathway from TLR 2, which may function together with the MyD88 dependent 
pathway. In some cases, blockage of MyD88 appeared to increase the levels of 
cytokines  produced,  although  these  were  not  quantified  and  therefore  no 
comment can be made on their significance.  There have been reports of cross 
talk between the FAK (integrin mediated) and MyD88 (TLR mediated) pathways.    
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The mechanism is poorly understood at present, but it has been suggested that 
FAK can mediate the phosphorylation dependent activation of MyD88 and other 
TLR signalling intermediates 
133. It may be that integrin dependent activation of 
TLR signalling intermediates (such as TIRAP/Mal) exist, although this still needs 
to be determined 
129.  
Alternatively,  it  could  be  hypothesised  that  TLR 2  plays  a  minor  role  in  this 
complex  and  is  important  in  external  recognition  and  not  internal  signalling. 
Thus, the inclusion of TLR 2 in this complex may activate a signalling pathway 
other than that originating from TLR 2 itself, leading to the activation of similar 
transcription  factors (NFκB).  In  this  case, the  signalling  events  may  originate 
from the αVβ3 and c FMS receptors and therefore could be modulated by the 
external  complex  which  contains  TLR 2  but  would  be  independent  of  MyD88 
signalling.  A  recent  study  suggested  that  the  αMβ2  integrin  was  capable  of 
signalling via the TLR pathway, by hijacking the signalling intermediates IRAK 
and TRAF, in a MyD88 independent process 
250. TLR 2 has also been shown to act 
as a scaffold for other signalling complexes. It is unfortunate that there are no 
data available from this analysis on the effect of the anti TLR 2 antibody on the 
activation of NFκB transcription factors or the levels of IRAK 1 in THP 1 cells 
treated  with  23C6  and  M CSF.  Further  analysis  is  underway  to  confirm  the 
existence  of  and  to  investigate  this  potential  complex,  including 
immunoprecipitaion and co localisation studies on these three receptors.  
The  reduction  in  cytokine  production  due  to  the  blockage  of  TLR 2  was  not 
associated  with  a  complete  change  in  the  cell  morphology  in  response  to 
23C6/M CSF treatment. The 23C6/M CSF treated cells still displayed a degree of 
change  in  morphology  associated  with  23C6  stimulation  (data  not  shown), 
although  these  experiments  need  to  be  repeated  to  confirm  the  accuracy  of 
these data. This suggests that the pathways leading to cytokine production and 
macrophage  activation  are  distinct,  although  they  may  be  overlapping,  as 
indicated by synergy in cytokine production and differentiation phenotype upon 
addition of M CSF. This is supported by the fact that antibodies that induce high 
levels  of  cytokine  production  do  not  necessarily  induce  the  morphological 
changes in the THP 1 cells.     
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The data presented in this chapter suggest that the αVβ3 integrin may have an 
important role in the function of monocytic cells in the immune systems, both by 
regulating  the  production  of  inflammatory  species  such  as  cytokines  and 
chemokines  which  may  affect  other  cells  in  the  body  but  also  by  directly 
influencing the biology of the monocyte itself.  
216 
 
 
 
 
 
 
 
6  DISCUSSION 217 
217 
6.1  CD23-Integrin Interaction 
CD23 interacts with four integrins, αVβ3, αVβ5, αMβ2 and αXβ2. The data in this 
thesis  describe  the  analysis  of  the  in  vitro  interaction  between  CD23/CD23 
derived  peptides  and  the  αV  integrins,  αVβ3  and  αVβ5.  We  mapped  the 
recognition  site  in  CD23  for  αVβ3  and  αVβ5  to  a  set  of  peptides  which  all 
contained a common tripeptide motif RKC 
75. The classical recognition site for 
integrins is the RGD motif, which mediates adhesive reactions and is bound at 
the interface of the α and β integrin subunits 
101. The interaction between the 
integrin and RKC containing peptides was determined to be cation independent, 
salt sensitive  and  occurred  even  in  the  presence  of  RGD containing  integrin 
ligands. In addition, the RKC peptide is basic in nature whereas the RGD binding 
site of integrins mediates binding of acidic motifs. These combined features of 
the  CD23 integrin  interaction  suggest  that  the  binding  site  for  the  RKC 
containing peptides on the integrin is not the RGD binding site. While the RGD 
sequence is a highly conserved recognition sequence, it is plausible to propose 
the existence of alternative sites on integrins for other ligands. This suggests 
that  the  RKC  motif  is  a  novel  motif  for  integrins  and  that  it  binds  to  an 
alternative  site  to  the  binding  of  RGD.  This  alternative  site  may  be  more 
important  in  non adhesion  based,  integrin  signalling  in  response  to  soluble 
ligands.  
Integrins are important receptors in adhesion reactions, but they also participate 
in complexes that could be considered “non adhesive” signalling. There is now a 
growing body of evidence suggesting an alternative site for the binding of non 
RGD based, soluble ligands in integrins, such as that observed between CD23 
derived  peptides  and  the  αV  integrins.  These  data  support  the  findings  of  a 
number of studies that have proposed the existence of an alternative site on 
integrins for ligand recognition. In all of these cases, the interaction is between 
a soluble ligand and occurs at a site distinct from the RGD binding site 
75, 109, 114, 
115.  
The potential existence of an alternative integrin recognition site for soluble 
ligands will be important for the design of anti integrin based drugs, especially 
since most drugs will be in solution in vivo. The majority of studies on integrins 
have  been  performed  in  adherent  cells,  although  there  is  now  a  growing 218 
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appreciation of the participation of integrins in alternative modes of signalling. 
Most studies on the biological roles of integrins have been performed in adherent 
cell types. It is possible that the conclusions based on studies in adherent cells 
are  not  applicable  to  integrin mediated  signalling  in  suspension  cells.  The 
possibility of an alternative mode of signalling is particularly interesting in the 
context of haematopoietic cells, including monocytes, which are non adherent, 
suspension cells, but nonetheless express a wide range of integrins and are the 
precursors  of  a  number  of  adherent,  terminally  differentiated  cells,  such  as 
macrophages and osteoclasts. Monocytes, therefore, are a model for the study of 
integrin based signalling in soluble and adherent situations. Chronic treatment 
of THP 1 cells with the anti αVβ3 antibody 23C6 in solution led to a change in 
morphology of the model cell line THP 1. The untreated THP 1 cells were small 
and  rounded  cells  in  suspension,  which  became  enlarged  and  adherent  after 
treatment with a soluble ligand, 23C6. This indicated that a soluble stimulus 
resulted in the activation of signalling pathways related to adhesion or that the 
pathways that have been previously described relating to adhesion are actually 
not exclusively reserved for adhesion based signalling. This further supports the 
suggestion that integrins participate in two different modes of signalling, and 
that it may or may not be possible to completely separate the adhesive and non 
adhesive based functions of integrins.  
6.2 A potential Integrin/Growth Factor Receptor/ 
TLR Complex 
Integrins are well known modulators of signalling from other receptors, often 
being  components  of  larger  signalling  complexes,  such  as  the  endotoxin 
signalling complex that is comprised of TLR 4/β2/CD14. We hypothesise that the 
αVβ3 integrin may form a similar complex with the M CSF receptor, c FMS, and 
TLR 2  and  that  this  is  one  example  of  a  range  of  complexes  that  involve 
integrins, TLRs and growth factor receptors. 
Macrophages activate in response to the presence of pathogens, often through 
the binding of TLRs. TLRs are a group of evolutionarily conserved receptors that 
form an important part of the innate immune response via their recognition of 
conserved  pathogen  associated  molecular  patterns  (PAMPs).  A  number  of 219 
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pathogens that interact with TLRs, have also been shown to bind integrins as 
receptors  for  entry  into  the  cell  (Table  6 1).  Many  pathogen  receptors 
incorporate an RGD sequence which they use to interact with integrins, although 
a number of pathogens also gain entry to cells by interactions with integrins that 
do  not  involve an  RGD  (or  related)  sequence and cannot  be  blocked by  RGD 
containing ligands 
251 255. In this manner, these RGD independent reactions with 
the  integrins  could  be  considered  similar  to  the  nature  of  the  interaction 
observed  with  the  interaction  between  CD23/CD23 derived  peptides  and  the 
integrins in vitro.  
Therefore, the existence of a pathogen response complex including a TLR and an 
integrin, along with additional macrophage activation receptors such as c FMS, 
would  couple  the  innate  sensing  mechanism  (TLRs)  with  a  mechanism  for 
inducing activation of  the cell  and cytokine  production  (integrins  and  growth 
factor  receptors).  Indeed,  such  a  complex  exists  for  endotoxin  sensing.  This 
complex is composed of the LPS receptor, CD14, TLR 4 and β2 integrins and in 
this case LPS contains binding sites for β2 integrins, TLR 4 and CD14 (Figure 6 1). 
It is possible that the formation of this complex is one example of a group of 
similar complexes which associate in response to different stimuli. Just as there 
are  known  specific  pairings  between  different  TLRs,  it  may  be  that  specific 
integrins form partnerships with particular TLRs and GFRs. Indeed, both LPS and 
zymosan have the ability to bind both integrins and TLRs 
256, 257.   
Our  signalling  data  suggested  that  pathways  activated  by  our  proposed 
αVβ3/TLR 2/c FMS complex during cytokine production are MyD88 independent.  
This indicates that in this case, the signalling is mediated not by the TLR 2 but 
rather  by  the  integrin  or  indeed  by  integrin mediated  enhancement  of c FMS 
signalling. Therefore, both the integrin and the TLR are accessory proteins that 
provide  the  mechanism  to  sense  and  enhance  the  response  to  a  potential 
pathogen. The most likely candidate for controlling the signalling pathways that 
connect ERK phosphorylation (from c FMS and/or αVβ3) to NFκB (from the TLR 
based signalling) is FAK, although this still needs to be determined conclusively. 
In certain cases, integrin signalling pathways have resulted in the activation of 
intermediates of other signalling pathways, including TLR pathways. This may 
represent a novel mechanism for integrin mediated synergy with other existing 
cellular signalling pathways, which will become clear as investigations continue.  220 
220 
 
Table   6-1 Pathogens that bind TLRs and Integrins  
 
Pathogen 
 
TLR 
 
Integrin 
 
Reference 
 
 
Adenovirus 
 
 
TLR 9 
 
 
 
αVβ3** 
αVβ5 
 
 
 
258 261 
 
 
Coxackievirus A9 
 
 
 
 
ND 
 
 
αVβ3* 
 
 
253, 262 
 
 
HIV 
 
 
TLR 7/8 (ssRNA) 
TLR 4 
 
 
 
αVβ3* 
 
263 266 
 
 
Hantavirus 
 
 
 
ND 
(potentially 3, 7, 9) 
 
 
αVβ3 
αIIbβ3 
 
 
252 
 
 
Rotavirus 
 
 
 
 
ND 
 
 
αVβ3* 
 
 
254 
 
 
Candida albicans 
 
 
 
 
TLR 2 
TLR 4 
 
 
αVβ3 
β2 
 
 
 
267 272 
 
 
Bacterial LPS 
 
 
 
 
TLR 4 
 
 
β2 
 
 
143, 273, 274 
 
 
Fungal Zymosan 
 
 
 
 
TLR 2 
 
 
β2 
 
 
256, 275, 276 
 
*Entry is RGD dependent 
** RGD dependent and RGD independent strains identified 
ND not determined 221 
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Figure   6-1 Potential Integrin/TLR/GFR receptor signalling complexes 
(A) Proposed TLR, integrin and growth factor complexes involved in the control of innate immune 
responses. (B) Examples of specific integrin/TLR/GFR complexes with defined functions, such as 
the endotoxin signaling complex containing CD14/TLR-4 and β2 integrin and the complex of TLR-
2/αVβ3/c-FMS proposed by this study. (C) Potential signalling pathways from the TLR/integrin/GFR 
complexes, connected by FAK.  222 
222 
6.3  Integrin-mediated cytokine production and the 
Immune System 
The  role  of  soluble  CD23  in  the  production  of  cytokines  by  monocytic  cells 
through interactions with the integrins aVβ3, αMβ2 and αXβ2 is well established. 
This study included the first analysis of the role  of the newly defined CD23 
binding integrin receptor, αVβ5 on monocytic cells. The data conclude that αVβ5 
is similar to the other integrin receptors for CD23 and is also involved in the 
regulation of production of cytokines by monocytic cells. Taken together, the 
data indicate that both the αV and β2 families of CD23 binding integrins control 
the production of the same types of cytokines in response to specific ligation. It 
therefore appears that there is no relative hierarchy between the different CD23 
binding integrins during cytokine production. It may be that the response of a 
particular cell to CD23 treatment will therefore be controlled by the relative 
expression levels of the different integrins. This hypothesis could be addressed 
by evaluating the cytokine responses of cells with targeted depletion of specific 
integrin isoforms using techniques such as RNAi.  
6.3.1    Induction of cytokine production is specific 
Although no hierarchy between the different integrin families was observed, it 
was determined that cytokine production was specific with respect to the site on 
the individual integrin subunit. Only those antibodies that recognised a specific 
epitope were effective at inducing cytokine production. This again highlights the 
importance  of  specific,  distinct  epitopes  during  the  regulation  of  integrin 
interactions and function. For example, ligation of the αVβ3 integrin with the 
23C6 antibody led to the release of high levels of cytokines, whereas ligation of 
the same integrin with the LM609 antibody did not induce cytokine production. 
Both  23C6  and  LM609  inhibit  adhesion dependent  reactions  of  αVβ3,  but  the 
antibodies recognise different sites on the integrin. Integrins are associated with 
a  range  of  different  diseases,  ranging  from  inflammatory  diseases  to  certain 
cancers. The specificity of the different integrin recognition sites is especially 
relevant in the case where integrins are targeted as therapies for diseases 
195, 277, 
278.  223 
223 
Table   6-2 Cytokine levels detected in serum during human diseases 
 
Disease 
 
Chemokine and Concentration Range 
(pg/mL) 
 
Ref 
 
Normal/control levels 
 
IL 8 
MIP 1β 
RANTES 
TNF α 
IL 10 
VEGF 
 
16.0  
60  
7900  
1 12  
44  
170  
 
279 
 
280 
 
 
Infectious disease 
 
Toxoplasmic retinochoroiditis 
(with vasculitis) 
 
IL 8        
 
 
35  
 
 
279 
 
Lyme Borreliosis 
 
IL 8 
MIP 1β 
 
 
100 800  
100 300  
 
281 
 
Viral infection (HCV) 
 
 
 
IL 8 
TNF α 
 
10 10000  
10 100  
 
280 
 
Inflammatory disease 
 
Multiple sclerosis 
 
 
IL 8 
RANTES 
 
40 200  
100 600  
 
282 
 
Rheumatoid Arthritis and 
Osteoarthritis * 
 
IL 8 
MIP 1β 
RANTES 
 
80 150  
80 120  
8000 12000  
 
283 
 
Systemic lupus erthymatosis * 
 
 
IL 8 
IL 10 
TNF α 
IFN γ 
 
40 
10 
10 300  
10 
 
284 
285 
 
Sjogren’s Syndrome * 
 
 
IL 8 
RANTES 
MIP 1β 
TNF α 
 
3  
1300  
20  
32  
 
286 
 
Inflammatory bowel disease/ 
Crohn’s Disease 
 
IL 10 
VEGF 
 
140  
440  
 
287 
288 
 
 
*Diseases associated with high serum levels of CD23 224 
224 
LM609 is the clone name for the anti αVβ3 integrin antibody based therapeutic 
known as Vitaxin 
289. This humanised anti αVβ3 antibody was developed by the 
company  MedImmune  as  a  treatment  for  inflammatory  diseases  and  certain 
cancers 
194, 290 292.  However, Vitaxin failed to prove effective in clinical trials for 
inflammatory diseases (such as rheumatoid arthritis and psoriasis). MedImmune 
have  subsequently  discontinued  the  development  of  Vitaxin  as  an  anti 
inflammatory treatment, although it is still in trials for use as an anti cancer 
agent 
293. In light of our data, it is tempting to speculate that the reason Vitaxin 
is ineffective as an anti inflammatory agent is that, while it targets the correct 
integrin, αVβ3, it is directed against the wrong epitope on the integrin. From the 
data presented herein, the critical site that governs cytokine production by αVβ3 
ligation is bound by 23C6 and not LM609. LM609 still inhibts adhesion and this 
may explain its continued potential to be effective in the prevention of cancer 
metastasis. This suggests that there are distinct sites on the integrin  one that 
mediates adhesive reactions and one that mediates cytokine production. These 
conclusions are consistent with the potential existence of distinct RGD and non 
RGD based binding sites on the integrins, as observed with the interaction of the 
αV integrins and CD23 derived peptides. It is also interesting to note that the 
inflammatory disorders (such as rheumatoid arthritis and psoriasis) in which αVβ3 
is  being  targeted  are  those  which  are  correlated  with  high  serum  levels  of 
soluble CD23 
294.  
 225 
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6.3.2    Role of cytokines in physiological and pathological 
immune function 
Specific  ligation  of  selected  integrins  led  to  the  production  of  high  levels  of 
cytokines and chemokines by monocytic cells and the subsequent activation of 
these  cells  to  develop  a  more  macrophage like  phenotype.  The  chemokines 
produced were capable of inducing the migration of THP 1 cells, Jurkat T cells 
and  IB4  B  cells  across  a  membrane  in  an  in  vitro  assay  for  migration.  The 
concentrations  of  cytokines  observed  during  these  experiments are  similar to 
concentrations observed in a number of infectious and inflammatory challenges 
observed in vivo (Table 6 2).These combined functions are all important during 
the immune response under both physiological and pathological conditions.  
Figure  6 2  suggests  how  the  combined  functions  of  integrin  ligation  could 
contribute in vivo to the establishment of inflammation during pathogen invasion 
and in inflammatory disease such as RA. The process can be considered as stages 
A D which encompass the onset of cytokine production by specific ligation of the 
integrin  (A),  the  recruitment  and  activation  of  immune  cells  from  the 
bloodstream  to  the  site  of  stimulation  (B),  autocrine  signalling  leads  to 
activation  of  the  resident  macrophage  population  (C),  and  when  the 
inflammatory environment is established (D), which may also lead to a change in 
the cytokine profile from the original stimulus. 226 
226 
 
Figure   6-2 Schematic representation of the role of integrins in a model of inflammatory disease/infection 
(A) Ligation of macrophage integrin by sCD23 or pathogen at the correct epitope triggers cytokine production. (B) Cytokines and chemokines have paracrine effects on 
surrounding cells and recruit immune cells from the bloodstream to the tissue. (C) Cytokines have autocrine effect on macrophage and lead to macrophage activation (D) 
Recruited cells and activated macrophages lead to establishment and maintenance of inflammation  
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Specific  ligation  of  the  integrin/integrin  signalling  complex  on  a  macrophage 
induces high levels of cytokine release. In the case of an infection, this binding 
would be mediated by a pathogen receptor, such as LPS or zymosan, whereas in 
an inflammatory disorder, such as rheumatoid arthritis, the stimulus for cytokine 
production could be induced by the high levels of CD23 detected in serum. The 
production  of  TNF α,  IL 8,  RANTES  and  MIP 1β  can  be  considered  as  pro 
inflammatory  cytokines,  which  lead  to  the  establishment  of  an  inflammatory 
state.  
The  cytokines  produced  in  response  to  integrin  ligation  will  induce  both 
paracrine  and  autocrine  effects.  The  concentrations  of  cytokines  and 
chemokines induced by integrin ligation are similar to the concentration ranges 
observed  in  the  serum  of  patients  with  infectious  and  inflammatory  diseases 
(Table 6 2).  The chemokines diffuse into the surrounding tissues and recruit 
cells to the site of stimulation by activating integrins and inducing extravasation 
of immune cells from the bloodstream into the tissue. The integrin ligation and 
cytokines produced also have an autocrine effect on the original macrophage, 
which leads to activation and continued production of cytokines, to establish the 
inflammatory  state. The  activation  of the  macrophage  by the initial  stimulus 
may lead to a change in the cytokine profile. For example, under the conditions 
of our experiments, high levels of VEGF production were observed 48 hours after 
stimulation,  suggesting  that  this  may  be  a  consequence  of  a  change  in  the 
monocyte/macrophage  biology.  The  initial  stimulus  will  determine  if  the 
inflammation  is  productive,  in  the  case  of  a  pathogenic  infection,  or  non 
productive, in the case of an auto immune/auto inflammatory disorder such as 
rheumatoid arthritis.   
228 
6.4 Conclusion 
This study has examined the interaction between CD23 and the αVβ3 and αVβ5 
integrins and attempted to define the individual roles of individual CD23 binding 
integrins  (αVβ3,  αVβ5,  αMβ2  and  αXβ2)  in  the  production  of  cytokines  by 
monocytic cells and the activation of these cells. Further analysis of integrin 
mediated  signalling  is  challenging  our  view  of  these  interesting  receptors  as 
mere adhesive structures. It is clear that integrins participate in a range of other 
modes of signalling in addition to those traditionally associated with adhesive or 
migratory functions. It is possible that these interactions will be mediated by an 
alternative site on the integrin that remains to be identified.  
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